UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.DC 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section
PROXY STATEMENT PURSUANT TO SECTION 14(a) of theSecurities Exchange Act of
OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment
(Amendment No. )
Filed by the Registrant | Filed by a |
Preliminary Proxy Statement | ||
Confidential, for Use of the Commission Only (as permitted by Rule | ||
Definitive Proxy Statement | ||
Definitive Additional Materials | ||
Soliciting Material under §240.14a-12 |
Vericel CorporationVERICEL CORPORATION
(Name of Registrant as Specified Inin Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
No fee | |||
Fee paid previously with preliminary | |||
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and |
2022 Notice of VirtualAnnual Meeting ofShareholders andProxy Statement
Message from the President and Chief Executive Officer
Message from Our President and |
| ||||
“Looking ahead to 2024, we expect another year of strong revenue growth and | Dear Shareholder: Vericel delivered another strong year of financial and business results in 2023, generating top-tier revenue growth and even higher growth in
Our commercial team continued to
We also made significant progress advancing our lifecycle management initiatives for MACI. Pre-launch activities for MACI Arthro™ are well underway and we plan to expand our surgeon target base to approximately 7,000 surgeons upon the expected launch of MACI Arthro later this year, to include surgeons that perform high volumes of cartilage repair predominantly through arthroscopic procedures. Initial feedback from surgeons that have used the MACI Arthro instruments during the development phase has been very positive, and we believe that MACI will be well-positioned to take a much more meaningful share of procedures treating cartilage defects in the |
1 |
Message from the President and Chief Executive Officer
In May 2019, we entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid® in North America. NexoBrid is a topically administered biologic product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial- and full-thickness thermal burns within four hours of application and without harming viable tissue. NexoBrid is approved in the European Union and other international markets and has been designated as an orphan biologic in the United States. We remain on track for a resubmission of the NexoBrid Biologics License Application (BLA) to the FDA in mid-2022 which, if approved, would position NexoBrid for a potential commercial launch in the first half of 2023.
Extensive pre-commercialization activities are underway to support the planned launch of NexoBrid. In addition to the ongoing disease state awareness campaign, we continue to advance our commercial launch plans, including a number of brand development and market access initiatives. Our medical affairs team remains engaged with burn centers in training and educational initiatives through the NEXT expanded access protocol, which we believe will be important for NexoBrid, once approved, to potentially replace surgical excision as the standard of care for removing eschar in patients with severe burns.
Finally, we are very pleased to have announced plans earlier this year for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility in the Boston area. The new facility, which is expected to begin commercial manufacturing in 2025, will significantly increase our manufacturing capacity and demonstrates our confidence in the continued growth trajectory of MACI and Epicel in the years ahead. In addition, the campus that Vericel will be a part of is designed and operated in accordance with existing LEED Gold and Fitwel Level 2 certifications and we are very pleased to locate our new facility in a campus focused on developing and managing environmentally responsible real estate.
In 2021, Vericel recognized full-year revenue of $156.2 million, an increase of approximately 26% over 2020, which was consistent with our compounded annual revenue growth rate (CAGR) since we launched MACI in 2017. The Company also generated strong cash flow in 2021, reporting approximately $29 million in adjusted EBITDA and operating cash flow. As a result, we increased our cash and investments by approximately $29 million to $129 million at the end of 2021, further strengthening our balance sheet while enhancing our overall financial position and strategic flexibility moving forward.
Looking ahead, in addition to delivering top-tier revenue growth, which we expect to be in the 20%+ CAGR range over the next several years, we expect to further enhance our profitability profile by delivering on our financial goals of approximately 70% gross margins and an adjusted EBITDA margin of approximately 30%. Despite the challenges since early 2020, we enter 2022 in a stronger position than ever and we are confident in our ability to deliver on these goals. We would not be in this strong position without the dedication of our employees and the support of our collaborators and shareholders, and we thank all of you for your continued support.
Sincerely,
Dominick C. Colangelo
We also are very pleased to have expanded our Burn Care commercial franchise with the U.S. commercial launch of NexoBrid during the fourth quarter of 2023. NexoBrid is an orphan biologic product indicated for the removal of eschar in adult patients with severe burns that provides burn surgeons a less invasive alternative to eschar removal than traditional surgical excision. Together with Epicel®, the only FDA-approved permanent skin replacement for adult and pediatric patients with large full-thickness burns, we believe that we have a premier portfolio of leading products to address both aspects of the treatment pathway for hospitalized burn patients.
Importantly, the addition of NexoBrid significantly expands our Burn Care total addressable market to $600 million and we are now targeting a significantly larger segment of hospitalized burn patients. Our expanded Burn Care franchise generated very strong revenue growth of more than 30% in the fourth quarter as Epicel benefited from a higher share of voice in the burn care market and NexoBrid generated strong engagement with burn centers in the early phase of its launch as the product builds a foundation for growth in 2024 and beyond.
Overall, the Company delivered a strong financial performance and enhanced value for our shareholders during 2023, exiting the year with a great deal of momentum across the business. Looking ahead to 2024, we expect another year of strong revenue growth and further improvement in our profitability metrics driven by continued strength across our portfolio and the first full year of NexoBrid on the market. In addition, the anticipated launch of MACI Arthro in the third quarter is expected to generate additional procedures toward the end of this year and more meaningfully contribute to our revenue growth in 2025 and beyond. Given the momentum in our business, the significant market opportunities for our products and our strong financial profile, we believe that Vericel is very well-positioned for sustained long-term growth in the years ahead.
On behalf of our executive leadership team and Board of Directors, I would like to thank our patients who inspire us, our employees for their dedication, and our customers and shareholders for your continued support. We look forward to continued success in 2024 and the years ahead.
Sincerely,
Dominick Colangelo
President and Chief Executive Officer
2 |
Notice of Virtual Annual |
Dear Shareholder of Vericel Corporation:
You are cordially invited to attend the Virtual Annual Meeting of Shareholders of Vericel Corporation (the “Annual Meeting”), a Michigan corporation. The Annual Meeting will be held on Wednesday, April 27, 2022,May 1, 2024, at 9:00 a.m. Eastern Time, via a live audio webcast at www.virtualshareholdermeeting.com/VCEL2022.VCEL2024. A list of shareholders entitled to vote at the Annual Meeting will be available for inspection by any shareholder at our offices in Cambridge, Massachusetts during ordinary business hours for a period of 10 days prior to the meeting. This list will also be available for shareholders to view online at the time of the meeting.
Voting Items
Proposal | Board Voting Recommendation | For Further Details | |
1 | To elect eight (8) directors, each to serve a term of one year expiring at the | each director nominee | Page |
2 | To approve, on an advisory basis, the compensation of our named executive officers | Page | |
3 | To cast an advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers | Every 1 YEAR | Page 63 |
4 | To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, | Page | |
Shareholders will also consider such other business as may properly come before the Annual Meeting and any adjournment thereof.
By Order of the Board of Directors,
Sean C. Flynn
Senior Vice President, General Counsel and Secretary
Cambridge, Massachusetts
March 17, 202221, 2024
|
BACKGROUND | |
Date and Time
May 1, 2024, at | |
Location Via a live audio webcast at www.virtualshareholder meeting.com/ | |
Who Can Vote You may vote at the Annual Meeting if you were a shareholder of record at the close of business on March | |
VOTING METHODS | |
Internet or Telephone Follow the instructions on your proxy card and | |
Vote, sign and return the proxy card to Broadridge Financial Solutions, 51 Mercedes Way, Edgewood, New York 11717 | |
Online at the Annual Meeting
|
If you attend the Annual Meeting, you may vote during the meeting even if you have previously voted via the Internet, by telephone, or by returning your proxy card.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE VERICEL 2024 VIRTUAL ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 1, 2024
The Notice of Virtual Annual Meeting of Shareholders, Proxy Statement, proxy card and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, are available at www.vcel.com by following the link for “Investor Relations.” To obtain more information concerning how to attend the Annual Meeting via the live audio webcast, please contact Vericel Corporation at (617) 588-5555.
Whether or not you plan to attend the Annual Meeting, please promptly complete your proxy as indicated above in order to ensure representation of your shares. For specific instructions on how to vote your shares, please review the instructions for each of these voting options as detailed in your Notice and in this Proxy Statement.
3 |
Table of Contents |
4 |
Proxy |
This Proxy Statement is being furnished in connection with the solicitation of proxies by the Board of Directors of Vericel Corporation (the “Board of Directors” or the “Board”), a Michigan corporation, for use at the Annual Meeting of Shareholders to be held on Wednesday, April 27, 2022,May 1, 2024, at 9:00 a.m. Eastern Time, via a live audio webcast at www.virtualshareholdermeeting.com/VCEL2022,VCEL2024 or at any adjournments or postponements thereof. An Annual Report to Shareholders, containing financial statements for the year ended December 31, 2021,2023, and this Proxy Statement are being made available to all shareholders entitled to vote at the Annual Meeting. This Proxy Statement and the form of proxy were first made available to shareholders on or about March 17, 2022.21, 2024. Unless the context requires otherwise, references to “we,” “us,” “our,” and “Vericel” refer to Vericel Corporation.
This overview highlights certain information contained elsewhere in this Proxy Statement and does not contain all of the information that you should consider. You should read the entire Proxy Statement carefully before voting. For more information about our business and 20212023 performance, please review our Annual Report on Form 10-K for the year ended December 31, 2021,2023, as filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022.
Table of Contents29, 2024.
About Vericel
Advanced Therapies for the Sports Medicine and Severe Burn Care Markets
Vericel is a leader inleading provider of advanced therapies for the sports medicine and severe burn care markets. We have aWhether we are treating damaged cartilage or severe burns, we provide advanced therapies to repair serious injuries and restore lives. Our highly differentiated portfolio of highly innovative advancedcell therapy and specialty biologic products combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and specialty biologics thathealthy knee cartilage.
Today, we are focused on changing the standard of careknown for patients with cartilage damage and severe burns. We currently market two advanced cell therapy products in the United States, MACI® and Epicel®, which are approved and regulated by the FDA as combination biologic/device products, with the biologic component being the use ofputting a patient’s own cells to work — and working for each of our patients. We deliver our therapies with personalized care and attention. This approach has created many promising possibilities for expanding our portfolio. As we grow, our purpose remains the same: to produce therapies as individual as the people who need them.
We currently market three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair damaged tissue and restore function. In lineof symptomatic, single or multiple full-thickness cartilage defects of the knee with our business development strategyor without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to add products to our portfolio that are synergistic with our existing commercial business, in 2019 we added a complimentary product to our burn care franchise when we entered into30% of total body surface area. We also hold an exclusive license and supply agreements with MediWound Ltd. (“MediWound”) for North American rights to NexoBrid®(anacaulase-bcdb), a biological orphanbotanical drug product containing proteolytic enzymes, which is indicated for removing burn tissue, orthe removal of eschar in patientsadults with severe thermaldeep partial-thickness and/or full-thickness burns.
Our Productsportfolio is unique in that there are significant barriers to entry for competitive products. For MACI and Epicel, which are regulated as combination biologic/device products by the FDA, there are no established generic biosimilar or 510(k) pathways to enter the market, so future entrants will almost certainly be required to follow a standard clinical trial pathway, which is challenging and the results of which are often uncertain. We believe there are no similarly situated competitors in either of these markets in the near-term.
We believe that our product portfolio provides an exceptionally solid foundation to deliver sustained strong revenue and profitability growth in the years ahead. We expect to further enhance our profile by reinforcing our position as a premier high-growth sports medicine business as we expand our leadership position in the knee cartilage repair market by maximizing certain MACI growth drivers within the product’s current indication, expanding MACI’s indication to encompass new delivery techniques and treatment targets, and creating a second high-growth franchise in burn care with the launch of NexoBrid and continued growth in the utilization of Epicel.
5 |
Our lead product is MACI, | ||
There are more than | ||
MACI represented a major technological advancement that resulted in a less invasive, simpler and faster way for orthopedic surgeons to treat patients suffering from knee cartilage damage. We are now focused on the potential arthroscopic delivery of MACI, which would represent the next major procedural advancement in our strategy of continuing to make MACI an even simpler and less invasive procedure for surgeons and patients. We believe the potential approval of MACI ArthroTM will drive continued strong growth for the product. Surgeons have indicated that an arthroscopic delivery method would not only allow the treatment of MACI patients in a less-invasive manner, but would also more easily permit the treatment of cartilage defects in the knee’s femoral condyle and increase the penetration into MACI’s largest market opportunity. The FDA has accepted our submission seeking to expand the MACI label to include arthroscopic delivery of MACI for the treatment of cartilage defects in the knee and we expect to commercially launch MACI Arthro during the third quarter of 2024. In addition to further procedural advancements, we are also making progress on our strategy to expand MACI’s use to other joints. Specifically, our MACI clinical development program is focused on studying MACI’s use to treat cartilage injuries in the ankle, which represents the largest cartilage repair opportunity outside of the knee, and an additional addressable market of approximately $1 billion. We are on track to initiate a MACI Ankle clinical study beginning in 2025 and, if approved, we believe MACI’s expansion into the ankle will be another longer-term growth driver for the product. | ||
Epicel | ||
Epicel is an important and potentially life-saving treatment option for patients with severe burns who may not be candidates for autografts due to the severity and extent of their burns. We estimate that there are approximately 600 surviving patients in the U.S. each year with full-thickness burns greater than 40% of total body surface area that are candidates for treatment with Epicel, representing a potential market opportunity of | ||
About Vericel
In 2023, we NexoBrid’s launch activities are well underway with our first patients treated in the U.S. soon after the product entered the market during the fourth quarter of 2023. We estimate that there are approximately 40,000 hospitalized burn patients in the U.S. each year, the majority of whom will require eschar removal and are candidates for treatment with NexoBrid, representing a potential market opportunity of |
6 |
Strong Financial | High-Growth Sports | Advancing | Second High-Growth |
Profile | Medicine Franchise | Pipeline | Franchise in Burn Care |
• Total net revenue growth of 20% to $197.5 million in 2023 • Gross margin expansion in 2023 to 69% • Full-year non-GAAP adjusted EBITDA* growth of 40% to $33.9 million, or 17% of total net revenue • $152.6 million in cash, restricted cash and investments and no debt as of December 31, 2023 | • Market leader in knee cartilage repair • 25% MACI revenue growth in 2023 to $164.8 million • Continued strong growth in MACI surgeons and MACI biopsies | • MACI Arthro human factors study submission accepted for review by the FDA • Commercial launch of MACI Arthro expected during Q3 2024 • MACI Ankle program advancing • NexoBrid’s BLA for pediatric indication accepted for review by the FDA | • NexoBrid launched commercially in Q4 2023 • High surgeon interest in NexoBrid |
Top-Tier Total Net Revenue Growth | Year-over-Year Total Net Revenue Growth Adjusted EBITDA* | |
About Vericel
Strong Performance Across Several Financial Measures in 2021 Despite the Continued Impact of the COVID-19 Pandemic
We believe that our highly innovative portfolio with significant barriers to entry will allow us to continue to generate sustained top-tier revenue growth in our large underpenetrated markets for many years. In addition, we believe that our business model, which is built on commercializing high-value products with concentrated call points, will continue to generate strong profits and operating cash flow in the years ahead.
Strong Track Record of Revenue and Profit Growth
• Durable growth platform equating to multiple years of top-tier revenue growth | |
• Significantly underpenetrated markets diversified across two franchises | |
• Strong reimbursement profiles |
• Converting strong revenue growth into cash flow generation | |
• Adjusted-EBITDA* growth of 40% during 2023 • $ | |
• 14 consecutive quarters with positive adjusted EBITDA* and |
| ||
* | For more information concerning Vericel’s presentation of non-GAAP measures, including a reconciliation of reported net (loss) income (GAAP) to adjusted EBITDA (non-GAAP), please refer to the Company’s discussion of “GAAP versus non-GAAP Measures”, on page |
2024 Proxy Statement | 7 |
About Vericel
Track Record of Creating Significant Shareholder Value
Trailing Stock Performance
(through March 8, 2024)
We are pleased that our performance and continued execution on our strategic and operational goals over the past five years hashave translated into significant value for our shareholders. Indeed, between 2016Between December 30, 2022 and 2020, an investment in our Company’s commonMarch 8, 2024, the value of Vericel’s publicly-traded stock has yielded a return of 1,189%increased approximately 72%, with a 27% return in 2021.
The graph above depicts the total shareholder return from December 31, 2016, through December 31, 2021, for (i) our common stock, (ii) the Nasdaq Composite Index (U.S.), and (iii)outperforming the Nasdaq Biotechnology Index. PursuantIndex, the Russell 2000 Index and the average of our Proxy Statement Peer Group during that period. For more information concerning our Peer Group companies, see page 48 of this Proxy Statement.
We recognize the importance of incorporating Environmental, Social, and Governance (“ESG”) principles into the core of our operations, for our organization and employees, and for the larger communities in which we operate. During 2022, Vericel published its inaugural ESG Report, which highlights for investors our Company’s steadfast commitment to applicable SEC rules, all values assume reinvestmentincorporating ESG principles into our everyday business activities. Below is a summary of some of our recent ESG-related activities and achievements.
The Vericel Board of Directors provides oversight of, and strategic guidance to, our executive leadership team on ESG topics. Our Board is comprised of industry leaders with extensive and diverse experiences, which span the business, healthcare, and scientific arenas. The Board continued its focus on developing and implementing the Company’s ESG strategy throughout 2023. The Board has continued to conduct educational programs with outside experts on ESG topics and was involved in the oversight of Vericel’s company-level Diversity and Inclusion Advisory Committee, which is a central component of Vericel’s steadfast commitment to integrating core diversity and inclusion concepts into corporate policies, initiatives, and programs across the organization. See “Oversight of Environmental, Social and Governance Matters” on page 32 of this Proxy Statement for more information on how the Board and its committees exercise ESG oversight.
We are committed to minimizing the environmental impact of the full amountCompany’s operations and as part of all dividends, however, no dividendsthat commitment we have been declared onimplemented several process improvements and adopted operational efficiencies to reduce our common stockenvironmental footprint. We have adopted environmentally sustainable practices into our facilities and manufacturing operations and have established procedures and policies to date. manage our electricity and water usage, as well as the handling of medical and hazardous waste.
The shareholder return shown onCompany is currently constructing a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility in the graph abovegreater Boston area. The 125,000 ft2 facility will significantly increase our cell therapy manufacturing capacity to support the long-term growth of our commercial products. Our manufacturing expansion will enable us to sustain our long-term revenue growth while helping us promote environmentally responsible operations and workforce well-being. We expect to begin occupying our new facility at the end of 2024.
Importantly, Vericel’s new facility will be located within a campus that is not necessarily indicative of future performance,designed and operated in accordance with existing LEED Gold and Fitwel Level 2 certifications. We will continue to evaluate opportunities to manage the Company’s environmental impact as we do not make or endorse any predictions asprepare to future stockholder returns.transition operations to our new facility.
About VericelWe are passionate, not only about serving the patients and healthcare professionals who use our products, but also about our continuing commitment to our employees.
Corporate Governance Highlights
Patients Access to Our Products | People Diversity, Equity & Inclusion | |
•More than 17,000 patients have benefited from our innovative advanced cell therapy and specialty biologics products to date. • We are currently developing a custom arthroscopic delivery system for MACI, which we believe could increase MACI’s ease of use for surgeons and reduce both the length of the procedure and the post-operative pain and recovery time for patients. The FDA has accepted our submission seeking to expand the MACI label to include arthroscopic delivery of MACI for the treatment of cartilage defects in the knee and we expect to commercially launch MACI Arthro during the third quarter of 2024. • We are continuing to advance our MACI Ankle indication program which we believe, if approved, could enable patients with cartilage defects in the ankle to be successfully treated with MACI. • We have established a patient support program with dedicated case managers who provide services related to coordination of patient insurance benefits. Product, Quality & Safety • We have established a Quality Management System, which ensures the highest quality standards for our products. •No documented cGMP violations or FDA enforcement actions with respect to any of our operations over the past five years. Compensation and Rewards Program •Pay equity is a core tenet of our compensation philosophy, and internal analyses are conducted regularly to maintain consistency in the administration of these programs. • Components of our compensation and rewards programs include competitive base salary, performance-based bonus targets to incentivize individuals towards the achievement of personal and corporate goals, long-term equity incentive compensation in the form of stock option and RSU grants, and additional employee appreciation programs and events. | We have an established Diversity and Inclusion Advisory Committee as part of our commitment to diversity, equity and inclusion (“DE&I”). During 2023, we continued to conduct robust DE&I training for both our executive team and employees. As part of that initiative, we implemented an electronic training platform intended to support Vericel in its obligation to train staff on important DE&I programs, as well as policies against harassment and discrimination. We partner with external experts each year to evaluate our Company demographics and determine areas where we can improve our workforce diversity. We are pleased with the diverse culture we have established at Vericel and with the fact that annual analyses of Vericel’s Affirmative Action Plan (the “Plan”) have not identified any statistically significant deficiencies for the hiring and advancement of women and minorities since the Plan’s inception in 2016. Benefit Programs and Employee Wellness We strive to provide employees with a comprehensive offering of programs to support health and wellness, including: • healthcare; • dental and vision insurance; • flexible spending accounts; • life and accidental death and dismemberment insurance; • employee assistance counseling and education programs; • company contributions to employee 401(k) accounts; • paid time off and leave programs; • tuition assistance; • fitness membership subsidies; and • other programs designed to foster employee health and well-being. We offer our employees internal development and advancement opportunities and encourage continued learning through internal and external programs and educational institutions. |
2024 Proxy Statement | 9 |
Board Independence and Composition | Board Performance Oversight Role | Policies, Programs and Guidelines | |||||||
Ethics & Compliance
• Robust compliance training and effective monitoring and auditing procedures are performed by members
• Engage with third-party partners to proactively identify and address compliance-related trends as well as state and federal legal and regulatory updates that apply to our business • Comprehensive updates to Vericel’s Code of Business Conduct and Ethics were adopted by the Board |
Board and Committee Meetings Attendance
Other Board Practices
• Annual Board and committee self-evaluations
| Shareholder Rights
| • Maintain a robust and
• Updated Policy for the Recoupment of Erroneously Awarded Incentive Compensation (the “Clawback Policy”) adopted by the Board of Directors in 2023 to comply with the requirements of applicable law and Nasdaq listing rules • Amendment to the Charter of the Governance and Nominating Committee during
Information Security & Privacy • Our integrated information technology systems are supported by policies aligned with the National Institute of Standards and Technology Cybersecurity Framework • During 2023, the Company completed a |
10 |
PROPOSAL 1: | |||||||
About Vericel
| The Board recommends a vote FOR each director nominee. | |||
To elect eight (8) directors, each to serve a term of one year expiring at the
|
|
2024 Proxy Statement | 11 |
Board | Skills and Experience | |||
Board of Directors
About Vericel
Board Snapshot
Skills and Experience
Shareholder Engagement | |||||||
Vericel greatly values the perspectives that we gain through direct engagement with our shareholders. | |||||||
Shareholder Engagement
In |
12 |
PROPOSAL 2: | ||||
About Vericel
| The Board recommends a vote FOR this proposal. | |||
To vote on an advisory resolution to approve the compensation of Vericel’s named executive officers.
|
2021 Financial Performance
| ||||
$197.5 million Record full-year total net revenue, | 40%* Adjusted EBITDA year-over-year | $164.8 million MACI net revenue, representing 25% | ||
$33.9 million* Non-GAAP adjusted EBITDA | $32.7 million Burn Care net revenue; commercial | $152.6 million Cash, restricted cash and investments |
Executive Compensation Objectives and Philosophy
We have designed our executive compensation program to attract, retain and motivate the executive talent necessary to advance our business of developing and commercializing advanced therapies for the sports medicine and severe burn care markets and to increase shareholder value. Our compensation program is aligned with our business strategy and priorities, encourages executive officers to work for meaningful shareholder returns and reflects a pay-for-performance philosophy. It does not encourage our executive officers to assume excessive risks or result in excessive pay levels. We achieve our pay objectives by providing short-term cash bonuses tied to our annual financial, product development and operational goals and by granting long-term equity awards. To this end, our compensation programs for executive officers are designed to achieve the following objectives:
* | For more information concerning Vericel’s presentation of non-GAAP measures, including a reconciliation of reported net (loss) income (GAAP) to adjusted EBITDA (non-GAAP), please refer to the Company’s discussion of “GAAP versus non-GAAP Measures”, on page |
13 |
About Vericel
The primary components of our executive officer compensation program are: (i) annual base salary; (ii) annual non-equity incentive compensation, which is based on the achievement of specified Company goals; and (iii) long-term equity incentive compensation in the form of periodic stock optionoptions and restricted stock unit (“RSU”) grants, with the objective of aligning the executive officers’ long-term interests with those of our shareholders.
Element | Target Mix | Strategy and Performance Alignment | ||||
Base Salary | Base salaries are established, in-part, based on the individual experience, skills and expected contributions of our executives, their performance during the prior year, and a comparison | |||||
Annual Non-Equity Incentive Compensation | The determination of annual incentives for our executives is tied to achieving our financial targets, advancing our commercial and development-stage products and accomplishing operational • Commercial and • Product Goals: 50% • Operational Goals: 10% Additional Upside Value Goal Opportunity (up to 15%) | |||||
Long-Term Equity Incentive Compensation | Long-term incentive compensation aligns employees with shareholders and further incentivizes our executive officers to drive stock price growth and allows them to share in any appreciation in the value of our common stock. |
14 |
About Vericel
Our Goals | Our Metrics | Our Performance | |||||
Commercial and Financial Performance Goals | Generate total net | ||||||
Achieve budget expense target of | •Budget expense target | ||||||
Achieve budgeted MACI surgeon engagement goals of increasing number of biopsy surgeons and | |||||||
Complete MACI, Epicel and NexoBrid long-term brand development initiatives | |||||||
Complete MACI Arthro human factors study and submit label update to the FDA by December 1, 2023 | •Exceeded target with respect to | ||||||
Complete manufacturing facility and key manufacturing/IT efficiency improvement initiatives | |||||||
Execute high-quality business development transaction | •Company strategically chose not to execute any business development |
2024 Proxy Statement | 15 |
What We Do | What We Don’t Do | |||||||
|
|
About Vericel
PROPOSAL 3: | |||
| |||
Advisory Vote on the Frequency | The Board recommends a vote that future non-binding, advisory votes to approve the compensation of our named executive officers be held every 1 YEAR | ||
To cast an advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers. | See page 63 |
2024 Proxy Statement | 17 |
PROPOSAL 4: | ||||
Ratification of Appointment of | The Board recommends a vote FOR this proposal. | |||
To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for
| ||||
The Audit Committee has selected PricewaterhouseCoopers LLP (“PwC”) as Vericel’s independent registered public accounting firm to audit the consolidated financial statements of Vericel for the fiscal year ending December 31, 2022.2024. PwC has acted in such capacity since its appointment in fiscal year 1996.
As part of its duties, the Audit Committee considered the provision of services, other than audit services, during the fiscal year ended December 31, 20212023 by PwC, our independent registered public accounting firm for that period, to ensure the firm maintains its independence. The following table sets forth the aggregate fees accrued by Vericel for the fiscal years ended December 31, 20202022 and 2021,2023, respectively, for PwC:
Name | Fiscal Year Ended December 31, 2020 ($) | Fiscal Year Ended December 31, 2021 ($) | ||||||
Audit Fees | 991,000 | (1) | 1,215,608 | (1) | ||||
Audit Related Fees | — | — | ||||||
Tax Fees | 20,893 | (2) | — | (2) | ||||
All Other Fees | 2,000 | (3) | 2,700 | (3) | ||||
Total | 1,013,893 | 1,218,308 |
Name | Fiscal Year Ended December 31, 2022 ($) | Fiscal Year Ended December 31, 2023 ($) | ||||||
Audit Fees | 1,261,700 | (1) | 1,329,500 | (1) | ||||
Audit Related Fees | — | — | ||||||
Tax Fees | — | — | ||||||
All Other Fees | 2,993 | (2) | 3,074 | (2) | ||||
Total | 1,264,693 | 1,332,574 |
(1) | The Audit Fees for the years ended December 31, |
(2) | |
All other Fees represent an annual license fee for technical accounting research software and the use of accounting disclosure checklists. |
18 |
Corporate |
| ||||
The Board | |||||||
The Vericel Board of Directors provides oversight of, and strategic guidance to, our Company’s senior management. The core responsibility of a director is to fulfill his or her duties of care and loyalty and otherwise exercise his or her business judgment in the best interests of the Company and its shareholders. The Board is responsible for overseeing the Company’s officers, including the President and Chief Executive Officer, and for ensuring that management advances the interests of the shareholders through the operation of the Company’s business. The Board recognizes that it is management’s responsibility to carry out the policies and strategies approved by the Board and to manage and carry out the operation of the Company’s business. Our Board is committed to legal and ethical conduct in fulfilling its responsibilities and it expects all directors, as well as officers and employees of the Company, to adhere to Vericel’s Code of Business Conduct and Ethics, a copy of which is available on the Company’s website.
Throughout 2021,
Our Board is committed to the continuous improvement of our Board was keenly focused on its commitment to importantcorporate governance structure, the principles of enterprise-wide diversity and inclusion, the oversight of our corporate ESG initiatives and bolsteringenhancing the Company’s overall corporate governance framework. This past yearcomposition and effectiveness of the Board continued its practice of receiving robust education from outside experts on ESG topics specific to the biotechnology industry and, for the first time, approved and oversaw the accomplishment of a set of ESG-related goals for our management team. Management executed on those objectives, which were focused on diversity and inclusion at both the Board and Company level and the enhancement of the Board’s policies and procedures. Our Board has designated the Governance and Nominating Committee (the “Governance Committee”) to periodically review and oversee management of the Company’s strategy, initiatives, risks, opportunities and related reporting with respect to significant ESG matters.itself.
Building on its longstanding commitment to diversity at all levels of the organization, after an extensive nationwide search the Vericel Board refreshed its ranks during 2021 with the addition of a new diverse director, Lisa Wright. Ms. Wright is President and Chief Executive Officer of Community Health Choice, Inc., a managed care organization in the greater Houston, Texas area. She is an accomplished healthcare executive with a track record of strong strategic, operations and financial performance across a number of leading healthcare organizations. She brings to the Vericel Board key expertise in the payer and provider aspects of the healthcare system, and her experiences will be valuable to Vericel as we aim to continue to be a high-growth commercial business with multiple products and product candidates with varied reimbursement models. During 2021, Vericel also established a Company-wide Diversity and Inclusion Advisory Committee with a mandate to integrate best practices for diversity, equity and inclusion into corporate initiatives, policies and programs throughout the organization.
Recent Governance Enhancements • Board adoption of enhanced Compensation Clawback Policy, as discussed further on page 52 (2023) • Oversight of an in-depth initiative to evaluate and enhance the Company’s cybersecurity incident response framework and readiness (2022-2023) •Termination of shareholder rights plan or “poison” pill (2021) • Implementation of comprehensive Corporate Governance Guidelines (2021) • Adoption of formal Stock Ownership Guidelines, with which all directors and officers were in compliance as of December 31, 2023 | |
Board Composition and Effectiveness • Added new director with expertise in healthcare operations and payer matters (2021) • Robust Board self-assessment process in place to continuously evaluate the relevant skills and attributes of the Board’s individual members as well as the effectiveness of the Board as a whole | |
Diversity & Inclusion • Increased gender and racial diversity of Board (2021) • Continued oversight of Vericel Diversity and Inclusion Advisory Committee, which is committed to furthering and strengthening our workforce diversity across all levels of the organization | |
ESG Oversight • Oversaw the creation and publication of Vericel’s inaugural ESG report highlighting our Company’s commitment to incorporating ESG principles into our everyday business activities (2022) • Designated the Governance and Nominating Committee to oversee management of ESG-related matters (2022) |
This past year our Board also focused on enhancing our governance policies for the benefit of shareholders. In February 2021, the Board unanimously approved the termination of the Company’s pre-existing shareholder rights agreement, commonly referred to as a “poison pill.” The Board also implemented comprehensive Corporate Governance Guidelines, which clarify for our investors the leadership exercised by each of the Board’s standing committees and their chairpersons and which serve as a flexible framework within which the Board conducts its oversight of our organization. Additionally, in furtherance of its belief that the Company’s senior leadership should have a meaningful ownership stake in the Company, in 2021 the Board adopted formal stock ownership guidelines for named executive officers and non-employee directors, which serve to further solidify the alignment of interests between senior leadership and our shareholders.
2024 Proxy Statement | 19 |
Our Company’s Amended and Restated Bylaws (“Bylaws”) provide that the Board of Directors will consist of not less than five nor more than nine members, as fixed from time-to-time by a resolution of the Board, and that all directors will be elected annually. The Board currently consists of eight (8) directors. The persons named below as nominees for director will, if elected, each serve a term of one year expiring at the 20232025 annual meeting of shareholders or until their successors are elected and qualified.
Corporate Governance
Vote Required
The affirmative vote of a plurality of the total shares of common stock entitled to vote and be represented in person or by proxy is required for the election of each of the nominees. It is the intention of the persons named as proxies to vote such proxy FOR the election of all nominees, unless otherwise directed by the shareholder. The Board of Directors knows of no reason why any of the nominees would be unable or unwilling to serve, but if any nominee should for any reason be unable or unwilling to serve, the proxies will be voted for the election of such other person for the office of director as the Board may recommend in place of such nominee.
Shares present or represented and not so marked as to withhold authority to vote for a particular nominee will be voted in favor of a particular nominee and will be counted toward such nominee’s achievement of a plurality. Shares present at the meeting or represented by proxy where the shareholder properly withholds authority to vote for such nominee in accordance with the proxy instructions and “broker non-votes” will not be counted toward such nominee’s achievement of a plurality.
Selection of Directors
The Company regularly examines the experience and expertise of our Board as a whole to ensure alignment between the Board’s abilities and our strategic priorities and long-range plan. We seek directors who will bring to the Board a deep and wide range of experiences in the business world and diverse problem-solving talents. The Company believes that the Board should represent an appropriate and relevant mix of skills, industry experience, backgrounds, ages and diversity (inclusive of race, gender and ethnicity). Typically, directors will be individuals who have demonstrated high achievement in business or another field, enabling them to provide strategic support and guidance to the Company. Particular areas of expertise include corporate strategy and development, commercial sales and marketing, commercial operations and execution, research and development, technical operations, familiarity with manufacturing biotechnology and medical device products, knowledge of the legal and compliance issues facing the life science industry, experience concerning the policies and procedures of public and private payers in the medical technology and biopharmaceutical space, corporate finance, financial and/or accounting expertise, organizational leadership, development and management, public company management and disclosure, and corporate risk assessment and prior experience in the medical technology, biopharmaceutical and complex biologics industries.
Corporate Governance
All of our director nominees exhibit high integrity, sound business judgment, innovative thinking, collegiality and a knowledge of corporate governance requirements and practices. As a group, our director nominees bring a balance of relevant skills and experience to our boardroom, including those listed below:
Robert L. Zerbe, M.D. | Dominick C. Colangelo | Heidi Hagen | Alan L. Rubino | Kevin F. McLaughlin | Steven C. Gilman, Ph.D. | Paul K. Wotton, Ph.D. | Lisa Wright | |
Prior BOD Experience | ||||||||
Industry Experience | ||||||||
Medical Technologies | ||||||||
BioPharma | ||||||||
Complex Biologics | ||||||||
Payer | ||||||||
Healthcare Operations | ||||||||
Functional Expertise | ||||||||
CEO/GM | ||||||||
Finance | ||||||||
Chief Operating Officer | ||||||||
Marketing/Sales | ||||||||
Research and Development | ||||||||
Technical Operations | ||||||||
Business Development | ||||||||
Geography | ||||||||
North America | ||||||||
Asia/Middle East | ||||||||
Europe | ||||||||
Demographics | ||||||||
Age | 71 | 58 | 53 | 67 | 65 | 69 | 61 | 47 |
Tenure | 2006 | 2013 | 2013 | 2005 | 2015 | 2015 | 2015 | 2021 |
Male/Female | M | M | F | M | M | M | M | F |
Board Diversity Matrix (As of January 21, 2022)
Total Number of Directors: 8
Female | Male | Non-Binary | Did Not Disclose Gender | |
Part I: Gender Identity | ||||
Directors | 2 | 6 | 0 | 0 |
Part II: Demographic Background | ||||
African American or Black | 1 | 0 | 0 | 0 |
Alaskan Native or Native American | 0 | 0 | 0 | 0 |
Asian | 0 | 0 | 0 | 0 |
Hispanic or Latinx | 0 | 0 | 0 | 0 |
Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
White | 1 | 6 | 0 | 0 |
Two or More Races or Ethnicities | 0 | 0 | 0 | 0 |
LGBTQ+ | 0 | 0 | 0 | 0 |
Did Not Disclose Demographic Background | 0 | 0 | 0 | 0 |
Directors who are Military Veterans: 0
Directors with Disabilities: 0
Directors who Identify as Middle Eastern: 0
Corporate Governance
Director Nominees for Election at the 2022 Annual Meeting of Shareholders
The biographical description below for each director nominee includes the specific experiences, qualifications, attributes and skills that led to the conclusion by the Board of Directors that such person should serve as a director of Vericel.
|
| |
|
|
| |
|
Corporate Governance
|
| |
|
Corporate Governance
|
| |
|
|
| |
|
Corporate Governance
|
| |
|
|
| |
|
Corporate Governance
|
| |
|
Identifying and Evaluating Candidates for Director
The Governance and Nominating Committee evaluates and recommends to the Board of Directors the nominees for each election of directors. Both the Governance and Nominating Committee and the Board use a variety of methods for identifying and evaluating such nominees, and the Governance and Nominating Committee, in consultation with the Chairman and other Board members, regularly assesses the composition of the Board and each committee to evaluate their effectiveness and whether or not changes should be considered. The full Board annually determines the diversity of specific skills and characteristics that could improve the overall quality and ability of the Board to carry out its oversight of the Company and other functions.
The Governance and Nominating Committee’s goal is to assemble a Board of Directors that brings to Vericel a variety of perspectives and skills derived from high quality business and professional experience, while considering the appropriate size of both the Board and its committees. In doing so, the Governance and Nominating Committee also considers candidates with appropriate non-business backgrounds. In general, the Governance and Nominating Committee seeks director nominees with the talents and backgrounds that provide the Board with an appropriate mix of knowledge, skills and experience for the needs of Vericel’s business. There are no stated minimum criteria for director nominees, and the Governance Committee may consider such other factors as it deems are in the best interests of Vericel and its shareholders. In general, and given Vericel’s position as a leader in the biotechnology and medical technology space, the Board believes it should be comprised of persons with skills and experience in areas such as:
The Governance and | ||
Current members of the | ||
If any member of the Board of Directors that is up for re-election at an upcoming annual meeting of shareholders does not wish to continue in service, the Governance and |
20 |
Corporate Governance
The Governance Committee also actively seeks out highly-qualified diverse candidates. In February 2020, the Board formalized its longstanding practice of considering women and minority candidates for open director positions by amending the Charter Current members of the Governance and Nominating Committee and its Director Nominations Policythe Board are polled for suggestions as to clearly state that in filling each open director positionindividuals meeting the criteria of the Governance Committee will endeavorand Nominating Committee.
Research may also be performed to actively seek out highly-qualified diverse candidates (including diversity on the basis of gender, race and ethnicity) to include in the pool from which director nominees are chosen. Additionally, in situations whereidentify qualified individuals.
If the Governance and Nominating Committee engagesbelieves that the Board requires additional candidates for nomination, the Governance and Nominating Committee may explore alternative sources for identifying additional candidates. This may include engaging, as appropriate, a third-party search firm to assist in a Board member search, the policy requires that the search firm actively seek out highlyidentifying qualified female and racially/ethnically diverse candidates, as well as individuals with diverse backgrounds, skills and experiences, to include in the candidate pool. The Board most recently added a member in 2021, when it conducted a nationwide search for a new director that resulted in the appointment of Lisa Wright on June 1, 2021.candidates.
3 | INDEPENDENCE AND BOARD COMPOSITION REQUIREMENTS |
The Governance and Nominating Committee recognizes that under applicable regulatory requirements at least one member of the Board of Directors must, and believes that it is preferable that more than one member of the Board of Directors should, meet the criteria for an “audit committee financial expert” as defined by SEC rules, and that at least a majority of the members of the Board must meet the definition of “independent director” under the Nasdaq listing standards or the listing standards of any other applicable self-regulatory organization that Vericel is subject to or governed by. The Governance and Nominating Committee also believes that it is appropriate for at least one member of Vericel’s management to participate as a member of the Board.
The
4 | ADDITIONAL QUALIFICATIONS |
There are no stated minimum criteria for director nominees, and the Governance and Nominating Committee identifies nominees by first evaluatingmay consider such other factors as it deems are in the current membersbest interests of Vericel and its shareholders. In general, and given Vericel’s position as a leader in the biotechnology and medical technology space, the Board believes it should be comprised of Directors willing to continue in service. Current members of the Boardpersons with skills and experience that are relevantin areas such as:
Corporate strategy and development; Commercial sales and marketing; Commercial operations and execution; Research and development; Technical operations; Manufacturing of biotechnology and medical device products; Knowledge of the legal and compliance issues facing the life science industry; Experience concerning the policies and procedures of public and private payers in the medical technology and biopharmaceutical space; | Corporate finance; Financial and/or accounting expertise and experience with regulatory and SEC requirements applicable to public companies; Organizational leadership, development and management; Public company management and disclosure; Corporate risk assessment, management, and prior experience in the medical technology, biopharmaceutical and complex biologics industries; and Knowledge of, and experience handling, cybersecurity-related issues currently facing publicly-traded organizations |
5 | MEETING AND ENGAGING WITH CANDIDATES |
Following the identification of one or more potential candidates to our business and who are willing to continue in service are considered for re-nomination, balancing the value of continuity of service by existing members of theserve on The Board, with that of obtaining a new perspective. If any member of the Board of Directors that is up for re-election at an upcoming annual meeting of shareholders does not wish to continue in service, the Governance Committee identifies the desired skills and experience of a new nominee in light of the criteria above. Current members of the Governance and Nominating Committee will generally be provided with a copy of each candidate’s resume and any additional information concerning the Board are polled for suggestions as to individuals meeting the criteriacandidate’s skills and qualifications. One or more members of the Governance Committee. Researchand Nominating Committee will then conduct an interview of each candidate. The Company’s CEO may also be performed to identify qualified individuals. Ifparticipate in such interview, if desired.
6 | DECISION AND NOMINATION |
Once the Governance and Nominating Committee believesidentifies an individual to serve as a new director, the Committee will generally commission an independent background check of that individual to confirm the candidate’s suitability to serve on Vericel’s Board. Upon obtaining the results of the background check, the Governance and Nominating Committee will again discuss the candidate’s suitability for membership on the Board requires additionaland will normally share its findings and recommendation with all members of the Board.
7 | ELECTION |
Once the Governance and Nominating Committee has reached a decision to invite a new member to the Board it will make a formal recommendation to the Board for the candidate’s election. Following approval of Board resolutions to elect the new member, an invitation to join the Board will be extended to the candidate, normally by the Chairman of the Board.
2024 Proxy Statement | 21 |
The Governance and Nominating Committee also actively seeks out highly-qualified diverse candidates. In February 2020, the Board formalized its longstanding practice of considering women and minority candidates for nomination,open director positions by amending the Charter of the Governance and Nominating Committee may explore alternative sources for identifying additional candidates. This mayand its Director Nominations Policy to clearly state that in filling each open director position the Governance and Nominating Committee will endeavor to actively seek out highly-qualified diverse candidates (including diversity on the basis of gender, race and ethnicity) to include engaging, as appropriate,in the pool from which director nominees are chosen. Additionally, in situations where the Governance and Nominating Committee engages a third-party search firm to assist in identifyinga Board member search, the policy requires that the search firm actively seek out highly qualified candidates.female and racially/ethnically diverse candidates, as well as individuals with diverse backgrounds, skills and experiences, to include in the candidate pool. The Board most recently added a member in 2021, when it conducted a nationwide search for a new director that resulted in the appointment of Lisa Wright on June 1, 2021.
All of our director nominees exhibit high integrity, sound business judgment, innovative thinking, collegiality and a knowledge of corporate governance requirements and practices. As a group, our director nominees bring a balance of relevant skills and experience to our boardroom, including those listed below:
Robert Zerbe, M.D. | Dominick Colangelo | Heidi Hagen | Alan Rubino | Kevin McLaughlin | Steven Gilman, Ph.D. | Paul Wotton, Ph.D. | Lisa Wright | |
Prior BOD Experience | ||||||||
Industry Experience | ||||||||
Medical Technologies | ||||||||
BioPharma | ||||||||
Complex Biologics | ||||||||
Payer | ||||||||
Healthcare Operations | ||||||||
Functional Expertise | ||||||||
CEO/GM | ||||||||
Finance | ||||||||
Chief Operating Officer | ||||||||
Marketing/Sales | ||||||||
Research and Development | ||||||||
Technical Operations | ||||||||
Business Development | ||||||||
Geography | ||||||||
North America | ||||||||
Asia/Middle East | ||||||||
Europe | ||||||||
Demographics | ||||||||
Age | 73 | 60 | 55 | 69 | 67 | 71 | 63 | 49 |
Tenure | 2006 | 2013 | 2013 | 2005 | 2015 | 2015 | 2015 | 2021 |
Male/Female | M | M | F | M | M | M | M | F |
Race/Ethnicity | ||||||||
African American or Black | ||||||||
Alaskan Native or Native American | ||||||||
Asian | ||||||||
Hispanic or Latinx | ||||||||
Native Hawaiian or Pacific Islander | ||||||||
White | ||||||||
LGBTQ+ |
Directors who are Military Veterans: 0
Directors with Disabilities: 0
Directors who Identify as Middle Eastern: 0
22 |
The biographical description below for each director nominee includes the specific experiences, qualifications, attributes and skills that led to the conclusion by the Board of Directors that such person should serve as a director of Vericel.
Robert Zerbe, Independent Chairman of the Board Retired Chief Executive Officer, Director Since: 2006 Other Current Public Company Directorships: • None Vericel Board committee(s): • Audit Committee | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• BioPharma: Dr. Zerbe has held numerous senior management positions at major pharmaceutical companies throughout his career, including serving as Chief Executive Officer of QUATRx Pharmaceuticals Company as well as senior positions at both Eli Lilly and Company and Pfizer. • CEO/GM: Served as CEO of a drug development company for over 15 years • Research & Development: Led the clinical development programs for a number of key products, including Lipitor and Neurontin, at Pfizer | ||||||
PROFESSIONAL HIGHLIGHTS • Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture-backed drug development company, which he co-founded (2000-2016) • Senior Vice President of Worldwide Clinical Research and Development of Pfizer (formerly Parke-Davis), as well as other senior executive management positions (1993-2000) • Managing Director, Lilly Research Center U.K., of Eli Lilly and Company (including Vice President of Clinical Investigation and Regulatory Affairs, as well as several other clinical research and development positions) (1982-1993) | OTHER LEADERSHIP POSITIONS AND EXPERIENCE • Member of the boards of directors of Metabolic Solutions Development Company and Cirius Therapeutics, both private companies focused on metabolic diseases EDUCATION • M.D. from Indiana University School of Medicine • Post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health | |||||
Dominick President and Chief Executive Officer, Vericel Director Since: 2013 Other Current Public Company Directorships: • Trevi Therapeutics, Inc. Vericel Board committee(s): • None | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• CEO/GM: Mr. Colangelo has more than 20 years of executive management experience in the biopharmaceutical industry. For the past 10 years he has served as President and CEO of Vericel, spearheading the acquisition of MACI and Epicel and leading the Company through an extended period of significant revenue and market growth. Mr. Colangelo also served for more than a decade in senior leadership positions at Eli Lilly and Company. • Finance: Mr. Colangelo possesses a significant accounting and finance background, which has been developed through education, strategy and business development roles, as well as his service on the audit committee of the board of directors of Trevi Therapeutics. • Marketing/Sales: Extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas • Business Development: Experience gained through a variety of executive positions in product development, pharmaceutical operations and corporate development | ||||||
PROFESSIONAL HIGHLIGHTS • President and Chief Executive Officer and a member of the Board of Directors of Vericel (2013-present) • Director of Strategy and Business Development for Eli Lilly’s Diabetes Product Group and founding Managing Director of Lilly Ventures at Eli Lilly and Company | OTHER LEADERSHIP POSITIONS AND EXPERIENCE • Member of the board of directors of Trevi Therapeutics, Inc., a publicly-traded clinical stage biopharmaceutical company focused on the development and commercialization of treatments for chronic cough conditions. Mr. Colangelo is a member of both the audit and compensation committees of the Trevi Therapeutics board. EDUCATION • B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo • J.D., with honors, from the Duke University School of Law |
2024 Proxy Statement | 23 |
Heidi Hagen, Independent Former Chief Technical Officer, Sonoma Biotherapeutics Director Since: 2013 Other Current Public Company Directorships: • None Vericel Board committee(s): • Compensation and Governance and Nominating (Chair) Committees | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• BioPharma/Complex Biologics: Ms. Hagen possesses more than 30 years of product development and leadership experience within the biopharmaceutical and medical device industries, having successfully built organizations and executed development programs within both established and start-up environments. • Chief Operating Officer/Technical Operations: Ms. Hagen has developed extensive operations experience throughout her career, including while serving at multiple commercial-stage biotechnology companies. In those capacities, Ms. Hagen has developed particular expertise in technical operations, where she has overseen production operations for multiple complex biologics across a variety of therapeutic areas. | ||||||
PROFESSIONAL HIGHLIGHTS • Chief Technical Officer of Sonoma Biotherapeutics, a privately-held biotechnology company (2021-2022) • Interim Chief Executive Officer and member of the board of directors of Ziopharm Oncology, Inc., a publicly-traded company developing immune-oncology gene and cell therapies (2019-2021) • Co-founder and Advisor and former Chief Strategy Officer of Vineti, Inc., a software platform company for cell and gene therapy supply chain management (2015-present) • Senior Vice President of Operations for Dendreon Corporation, a commercial biotechnology company (2002-2012) | OTHER LEADERSHIP POSITIONS AND EXPERIENCES • Member of the boards of directors of Obsidian Therapeutics, Inc., a privately-held organization focused on treating cancer through cell and gene therapies, Applied Stem Cell, a privately-held organization developing proprietary gene editing and stem cell technology platforms, and A-Alpha Bio, a privately-held organization focused on developing synthetic biotechnology and machine learning to accelerate drug development EDUCATION • B.S. in cell and molecular biology, M.S. in bioengineering, and M.B.A. from the University of Washington |
24 |
Alan Rubino, Independent Former Chief Executive Officer, Emisphere Technologies, Inc. Director Since: 2005 Other Current Public Company Directorships: • None Vericel Board committee(s): • Audit and Compensation (Chair) Committees | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• CEO/GM: Mr. Rubino possess a wealth of experience across multiple disciplines within the biotechnology and pharmaceutical industries. Mr. Rubino recently served for seven years as CEO of Emisphere Technologies, Inc., a publicly-traded drug delivery company, as well as CEO of RenovaCare, a publicly-held biotechnology company. • Marketing/Sales/Business Development: Mr. Rubino spent 24 years with Roche where he served as a member of the executive committee for ten years and presided over 30 product launches and brand marketing execution plans. He also had leading roles in the acquisitions of Syntex Labs and Boehringer-Mannheim. • Operations: Throughout his career, Mr. Rubino has provided enterprise-wide leadership over corporate, marketing, sales, supply chain and human resources management functions. | ||||||
PROFESSIONAL HIGHLIGHTS • President and Chief Executive Officer of RenovaCare, a publicly-held biotechnology company (2019-2021) • Chief Executive Officer of Emisphere Technologies, Inc., a publicly-held drug delivery company, which was acquired by Novo Nordisk for $1.8B (2012-2019) • Chief Executive Officer and co-founder of New American Therapeutics, Inc., which acquired Denavir from Novartis (New American was subsequently sold to Renaissance Pharma, LLC for a 49% IRR to investors) • Chief Executive Officer and co-founder of Akrimax Pharmaceuticals, LLC, where he in-licensed Tirosint from IBSA Institut Biochimique SA for the U.S. market | OTHER LEADERSHIP POSITIONS AND EXPERIENCES • Currently serves as Executive Chairman of the board of directors of AMO Pharma Limited, a privately-held UK-based company focused on special therapeutics for rare diseases (2021-present) • Former member of boards of directors of numerous public and privately-held organizations, including SANUWAVE Health, Inc., and Genisphere, Inc. EDUCATION • B.A. in economics from Rutgers University with a minor in biology/chemistry • Post-graduate educational programs at the University of Lausanne and Harvard Business School | |||||
Kevin Independent Former Chief Financial Officer and Treasurer, Acceleron Pharma Inc. Director Since: 2015 Other Current Public Company Directorships: • None Vericel Board committee(s): • Audit (Chair) Committee | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• BioPharma: Mr. McLaughlin has more than 40 years of operating management and financial experience spanning the biotech, high-tech and education industries. • Finance: Mr. McLaughlin served for 11 years as the Senior Vice President, Chief Financial Officer and Treasurer of Acceleron, Pharma Inc., until its acquisition by Merck & Co. in 2021. Prior to Acceleron, he served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company. | ||||||
PROFESSIONAL HIGHLIGHTS • Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma Inc., a publicly-traded biopharmaceutical company (2010-2021) • Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company (2009-2010) • Co-founder, Chief Operating Officer and a director of Aptius Education, Inc., a publishing company (2007-2009) • President and Chief Executive Officer and a member of the board of directors of PRAECIS Pharmaceuticals until its sale to GSK plc (formerly GlaxoSmithKline). Mr. McLaughlin joined PRAECIS as its first Chief Financial Officer and also served as Chief Operating Officer. | OTHER LEADERSHIP POSITIONS AND EXPERIENCES • Former member of the board of directors of Decibel Therapeutics, a clinical-stage and public biotechnology company dedicated to discovering treatments to restore and improve hearing and balance, which was acquired by Regeneron Pharmaceuticals in 2023 • Member of the board of directors of Combined Therapeutics, Inc., a privately-held company focused on the development of mRNA treatments EDUCATION • B.S. in business from Northeastern University and an M.B.A. from the F.W. Olin Graduate School of Business at Babson College |
2024 Proxy Statement | 25 |
Steven Gilman, Independent Retired Chairman and Chief Executive Officer, ContraFect Corporation Director Since: 2015 Other Current Public Company Directorships: • SCYNEXIS, Inc. • Akebia Therapeutics, Inc. Vericel Board committee(s): • Compensation Committee | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• BioPharma: Dr. Gilman has a wealth of leadership experience in the biopharmaceutical space, which has been developed while serving in senior roles across the industry. Dr. Gilman has served as the Chief Executive Officer at both ContraFect Corporation until his retirement in 2019, and earlier in his career at ActivBiotics, Inc., a privately-held biopharmaceutical company. • Research & Development/Technical Operations: In addition to his core management experience, Dr. Gilman has served in key Research and Development and Operations roles during his career. Notably, Dr. Gilman served as Executive Vice President, Research and Development and Chief Scientific Officer for five years at Cubist Pharmaceuticals, before the company’s acquisition by Merck & Co. in 2015. | ||||||
PROFESSIONAL HIGHLIGHTS • Chairman and Chief Executive Officer of ContraFect Corporation (2015-2019) • Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals (2010-2015) • Chairman and Chief Executive Officer of ActivBiotics, Inc., a privately-held biopharmaceutical company (2004-2007) • Vice President and General Manager, Inflammation, at Millennium Pharmaceuticals, Inc. • Group Director, Global Research and Development, Pfizer • Held scientific, business, and academic appointments at Wyeth Pharmaceuticals, Inc., Cytogen Corporation, Temple Medical School, and Connecticut College | OTHER LEADERSHIP POSITIONS AND EXPERIENCES • Former member of board of directors of the Massachusetts Biotechnology Association • Former member of the boards of directors of ContraFect Corporation and Momenta Pharmaceuticals, Inc. • Held advisory roles on the Penn State University biotechnology board and the Northeastern University drug discovery board EDUCATION • B.A. in microbiology from Miami University of Ohio • Ph.D. and M.S. in microbiology from Pennsylvania State University • Post-doctoral training at Scripps Clinic and Research Foundation |
26 |
Paul Wotton, Independent Executive Director and Chairman of the Board, Rice Biotech Launch Pad; Adjunct Professor, Rice University Director Since: 2015 Other Current Public Company Directorships: • Cynata Therapeutics Limited Vericel Board committee(s): • Governance and Nominating Committee | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• BioPharma/Complex Biologics/Business Development/Marketing and Sales: Dr. Wotton has served in key leadership roles across the pharmaceutical and biotech industries throughout his career and has been integral in a number of high-profile business development transactions during that period. While CEO of Obsidian Therapeutics, Inc., Dr. Wotton spearheaded key deals with Vertex Pharmaceuticals and M.D. Anderson, and earlier in his career, while CEO at Siglion Therapeutics, Inc., he oversaw the eventual acquisition of the company by Eli Lilly and Company. Dr. Wotton’s experiences provide key insight to the Vericel leadership team as the Company continues to investigate expanding its product portfolio with another highly-synergistic therapy. | ||||||
PROFESSIONAL HIGHLIGHTS • President and Chief Executive Officer and a board member of Obsidian Therapeutics, Inc., a privately-held company (2019-2022) • Founding President and Chief Executive Officer of Sigilon Therapeutics, Inc., a cell therapeutics company (2016-2019) • President and Chief Executive Officer and member of the board of directors of Ocata Therapeutics, Inc. (from July 2014 until its acquisition by Astellas Pharma US, Inc. in February 2016) • President and Chief Executive Officer and member of the board of directors of Antares Pharma, Inc., a publicly-traded biopharmaceutical company (2008-2014) • Held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme | OTHER LEADERSHIP POSITIONS AND EXPERIENCES • Chair of the board of directors of Kytopen, a privately-held biotechnology company focused on developing cellular and genome engineering platforms • Former member of the board of directors and Chairman of the compensation committee of Veloxis Pharmaceuticals A/S • Past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada • Named Ernst & Young Entrepreneur of the Year for Life Sciences, New Jersey, in 2014 EDUCATION • Bachelor’s in Pharmacy, with honors, from University College London • Ph.D. in pharmaceutical sciences from the University of Nottingham • M.B.A. from Kingston Business School |
2024 Proxy Statement | 27 |
Lisa Wright, 49 Independent President and Chief Executive Officer, Community Health Choice, Inc. Director Since: 2021 Other Current Public Company Directorships: • None Vericel Board committee(s): • Governance and Nominating Committee | KEY EXPERIENCE AND QUALIFICATIONS | |||||
• CEO/GM/Payer/Healthcare Operations: Ms. Wright is President and Chief Executive Officer of Community Health Choice, Inc., a managed care organization with approximately 430,000 members and a provider community consisting of over 10,000 physicians and 100 hospitals in the greater Houston area. She is an accomplished healthcare executive with a track record of strong strategic, operations and financial performance across a number of leading healthcare organizations. • Importantly, Ms. Wright brings to the Vericel Board key expertise in the payer and provider aspects of the healthcare system, which is bolstered by her deep understanding of healthcare economics and the full healthcare ecosystem. Her experiences will prove valuable as we continue our journey as a high-growth commercial business with multiple products with varied reimbursement models. | ||||||
PROFESSIONAL HIGHLIGHTS • President and Chief Executive Officer of Community Health Choice, Inc., a local, non-profit, Managed Care Organization (MCO), offering Children’s Medicaid (STAR), CHIP (Children’s Health Insurance Plan) and DSNP (Dual Special Needs Plan), and participant in the Health Insurance Marketplace (2020-present) • North Regional Medicare President for WellCare Health Plans (2018-2020) • President of the Dual Special Needs Plan, Medicare-Medicaid Plan and Nursing Facilities lines of business in Texas at UnitedHealthcare (2014-2018) • Began career in a variety of roles of increasing responsibility at Anthem | OTHER LEADERSHIP POSITIONS AND EXPERIENCES • Member of the boards of directors of several non-profit organizations in Houston EDUCATION • B.A. in communication from the University of Kentucky • M.B.A. from the University of Maryland |
28 |
The Governance and Nominating Committee will evaluate any recommendation for director nominees proposed by a shareholder whowho: (i) has continuously held at least 1% of the outstanding shares of our common stock entitled to vote at the annual meeting for at least one year by the date the shareholder makes the recommendation,recommendation; and (ii) undertakes to continue to hold the common stock through the date of the meeting. In order to be evaluated in connection with Vericel’s established procedures for evaluating potential director nominees, any recommendation for a director nominee submitted by a qualifying shareholder must be received by Vericel no later than 120 days prior to the anniversary of the date proxy statements were made available to shareholders in connection with the prior year’s annual meeting. Any shareholder recommendation for a director nominee must be submitted to the General Counsel and Secretary, in writing, at 64 Sidney St., Cambridge, Massachusetts 02139, and must contain the following information:
A statement by the shareholder that he/she is the holder of at least 1% of our common stock and that the stock has been held for at least one year prior to the date of the submission and that the shareholder will continue to hold the shares through the date of the annual | |
The candidate’s name, age, contact information and current principal occupation or | |
A description of the candidate’s qualifications and business experience during, at a minimum, the last five years, including the candidate’s principal occupation and employment and the name and principal business of any corporation or other organization at which the candidate was | |
The candidate’s |
The Governance and Nominating Committee will evaluate recommendations for director nominees submitted by directors, management or qualifying shareholders in the same manner, using the criteria stated above.
All directors and director nominees will submit a completed director and officer questionnaire as part of the nominating process. The process may also include interviews and additional background and reference checks for non-incumbent nominees, at the discretion of the Governance and Nominating Committee.
Corporate Governance
Board’s Role and Responsibilities
Overall Role of the Board of Directors
The Board is elected by the shareholders to oversee their interests in the long-term success of the Company. The Board serves as the ultimate decision-making body of the Company, except for those matters reserved to, or shared with, the shareholders. The core responsibility of a director is to fulfill his or her duties of care and loyalty and to otherwise exercise sound business judgment in the best interests of Vericel and its shareholders. The Board oversees the proper safeguarding of the Company’s assets, the maintenance of appropriate financial and other internal controls and the Company’s compliance with applicable laws and regulations and proper governance. The Board selects the Chief Executive Officer (“Chief Executive Officer” or “CEO”) and oversees the members of senior management, who are charged by the Board with conducting the business of the Company.
2024 Proxy Statement | 29 |
Oversight of Corporate Strategy | Oversight of Risk Management | Oversight of ESG and Human Capital Management | ||
|
|
•The Board oversees the creation and retention of a talented employee base
| ||
Our Board actively oversees management’s establishment and execution of corporate strategy, including major business and organizational initiatives, annual budget and long-term strategic plans, capital allocation priorities and corporate development opportunities. Our Board also reviews and approves strategic transactions, including significant investments, acquisitions and collaborations. At the Board and committee meetings and throughout the year, our Board regularly receives information and formal updates from our management and actively engages with the seniorexecutive leadership team with respect to our corporate strategy. The Board’s independent directors also hold regularly scheduled executive sessions at which strategic matters are discussed.
Corporate Governance
Board’s Role in the Oversight of Risk
ManagementManagement/Oversight
Vericel management is responsible for assessing and managing risk to the Company, subject to the oversight of the Board. The Board exercises its oversight responsibility directly and through its committees. The Board considers specific risk topics directly, such as risks associated with the Company’s overall strategy, including clinical, product development, and financing strategies, business continuity, crisis preparedness and corporate reputational risks. The Board is kept informed of the committees’ risk oversight activities through periodic reports to the Board. The Board and its committees meet regularly with members of management responsible for managing risk.
30 |
The committees of the Board of Directors execute their oversight responsibility for risk management as follows:
Audit Committee | Compensation Committee | ||
The Audit Committee has primary responsibility for overseeing risk associated with:
The Audit Committee also reviews transactions between Vericel and its officers, directors, affiliates of officers and directors or other related parties for conflicts of interest. The Audit Committee also receives regular reports and feedback from | |||
The Compensation Committee is responsible for overseeing risks related to Vericel’s cash and equity-based compensation programs and practices and ensuring that executive and employee compensation plans are appropriately structured so that they do not incentivize excessive risk-taking and are not reasonably likely to have a material adverse effect on Vericel. | |||
Governance and Nominating Committee | |||
The Governance and Nominating Committee is responsible for overseeing risks related to the composition and structure of the Board of Directors and its committees, | |||
Cybersecurity Risk Management | ||
Role of Management: • We have developed processes for assessing, identifying and managing material risks from cybersecurity threats. Our enterprise risk management system incorporates risks from cybersecurity threats alongside other risks to the Company. As part of this risk management system, our information technology team oversees and implements security controls designed to minimize the risk or impact of any breach or unauthorized disclosure of our confidential and sensitive data. These controls include security management, intrusion detection and monitoring applications, and multifactor authentication, among other mitigation efforts. • Our Executive Director, Corporate Information Systems, along with our General Counsel, Information Technology management team, and Chief Operating Officer, oversees our approach to cybersecurity and is responsible for assessing and managing our material risks from cybersecurity threats. In this role, our Executive Director, Corporate Information Systems has access to an external information security firm and an industry-leading intelligence platform and, leveraging these tools, monitors the prevention, detection, mitigation and remediation of cybersecurity incidents across the organization. • Throughout 2022 and 2023, management worked extensively with external consultants to evaluate the Company’s cybersecurity incident response planning framework and to develop an enhanced enterprise-wide incident response plan to be deployed in the event of, and to help mitigate the impact of, a cybersecurity incident. The Board was actively engaged in this endeavor and received periodic updates and reports concerning the Company’s progress. |
2024 Proxy Statement | 31 |
Board and Committee Updates: • The Audit Committee of Continuing Education: • The entire Board receives annual training |
Board of Directors | Governance and Nominating Committee | Management | ||
• Provides oversight of, and strategic guidance to, our executive leadership team on ESG topics • Is comprised of industry leaders with extensive and diverse experiences, which span various business, healthcare, and scientific areas | • Periodically reviews and oversees management of Vericel’s strategy, initiatives, risks, opportunities and related reporting with respect to significant ESG matters • Oversees corporate ESG matters as they pertain to the Company’s business and long-term strategy and identifies emerging trends and issues that may affect our operations, performance and external stakeholder relationships • Periodically receives updates on the Company’s ongoing and future ESG programs, products and disclosures, and the Company’s corporate social responsibility and diversity and inclusion programs and activities | • Management is tasked with executing on the Company’s ESG strategy and initiatives set by the Board. • Vericel’s commitment to ESG permeates all levels of the organization, whether it be our Company-level Diversity and Inclusion Advisory Committee, which is designed to further cultivate the diverse culture we have created at Vericel, or whether it be our operations team, which is tirelessly working to complete our new state-of-the-art manufacturing facility and corporate headquarters in Burlington, Massachusetts. |
32 |
The Board is actively engaged in overseeing the Company’s people and culture strategy. Our Board believes that human capital management and succession planning, including diversity and inclusionDE&I initiatives, are vital to Vericel’s continued success. OurDuring 2023, our Board remained keenly engaged with, and received periodic updates concerning the progress of, the Company’s Diversity and Inclusion Advisory Committee, which is tasked with enhancing diversity across the organization and cultivating a culture and environment that respects, supports and promotes people of all races, ethnicities, religions, nationalities, genders, sexual orientations, and all other qualities that make each of us unique. Additionally, our Board’s involvement in leadership development and succession planning is ongoing, and the Board provides input on important decisions in each of these areas. Our Board, with leadership from our Chairman, has primary responsibility for succession planning for the Chief Executive Officer and in talent retention and development programs for members of senior management. Our Compensation Committee performs an annual formal evaluation of the Chief Executive Officer, and our CEO, in consultation with the Governance Committee, recommends to the Board an emergency succession plan that covers such matters as the unexpected departure, disability or death of the CEO or other key members of senior management.
Corporate Governance
During 2021, the Board approved a specific ESG-related corporate goal for management, which was focused, in part, on enhancing diversity and inclusion initiatives at all levels of the organization. The Company executed on the Board’s direction during the past year, increasing diversity at the Board level, conducting robust diversity and inclusion training for our officers and managers, and establishing a Diversity and Inclusion Advisory Committee, with a direct line of communication to our Executive Leadership Team.
Human Capital Management Focus Areas
|
| Board Committees’ Responsibilities | |||
Our committees assist the Board with succession planning as follows: | |||||
• Our Board, with leadership from our Chairman, maintains primary responsibility for succession planning for the Chief Executive Officer and talent retention and development programs for members of senior management • In 2023, the Board, in conjunction with the Governance and Nominating Committee, reviewed a comprehensive plan that included the Company’s strategy to meet ongoing goals in the event of both planned and unforeseen vacancies at the director level and above, as well as the potential of such individuals to assume increased leadership in the organization | Governance and NominatingCommittee • At least annually, meets with our CEO to discuss succession planning for members of the executive management team • Considers the procedure for timely and efficient transfer of CEO responsibilities in the event of an emergency or the sudden incapacity, death, resignation or retirement of Mr. Colangelo, or the occurrence of any other event that would have a material impact on Mr. Colangelo’s ability to fulfill his job duties • In connection with its oversight of Emergency Succession planning, receives an assessment of the performance of members of senior management and their potential to assume the position of CEO and other key positions within the Company | Compensation Committee • Performs an annual formal evaluation of the CEO in consultation with the Governance and Nominating Committee |
2024 Proxy Statement | 33 |
|
Corporate Governance
Management Succession Planning
At least annually, the Governance Committee meets with our CEO to discuss succession planning for the executive management team. The Governance Committee also considers the procedure for timely and efficient transfer of CEO responsibilities in the event of an emergency or the sudden incapacity, death, resignation or retirement of Mr. Colangelo, or the occurrence of any other event that would have a material impact on Mr. Colangelo’s ability to fulfill his job duties.
Oversight of Environmental, Social and Governance Matters
Our Governance Committee periodically reviews and oversees management of Vericel’s strategy, initiatives, risks, opportunities and related reporting with respect to significant ESG matters. In that connection, the Governance Committee oversees corporate ESG matters as they pertain to the Company’s business and long-term strategy and identifies emerging trends and issues that may affect our operations, performance and external stakeholder relationships. Importantly, the Governance Committee periodically receives updates on the Company’s ongoing and future ESG programs, products and disclosures, the Company’s progress and performance against ESG goals and the Company’s corporate social responsibility and diversity and inclusion programs and activities.
Code of Ethics
TheIn 2023, the Board of Directors has adoptedoversaw a comprehensive review and revision of the Company’s Code of Business Conduct and Ethics, thatwhich applies to all of our employees, officers and directors, and which sets the bedrock principles of our Patients First mission, including expectations for integrity, compliance and ethical conduct in everything we do as well asa business. The Company also maintains a separate Code of Ethics for Senior Financial Officers. These documents are available on the Investor Relations page of our website, www.vcel.com. We will also make information related to any amendments to, or waivers from, these Codes of Ethics available on the website as required by law.
Corporate Governance
Board Leadership Structure
The Board of Directors does not have a formal policy on whether the positions of CEO and Chairperson of the Board should be separate or united, but rather will make that determination from time to time in its judgment. The Chairperson of the Board is currently an independent director, but if the Chairperson of the Board is not independent, the Board will appoint an independent lead director. The Chairperson of the Board shall preside at all meetings of the Board and the shareholders, and shall perform such other duties, and exercise such powers, as prescribed by the Bylaws or by the Board, from time to time. If the Chairperson of the Board is not independent and a lead director has been appointed, he or she shall preside at executive sessions of the independent directors and will bear such further responsibilities as the Board may designate from time to time. Currently, Dr. Zerbe serves as the Board’s independent Chairman.
The independent members of the Board of Directors have periodically reviewed this leadership structure and believe it is appropriate for Vericel at the current time. The CEO is responsible for setting the strategic direction for Vericel, as well as the day-to-day leadership and performance of the Company, while the Chairman of the Board of Directors provides guidance to the CEO and sets the agenda for, and presides over, meetings of the full Board of Directors. The CEO and Chairman of the Board of Directors provide leadership to the Board and work with it to define its structure and activities in the fulfillment of its responsibilities. The Chairman of the Board of Directors presides over executive sessions, and ensures that no conflict of interest arises between management and the functions of the Board of Directors, and facilitates communication among the directors. The Chairman of the Board and the CEO work together to provide an appropriate information flow to the Board, and the Chairman works with other Board members to provide strong, independent oversight of Vericel’s management and affairs. Thus, the Board of Directors believes that the current structure balances the needs for the CEO to run Vericel on a day-to-day basis with the benefit provided to Vericel by significant involvement and leadership of an independent Chairman of the Board of Directors.
The Board of Directors has affirmatively determined that all of the members of the Board and each director nominee, other than Mr. Colangelo, are independent within the meaning of the director independence standards of Nasdaq and the SEC. Mr. Colangelo is not considered independent because of his current employment as the President and CEO of Vericel. There are no family relationships between any of our directors, persons nominated or chosen to be a director or an officer and any of our executive officers.
Applicable Nasdaq listing standards require that the independent directors meet from time-to-time in executive session.sessions. In fiscal year 2021,2023, our independent directors met in regularly scheduled executive sessions with only independent directors present at each Board and committee meeting.
34 |
Corporate Governance
Committees of the Board
Audit Committee
Audit Committee |
Kevin McLaughlin Chairperson
Alan Rubino Robert Zerbe, M.D.
| RESPONSIBILITIES Under the terms of its current
The Audit Committee may delegate duties or responsibilities to subcommittees or to one member of the Audit Committee. During the fiscal year ended December 31, PAST-YEAR HIGHLIGHTS In addition to its important oversight of Vericel’s financial statements and of our independent registered public accounting firm, during |
Compensation Committee
2024 Proxy Statement | 35 |
Compensation Committee |
Alan Rubino Chairperson
Heidi Hagen Steven Gilman, Ph.D.
| RESPONSIBILITIES Under the terms of its current
In carrying out these responsibilities, the Compensation Committee reviews all components of executive officer compensation for consistency with the Committee’s compensation philosophy and strategy as well as relevant compensation guidelines. The Compensation Committee may delegate duties or responsibilities to subcommittees or to one member of the Committee. During the fiscal year ended December 31, PAST-YEAR HIGHLIGHTS During 2023, the Compensation Committee approved of certain amendments to its Charter to reflect its administration and oversight of the Company’s Deferred Compensation Plan, which was adopted in May of 2023. The Deferred Compensation Plan, which is discussed in more detail on page 57 is limited to non-employee directors and a select group of management or highly compensated employees at the Company. |
36 |
Governance and Nominating Committee |
Corporate Governance
Governance and Nominating Committee
Chairperson
| RESPONSIBILITIES Under the terms of its current
Consistent with this function, the Governance and Nominating Committee encourages continuous improvement of, and fosters adherence to, our corporate governance policies, procedures and practices at all levels. The Governance and Nominating Committee may delegate duties or responsibilities to subcommittees or to one member of the Governance and Nominating Committee. During the fiscal year ended December 31, PAST-YEAR HIGHLIGHTS As part of the Board’s regular governance enhancement process, in 2023, the Governance and Nominating Committee |
Corporate Governance
Board Practices, Policies and Processes
History of Commitment to Good Governance Practices
Board Practices | ||||
• Non-employee members meet in executive session without management at each regularly scheduled Board and committee meeting
|
• Board performance evaluations and assessment of
| Shareholder Rights • No active Shareholder Rights Plan • Robust stock ownership guidelines that apply to our directors and named executive officers and with which each of our directors and officers were in compliance as of December 31, 2023 |
|
During the fiscal year ended December 31, 2021,2023, the Board of Directors held eight (8)seven (7) meetings. Each director serving on the Board of Directors during 20212023 attended at least 85% of the meetings of the full Board, and all but one director attended 100% of such meetings. Each member of the Board of Directors attended 100% of the meetings of the committees on which he or she served.
The Board of Directors has adopted a Board Member Attendance at Annual Meetings Policy. This policy is available on the Investor Relations page of our website, www.vcel.com. All of the directors then in office attended our 20212023 annual meeting of shareholders, which was held in April 2021May 2023 and conducted in a virtual, audio webcast format due to restrictions related to the COVID-19 pandemic.format.
Our relationship with our shareholders is an important part of our corporate governance program. Engaging with shareholders helps us to understand how they view the Company, set goals and expectations for our performance and identify emerging issues that may affect our strategies, corporate governance, compensation practices or other aspects of our operations. The Board of Directors has adopted a Shareholder Communications with Directors Policy to inform shareholders how they may pose questions or communicate their views to our Board of Directors. The Shareholder Communications with Directors Policy is available on the Investor Relations page of our website, www.vcel.com.
Corporate Governance
Director Continuing Education
The Board of Directors recognizes the importance of ensuring that its members are continuously updated on matters of importance to its oversight of the Company from both an internal and external perspective. The Governance and Nominating Committee maintains responsibility for determining issues and subject matter areas that require further education for Board members, whether because of external developments or changes in Company direction. During 2021,2023, the Board of Directors received education from Vericel’s General Counsel and outside advisors in the areas of cybersecurity sustainability, and ESG matters.SEC compliance.
The Board of Directors is committed to upholding the highest legal and ethical conductstandards in fulfilling its responsibilities and recognizes that related-party transactions can present a heightened risk of potential or actual conflicts of interest. Accordingly, and as a general matter, it is Vericel’s preference to avoid related-party transactions.
Our Audit Committee has primary responsibility for reviewing and approving in advance, or ratifying, all related-party transactions. In conformance with SEC regulations, we define related persons to include our executive officers, our directors and nominees to become directors of our Company, any person who is known to us to be a beneficial owner of more than 5% of any class of our voting securities, any immediate family member of any of the foregoing persons, and any firm, corporation or other entity in which any of the foregoing persons is employed, is a general partner or in which such a person has a 5% or greater beneficial ownership interest.
We have several processes that we use to ensure that we identify and review all related-party transactions. First, each executive officer is required to notify either our General Counsel or Chief Financial Officer of any potential transaction that could create a conflict of interest, and the General Counsel or Chief Financial Officer is required to notify the Audit Committee of the potential conflict. The directors, President and Chief Executive Officer, Chief Financial Officer and General Counsel are required to notify the Audit Committee of any potential transaction that could create a conflict of interest. Second, each year, we require our directors and executive officers to complete directors’ and officers’ questionnaires identifying any transactions with us in which the executive officer or director or their family members have an interest.
The Audit Committee reviews related-party transactions due to the potential for such transactions to create a conflict of interest. A conflict of interest occurs when an individual’s private interest interferes, or appears to interfere, with our interests. Our Board and its committees only approve a related-party transaction if it is determined that a transaction is in the best interests of shareholders or is at least not inconsistent with those interests. This includes situations where the Company may obtain products or services of a nature, quantity or quality, or on other terms, that are not readily available from alternative sources or when the transaction is on terms comparable to those that could be obtained in arm’s length dealings with an unrelated party. There were no such reportable relationships or related party transactions during the fiscal year ended December 31, 2021.2023.
Our directors play a critical role in guiding our strategic direction and overseeing the management of Vericel. The many responsibilities and risks and the substantial time commitment of being a director require that we provide adequate compensation commensurate with our directors’ workload and opportunity costs. Our philosophy is to provide competitive compensation necessary to attract and retain high-quality non-employee directors and appropriately compensate them for the time, expertise and effort required to serve as a director of a commercial stage, publicly-traded company that operates in a dynamic and highly-regulated industry. Non-employee directors receive a combination of annual cash retainers and stock option and RSU grants in amounts that correlate to their responsibilities and levels of Board participation, including service on Board committees. At least every three (3) years, the Compensation Committee engages an independent consultant to perform an analysis of the non-employee director compensation program. In Table ofBack to Contents Corporate GovernanceCompensation of Directors
2021,2023, the Compensation Committee engaged Frederic W. Cook & Co., Inc. (“FW Cook”) to perform an independent review of the compensation program for non-employee directors.How Our Director Compensation Program Aligns with Long-Term Shareholder Interests
Focus on Equity Compensation | Stock Ownership Guidelines | |
A substantial portion of non-employee director compensation is in the form of equity | In 2021, the Board adopted Stock Ownership Guidelines applicable to all non-employee directors The share ownership target for each non-employee director is share value equating to three times (3x) his or her annual cash retainer As of December 31, 2023, all non-employee directors were in compliance with their respective stock ownership targets |
2024 Proxy Statement | 39 |
The director compensation table reflects all compensation awarded to, earned by or paid to our non-employee directors for the fiscal year ended December 31, 2021.2023.
Name | Fees Earned or Paid in Cash ($) | Stock Awards ($)(1) | Option Awards ($)(2) | Total ($) | ||||
Robert L. Zerbe | 87,500 | 164,372 | 258,723 | 510,595 | ||||
Kevin F. McLaughlin | 67,500 | 164,372 | 258,723 | 490,595 | ||||
Alan L. Rubino | 72,375 | 164,372 | 258,723 | 495,470 | ||||
Heidi Hagen | 64,875 | 164,372 | 258,723 | 487,970 | ||||
Paul K. Wotton | 52,500 | 164,372 | 258,723 | 475,595 | ||||
Steven C. Gilman | 54,875 | 164,372 | 258,723 | 477,970 | ||||
Lisa Wright(3) | 36,113 | 206,245 | 328,268 | 570,626 |
Director(1) | Fees Earned or Paid in Cash ($) | Stock Awards ($)(2) | Option Awards ($)(3) | Total ($) | ||||
Robert L. Zerbe(4) | 97,500 | 102,784 | 154,357 | 354,641 | ||||
Kevin F. McLaughlin | 70,000 | 102,784 | 154,357 | 327,141 | ||||
Alan L. Rubino | 76,875 | 102,784 | 154,357 | 334,016 | ||||
Heidi Hagen | 67,500 | 102,784 | 154,357 | 324,641 | ||||
Paul K. Wotton | 55,000 | 102,784 | 154,357 | 312,141 | ||||
Steven C. Gilman | 57,500 | 102,784 | 154,357 | 314,641 | ||||
Lisa Wright | 55,000 | 102,784 | 154,357 | 312,141 |
(1) | As permitted by SEC rules, Mr. Colangelo’s compensation from the Company for 2023 is set forth in the 2023 Summary Compensation Table. Mr. Colangelo did not receive any additional compensation for his service as a director. |
(2) | Amount reflects the grant date fair value of awards of time-based RSUs made to the named director in |
Amount reflects the grant date fair value of stock option awards made to the named director in | |
Additionally, non-employee directors held the following unvested RSUs and unexercised stock options as of |
Additionally, non-employee directors held the following unvested RSUs and unexercised stock options as of December 31, 2021:
Director | Stock Awards | Shares Underlying Stock Options | Stock Awards | Shares Underlying Stock Options | ||||
Robert L. Zerbe | 2,600 | 63,250 | 3,200 | 71,750 | ||||
Alan L. Rubino | 2,600 | 110,750 | 3,200 | 119,250 | ||||
Heidi Hagen | 2,600 | 101,750 | 3,200 | 116,250 | ||||
Steven C. Gilman | 2,600 | 55,250 | 3,200 | 69,750 | ||||
Kevin F. McLaughlin | 2,600 | 102,750 | 3,200 | 117,250 | ||||
Paul K. Wotton | 2,600 | 6,500 | 3,200 | 21,000 | ||||
Lisa Wright | 3,651 | 9,127 | 3,634 | 23,627 |
Fees Earned or Paid in Cash.Cash. The Chairman of the Board of Directors receives an annual fee of $90,000 (increased from $80,000 effective as of April 28, 2021) paid in equal quarterly increments and does not receive additional fees for service as a member of the Board of Directors or as an individual committee member. Each other non-employee director receives an annual fee of $50,000 (increased from $40,000 effective as of April 28, 2021) paid in equal quarterly increments. The chairperson of each standing committee receives an additional annual fee of $20,000 for the Audit Committee, $15,000 (increased from $14,500 effective as of April 28, 2021)$17,500 for the
Corporate Governance
Compensation Committee and $10,000 for the Governance and Nominating Committee. Effective as of April 28, 2021, theThe non-chair members of the Audit Committee each receivesreceive an additional $10,000 annual fee, each non-chair committee member of the Compensation Committee receives an additional $7,500 (increased from $7,000 effective as of April 28, 2021) annual fee and each non-chair committee member of the Governance and Nominating Committee receives an additional annual fee of $5,000, in each case payable quarterly.
Equity Awards.Awards. Under Vericel’s Amended and Restated 20192022 Omnibus Incentive Plan (the “2019“2022 Plan”) and Vericel’s Amended and Restated Non-Employee Director Compensation Guidelines, each non-employee director who continues to serve beyond an annual meeting receives a stock option to purchase 6,5008,000 shares (decreased from 13,125 shares effective as of April 28, 2021) granted on the date of each annual meeting, with an exercise price equal to the fair market value of our common stock on the date of grant, and a grant of 2,600 RSUs (increased from 1,750 RSUs effective as of April 28, 2021).3,200 RSUs. Each non-employee director with the exception of Ms. Wright, received a stock option to purchase 6,5008,000 shares and a grant of 2,6003,200 RSUs at the 20212023 annual meeting. Such stock options vest in equal monthly increments over a period of one year, subject to continued service through the applicable vesting dates. The RSUs vest on the earlier of the first anniversary date of the RSU grant or the date of the first annual meeting following the grant, subject to continued service through the vesting date. Newly-elected directors joining the Board of Directors during the period between annual meetings receive a grant representing a pro-rata amount of the shares subject to the option (reflecting the period of time until the next annual meeting) and a pro-rata amount of the annual RSUs awarded (reflecting the period of time until the next annual meeting). Unless the non-employee director elects deferred settlement, the RSU grant will settle on vesting.
40 |
In addition, each future non-employee director who joins the Board of Directors will also receive a one-time initial stock option to purchase 3,2504,000 shares (decreased from 17,500 shares effective as of April 28, 2021) on the date of such director’s appointment, which will vest in equal monthly installments over three years, subject to continued service through the applicable vesting dates and a one-time initial grant of 1,3001,600 RSUs, (newly added effective as of April 28, 2021), which will vest in 1/3 annual increments over the course of three years, subject to continued service through the applicable vesting dates. Ms. Wright was appointed to the Board on June 1, 2021. Accordingly, in addition to the aforementioned one-time initial grants, as a newly-appointed director she received pro-rata grants of an option to purchase 5,877 shares of common stock and 2,351 RSUs at the time of her appointment, reflecting the period of time until Vericel’s next annual meeting. These equity grants were made under the terms of Vericel’s then-existing equity compensation plans, as previously approved by the shareholders. Stock options issued to directors shall terminate and may no longer be exercised after the first to occur of (a) the expiration date of the option, (b) 24 months after the date on which the director’s service with Vericel is terminated, or (c) a change-in-control to the extent provided in the stock option agreement. Non-employeeUnder the terms of the Company’s Deferred Compensation Plan, which was adopted May 3, 2023, non-employee directors have the ability under Vericel’s Non-Employee Director Deferred Compensation Program, to elect to receive RSUs upon vestingdefer payment of all or a portion of their annual fees and/or defer settlement of all or a portion of their grant of RSUs. RSUs with a deferred settlement. A non-employee director must elect to defer the receipt of a RSU grant by December 31st of the year prior to the grant and during an open-trading window; provided, however, newly elected non-employee directors must make an election within thirty (30) days of joining the Board. RSUs with deferred settlement are subject to vesting, but the shares are not issued until the deferred settlement date. A non-employee director must make an election to defer his or her annual fees and/or RSU grant by December 31 of the year prior to the year such amounts will be earned, or such grants made. In addition, a deferral election for the RSU grant must be made during an open-trading window. Newly elected non-employee directors must make an election within thirty days of joining the Board. A non-employee director may elect to defer payment of the annual fees and/or grant of RSUs until a date specified in the non-employee director’s election. The deferred annual fees and/or grant of RSUs will be paid or settled on the earlier of (i) the date specified in the non-employee director’s separation fromelection, (ii) the termination of the non-employee director’s service withto Vericel (including due to death), (iii) the non-employee director becoming disabled, or (ii)(iv) a change-in-control, as defined in the 20192022 Plan. Further, under the Non-Employee Director Deferred Compensation Program,Plan, upon the occurrence of such event, the amounts credited in the non-employee director’s account shall be paid in cash and/or shares of stock, as applicable, as soon as practicable, but in no event after the last day of the calendar year in which the distribution event occurs or two and one-half months after the event occurs, whichever comes later.occurs.
New
The Board believes that both non-employee directors and the Company’s named executive officers should maintain a meaningful equity interest in the Company to promote the Company’s long-term interests, achieve strategic goals, and further align shareholder and executive interests. Accordingly, inIn April 2021, the Board adopted Stock Ownership Guidelines pursuantapplicable to whichnon-employee directors. Pursuant to these guidelines, non-employee directors and named executive officers are expected to meet share ownership targets that are determined based on their annual retainer or annual salary, respectively, within five years of the adoption of the guidelines. In addition, non-employee directors and named executive officers who join the Board or the Company after the establishment of the guidelines have five years from such date to reach their target. Pursuant to the guidelines, the share ownership target for the directors is three times (3X) their annual cash retainer. The share ownership target for the Company’s CEOnon-employee directors is fivethree times (5X) his base salary, while other named executive officers have a target(3x) their annual retainer, and as of two times (2X)December 31, 2023, all non-employee directors are in compliance with their respective base salaries.stock ownership targets.
Executive | |
PROPOSAL 2: | ||||||
Advisory Vote to Approve the Compensation of Our Named Executive Officers | The Board of Directors unanimously recommends a vote FORthe approval of this resolution. | |||||
Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), this proposal gives our shareholders the opportunity to vote to approve or not approve, on an advisory basis, the compensation of our named executive officers. This is commonly known, and referred to herein, as a “say-on-pay” proposal or resolution. Under Section 14A(a)(1) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), generally, each public company must submit a say-on-pay proposal to its shareholders not less frequently than once every three years. We intend to hold an advisory vote to approve the compensation of our named executive officers annually, until at leastand as outlined in Proposal 3 of this Proxy Statement, the Board of Directors unanimously recommends that shareholders approve of holding future advisory votes to approve executive compensation on an annual basis. Following this year’s vote, the next advisory vote on the frequency of such advisory say-on-pay votes which will occur no later than our 20242030 annual meeting.
As discussed under the Compensation Discussion and Analysis (“CD&A”) below, we believe that our executive compensation programs emphasize sustainable growth through a pay-for-performance orientation and a commitment to both operational and organizational execution. We believe that the compensation program for our named executive officers was instrumental in helping us achieve strong strategic and financial performance in 2021, notwithstanding the continued and wide-ranging impacts of the COVID-19 pandemic.2023.
We are asking our shareholders to vote “FOR” the following resolution at our Annual Meeting:
“RESOLVED, that the compensation paid to Vericel’s named executive officers, as disclosed in this Proxy Statement pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion, is hereby APPROVED.”
We are asking shareholders to indicate their support for our named executive officers’ compensation as described in this Proxy Statement. This vote is not limited to any specific item of compensation, but rather addresses the overall compensation of our named executive officers and our philosophy, policies and practices relating to their compensation as described in this Proxy Statement pursuant to Item 402 of Regulation S-K.
The say-on-pay resolution is advisory, and therefore will not have any binding legal effect on Vericel, the Board of Directors or the Compensation Committee. However, the Board of Directors and the Compensation Committee value the opinions of our shareholders and intend to take the results of the vote on this proposal into account in its future decisions regarding the compensation of our named executive officers. Abstentions and broker non-votes will have no effect on this Proposal 2. If you sign and submit your proxy card without marking your voting instructions, your shares will be voted “FOR” Proposal 2.
We believe that our compensation program for our named executive officers is in the best interests of Vericel and the Company’s shareholders.
Dominick President and Chief Executive Officer Dominick Joe Mara Chief Financial Officer Joe Mara, age Michael Halpin Chief Operating Officer Michael Halpin, age Table ofBack to Contents Executive CompensationVericel’s Executive Officers
C. Colangelo C. Colangelo, age 58,60, joined Vericel in 2013 with more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development, and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received his B.S.B.A. in Accounting, Magna Cum Laude,, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law. 47,49, joined Vericel in January 2021 with more than 20 years of financial, strategic and operational experience, including more than 14 years of experience in the biotech industry. Prior to joining Vericel, Mr. Mara served as Vice President, Finance and Head of Investor Relations at Biogen Inc. While at Biogen, Mr. Mara held several finance leadership roles, including Vice President, Global Financial Planning and Analysis and Strategic Corporate Finance and Vice President, U.S. Finance and Operations. Mr. Mara worked across the entire Biogen organization in roles of increasing responsibility within Finance, including R&D, Corporate Finance, Corporate Strategy and Commercial operations, supporting company strategy, business development and several commercial launches. Prior to joining Biogen, Mr. Mara held finance and strategy roles in the financial services and technology industries, including at Thomson Reuters Corporation and Fidelity Investments. Mr. Mara earned a B.A. degree in Economics and International Studies from Northwestern University and an M.B.A. from the Sloan School of Management at M.I.T. 60,62, joined Vericel in April of 2017 with overmore than 28 years of regulatory, quality assurance, and clinical research experience with a variety of medical device, combination product, small molecule, biologic, and advanced therapy technologies. Prior to joining Vericel, Mr. Halpin was with Sanofi and Genzyme Corporation, most recently as Vice President, North American region regulatory head with responsibility for Sanofi Genzyme’s rare disease, immuno-inflammatory, multiple sclerosis and other business unit products. Mr. Halpin has also served as Vice President, Regulatory Affairs for Genzyme’s biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Carticel®, Epicel, and MACI. Prior to Genzyme, Mr. Halpin held a number of regulatory, quality, and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard, and Abiomed, Inc. Mr. Halpin received his master’s degree in biomedical engineering and bachelor’s degree in biochemistry from the University of Virginia.2024 Proxy Statement 43 38Executive CompensationBack to Contents
Sean Senior Vice President, General Counsel and Secretary | ||
Sean Flynn, age | ||
Dr. Jonathan Hopper Chief Medical Officer | ||
Jonathan Hopper, age |
The Compensation Committee of our Board of Directors, which is comprised solely of independent directors as defined by Nasdaq outside directors as defined by Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), and non-employee directors as defined by Rule 16b-3 of the Exchange Act, has been delegated the authority and responsibility to review and determine (and in the case of our CEO,Chief Executive Officer, Mr. Colangelo, recommend for approval by the Board of Directors) the compensation packages of our executive officers. The individuals who served as our named executive officers during fiscal year 2021 are those individuals listed in the “2021 Summary Compensation Table” below. Other information concerning the structure, roles and responsibilities of our Compensation Committee is set forth in the “Board Meetings and Committees—“Committees of the Board—Compensation Committee” section of this Proxy Statement.
A discussion of the policies and decisions that shape our executive compensation program, including the specific objectives and elements, is set forth below.
This CD&A focuses on the compensation for our CEO, each person who served as our Principal Financial Officer, during 2021 and our three other most highly compensated executive officers. Collectively, these officers are referred to as the named executive officers or NEOs. At times during 2021, both Joe Mara, our Chief Financial Officer, and Sandra Pennell, our former Vice President and Controller served as Principal Financial OfficerOur NEOs for the Company. Ms. Pennell served as the Company’s Principal Financial Officer and Principal Accounting Officer between September 30, 2020, and January 25, 2021. Following Mr. Mara’s appointment as Chief Financial Officer and Principal Financial Officer in January 2021, Ms. Pennell continued to serve as Vericel’s Principal Accounting Officer until her resignation of employment with Vericel in July 2021.2023 are:
Michael Halpin |
Sean Flynn |
Jonathan Hopper |
44 |
Our Approach to Compensation
Executive Compensation Objectives and Philosophy
The objectives of our executive compensation program are to attract, retain and motivate talented executives who are critical tofor the continued growth and success of Vericel and to align the interests of these executives with those of our shareholders. As such, our executive compensation program seeks to focus our leadership team on those key metrics that are critical drivers for executing on the Company’s strategy and achieving long-term sustainable growth. We foster a “pay-for-performance”pay-for-performance culture by setting metrics in our incentive compensation plans that reflect our business plan, the operating framework for achieving it and the goals we communicate to investors. We set target performance levels that are challenging but achievable and are aligned with our strategy and our longer-term financial outlook. To this end, our compensation programs for executive officers are designed to achieve the following objectives:
Attract talented and experienced executives to join Vericel | Motivate, reward and retain executives whose knowledge, skills and performance are critical to our success | Focus executive behavior on the achievement of our corporate mission and short-term and long-term corporate objectives and strategy | |||||||||
Maintain a culture of “pay-for-performance” | Ensure fairness among the executive management team by recognizing the contributions each executive makes to our success | Align the interests of management and shareholders by providing management with longer-term incentives through equity ownership | |||||||||
We also strive to provide an effective mix of compensation elements, including providing an appropriate balance between current and long-term compensation and between cash and equity incentive compensation. Cash payments are primarily aligned with and reward short-term performance, while equity awards encourage our named executive officers to deliver sustained strong results over multi-year performance periods, thereby encouraging strong performance, ensuring fairness among the executive management team by recognizing the contributions each executive makes to our success, supporting our talent attraction and retention objectives, and fostering alignment with investors.
Elements of Compensation
CEO | Other NEOs | |
Performance Metrics That Determine Our Variable Compensation and Their Relation to Our Strategy
Vericel is a high-growth commercial-stage company with a portfolio consisting of two commercial products, MACI and Epicel, which are currently sold in the U.S. market, and a development stage asset, NexoBrid, for which a BLA resubmission to the FDA is planned for mid-2022. Our objective is to become the leading developer of advanced therapies and specialty biologics for the sports medicine and severe burn care markets. In pursuing this strategy, we seek to increase our commercial product revenue by increasing the number of surgeons implanting MACI, the average number of MACI procedures each such surgeon performs and expanding the number of burn centers consistently using Epicel. Additionally, it is our objective to increase profits and operating cash flow that we are generating through product improvements and other strategies. We also are focused on helping secure the approval of NexoBrid by the FDA and adding it to our commercial portfolio in the near future.
Our executive officers’ performance metrics have been designed by the Compensation Committee of our Board of Directors, with the approval of the full Board. Those metrics consist of financial targets, as well as product, operational, ESG and upside value goals in order to focus our management on advancing our overall corporate strategy and furthering both the short- and long-term growth of the Company. During 2021, those performance metrics consisted of the following targets:
Executive Compensation
2024 Proxy Statement | |||
OUR STRATEGYVericel is a high-growth commercial-stage biopharmaceutical company, which markets two autologous cell therapy products, MACI and Epicel, and one specialty biologic product, NexoBrid, in the United States. Our objective is to become the leading developer of advanced therapies for the sports medicine and severe burn care markets. In pursuing this strategy, we seek to increase our commercial product revenue by increasing the number of surgeons implanting MACI, increasing the average number of MACI procedures each such surgeon performs, expanding the clinical indications for which the MACI procedure is approved, and optimizing the ease of use of the MACI procedure for surgeons through, among other efforts, developing and potentially commercializing an arthroscopic delivery method for MACI. Additionally, we seek to increase our Burn Care revenues by expanding the number of burn centers and surgeons consistently using Epicel and NexoBrid, and achieving the long-term growth of NexoBrid in the U.S. market. |
2021 Performance Impact on Executive Pay
Led by its executive management team, Vericel delivered strong results during 2023, as the Company achieved strong performance during 2021 across a varietyrecord full-year commercial revenues of metrics. The Company recorded commercial revenue of $156.2$197.5 million, representing revenue growth of 26% compared20% for the year. Vericel’s MACI commercial team performed exceptionally well, securing record full-year MACI revenues of $164.8 million, representing 25% growth for the year. MACI’s continued upward trajectory was driven by strong business fundamentals. During the fourth quarter of 2023, the Company experienced the highest number of MACI implants, implanting surgeons, surgeons taking MACI biopsies and biopsies as in any quarter since the launch of the product. The commercial team’s execution during 2023 helped increase surgeon adoption of MACI and expand our surgeon customer base as the Company drove double-digit growth in surgeons taking biopsies in 2023. Epicel revenues were $31.6 million for the year, and we were pleased to 2020,see the continued strong utilization of this lifesaving product, which is consistentcontinues to be an important component of a burn surgeon’s armamentarium for treatment of the most severely burned patients in the United States.
Importantly, in 2023 we were successful in expanding our Burn Care franchise with the approximate 25% compounded annual growth rate we have achieved since the commercial launch of MACI in 2017. The Company’s 2021 commercialNexoBrid during the fourth quarter. NexoBrid is an innovative treatment for burn patients, and financial performance was accomplished notwithstanding the ongoing impacts of the COVID-19 pandemic, which caused disruptions across the healthcare industry, including restrictions on the performance of elective surgical procedures, like MACI, at various points throughout the year. Ultimately, we were able to drive full-year net revenue growth for both MACI and Epicel, securing record volumes for both products. Record full-year MACI revenue totaled $111.6 million, representing growth of 18% over 2020. Although the impacts of the COVID-19 pandemic caused total net revenue to fall short of the Company’s full-year goal,significantly expands our MACI commercial team’s perseverance helped the Company achieve its goal of growing the number of surgeons taking MACI biopsies by 20%, while also driving biopsy growth of 30% for the full year. This strong biopsy growth was also driven by an increase in biopsies per surgeon of approximately 10%, another important indicator of the core strength of the MACI business.
We also reported record full-year Epicel revenue of $41.5 million, representing 51% growth compared to 2020. Epicel’s outstanding performance was driven by strong execution from ouraddressable burn care team, which helped drive a significant increase in bothmarket as we move into 2024. NexoBrid is highly synergistic with Epicel and NexoBrid’s addition to our commercial portfolio significantly expands the numbersegment of hospitalized burn centers utilizing Epicel, as well as an increasepatients in the numberU.S. that we will be targeting moving forward. We believe that this larger share of voice in the burn care market will drive both NexoBrid uptake and increased Epicel grafts that were appropriately utilized per patient.utilization.
Ultimately, the ability of our teamcommercial teams to adapt and execute in an extremely challenging environment,across our disciplined approach toproduct portfolio, along with continued expense management, and our significant efforts to protect the health and well-being of our critical production employees during 2021 allowed Vericel to help treat more patients with knee cartilage injuries and severe burns than ever. We also generatedgenerate approximately $29.5$34 million of adjusted EBITDA* and grew, representing full-year adjusted EBITDA growth of 40%. We continued to grow our cash, restricted cash and investments balance by approximately $29 million in 2021, ending2023, notwithstanding capital expenditure investments associated with our new facility, which is under construction. We ended the year with $129$152.6 million in cash, restricted cash, and investments and no debt.
In addition to generating strong financial results, Vericel also made significant progress advancing our pipeline during 2023, highlighted by our completion of a human factors study of an arthroscopic method for the delivery of MACI in the knee, and the FDA’s subsequent acceptance of a prior approval supplement, which seeks to add instructions for arthroscopic delivery of MACI to the product’s approved labeling. We believe that MACI Arthro will be an attractive alternative for both patients and surgeons and help drive MACI’s growth, while at the same time allowing more patients to benefit from receiving MACI. We anticipate the potential launch of MACI Arthro in Q3 of 2024. Additionally, our clinical and regulatory teams made additional progress advancing our MACI Ankle program and helped secure the FDA’s acceptance of a supplemental BLA for a new pediatric indication for NexoBrid in the United States.
* | For more information concerning Vericel’s presentation of non-GAAP measures, including a reconciliation of reported net (loss) income (GAAP) to adjusted EBITDA (non-GAAP), please refer to the Company’s discussion of “GAAP versus non-GAAP Measures”, on page |
46 |
TableConsideration of
Contents
Executive Compensation
At the same time, we were able to advance our long-term product and operational objectives, completing key long term brand development initiatives and manufacturing facility and information technology improvement efforts. The Vericel clinical and regulatory teams, in partnership with MediWound, are focused on addressing the questions raised by the FDA in its complete response letter concerning NexoBrid, and remain on track to resubmit the NexoBrid BLA in mid-2022, which, if approved, would position us for a potential launch of the product in early 2023.
Finally, during 2021, the Board approved a specific ESG-related corporate goal for management, which was focused, in part, on enhancing diversity and inclusion initiatives at all levels of the organization. The Company executed on the Board’s direction during the past year by increasing the Board’s diversity profile, conducting diversity and inclusion training for our officers and managers, and establishing a Diversity and Inclusion Advisory Committee with a direct line of communication to our Executive Leadership Team.
Say-On-Pay Vote
There was strong support at both the 20202023 and 20212022 annual meetings for the compensation program provided to Vericel’s named executive officers, with more than 96%92% and 86% of votes cast in favor, of approval of the compensation paid to Vericel’s named executive officers in both years.respectively. In light of the recent strong support for our executive compensation program reflected by the results of these “say-on-pay” proposals, the Compensation Committee maintained the same general structure and approach to Vericel’s executive compensation program for 2021.2023. Although the results of the say-on-pay proposal are not binding, our Board and Compensation Committee value the input of our shareholders and intend to continue to consider the outcome of say-on-pay votes, as well as feedback received throughout the year, when making compensation decisions for our named executive officers in the future.
Balance
Retain an independent compensation consultant reporting directly to the Compensation Committee
Provide shareholders with an annual say-on-pay vote
Prohibit short sales, hedging, pledging or other inherently speculative transactions by our executives, non-employee directors and other Company employees (for more information, please see our Special Trading Procedures for Insiders, available at www.vcel.com)
Conduct competitive benchmarking to align executive compensation with the market
Maintain robust stock ownership guidelines that apply to our directors and named executive officers
Maintain a compensation | |||||||
What We Don’t Do | |||||
No tax gross-ups on executiveperquisites or on executive severance or change-in-control benefits No single-trigger change-in-control benefits Do not provide supplemental company-paidretirement benefits Our equity plan does not permit “evergreen”replenishment of shares Do not provide dividends or dividendequivalents on unearned equity awards
| |||||
Executive Compensation
The Compensation Committee performs a review of compensation for our executive officers annually. As part of this review, the Compensation Committee takes into consideration its understanding of external market data, which is primarily based on compensation practices of comparable companies (based on size and stage of development). Periodically, the Compensation Committee engages FW Cook, an independent consultant, to perform an analysis of the current compensation program. In late 2020,2022, the Compensation Committee engaged FW Cook to perform an independent review of the compensation program for our executive officers to assist with setting 20212023 compensation. FW Cook reports directly to the Compensation Committee. Other than the work it performs for the Compensation Committee, FW Cook does not provide any consulting services to Vericel or its executive officers. Our Compensation Committee performs an annual assessment of the independence of its compensation advisers. Our Compensation Committee has determined that FW Cook is independent and that their work has not raised any conflict of interests.
Generally, our Compensation Committee reviews and approves compensation arrangements for executive officers in the first quarter of each year and in connection with the hiring of new executives. Other than with respect to the compensation of our Chief Executive Officer, our Compensation Committee also takes into consideration the recommendations for executive compensation made by our Chief Executive Officer, which recommendations are generally presented at the time of our Compensation Committee’s review of executive compensation arrangements.
The compensation decisions made at the beginning of 20212023 occurred in the context of sustained strong long-term performance, evidenced by our 78%20% three-year compound annual total shareholder return through December 31, 2020,January 13, 2023, which was atin the 100th percentile amongtop quartile of our peer group.
For taxable years prior to 2018, Section 162(m)
2024 Proxy Statement | 47 |
As part of the Code as then in effect and related treasury regulations restricted deductibility ofits engagement, FW Cook analyzed compensation paiddata relating to our named executive officers (other than our principal financial officer) to the extent such compensation exceeded $1,000,000 and did not qualify for an exceptionpeer group companies as commission-based compensation or “qualified performance-based compensation.” Beginning in 2018, tax legislation (1) expanded the scope of Section 162(m) such that all named executive officers are “covered employees” and anyone who was a named executive officer in any year after 2016 will remain a covered employee for as long as he or she (or his or her beneficiaries) receives compensation from the Company, and (2) eliminated the exception to the deduction limit for commission-based compensation and performance-based compensation except with respect to certain grandfathered arrangements in effect as of November 2, 2017 that are not subsequently materially modified. Accordingly, beginning in 2018, any compensation paid to a covered employee in excess of $1,000,000 will be non-deductible, unless paid pursuant to a grandfathered arrangement, as discussed above. The Compensation Committee believes that shareholder interests are best served if the Committee retains maximum flexibility to design executive compensation programs that meet stated business objectives. For these reasons,approved by the Compensation Committee while considering tax deductibility aswith input and guidance from FW Cook. The compensation analysis was performed in late 2022 and early 2023 and informed the 2023 compensation program. The peer group companies were reviewed in fall 2022 and consisted of 16 publicly-traded companies in the biotechnology/pharmaceutical, health care equipment & supplies, and life sciences tools & services industries, which had a factor in determining executive compensation, will not limit such compensationmedian market capitalization of $1.57 billion on September 30, 2022 (comparable to those levelsour $1.1 billion market capitalization at that will be deductible, particularly in light of the expansion of the covered employee grouptime), and the eliminationmajority of which either have commercial operations or an FDA-approved product. All peers had September 30, 2022 market capitalization in a range of 0.3 to 3.1 times our market capitalization at that time. The peer group companies that informed 2023 executive officer compensation decisions were: Agenus, Inc., Agios Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Anika Therapeutics, Inc., Artivion, Inc., AtriCure, Inc., AxoGen, Inc., Cardiovascular Systems, Inc., Corcept Therapeutics, Inc., Cryoport, Inc., Glaukos Corporation, Ironwood Pharmaceuticals, Inc., PTC Therapeutics, Inc., STAAR Surgical Company, Supernus Pharmaceuticals, Inc., and Vanda Pharmaceuticals, Inc. The only change compared to the exception for performance-based compensation under Section 162(m).previous year peer group was the removal of Flexion Therapeutics, Inc., due to its acquisition.
Design and Structure of 2021 Executive Compensation
Our Business and Our Compensation Philosophy
The objectives of our executive compensation program are to attract, retain and motivate talented executives who are critical for the continued growth and success of Vericel and to align the interests of these executives with those of our shareholders. To this end, our compensation programs for executive officers are designed to achieve the following objectives:
The Compensation Committee reviews the allocation of compensation components regularly to help ensure alignment with strategic and operating goals, competitive market practices and legislative changes. The Compensation Committee does not apply a specific formula to
Executive Compensation
determine the allocation between cash and non-cash forms of compensation. Certain compensation components, such as base salaries, benefits and perquisites, are intended primarily to attract and retain qualified executives. Other compensation elements, such as annual and long-term incentive opportunities, are designed to motivate and reward performance. The annual incentive motivates named executive officers to achieve specific operating objectives for the fiscal year. Long-term incentives are intended to retain executives through the vesting period, reward our long-term performance and the achievement of specific financial goals and strongly align named executive officers’ interests with those of shareholders.
The primary components of our executive officer compensation program are: (i) annual base salary; (ii) annual incentive compensation, which is based on the achievement of specified Company goals; and (iii) long-term equity incentive compensation in the form of periodic stock option and RSU grants, with the objective of aligning the executive officers’ long-term interests with those of our shareholders.
In establishing overall executive compensation levels and making specific compensation decisions for the executives in 2021,2023, the Compensation Committee considered a number of criteria, including theeach executive’s position, prior compensation levels, scope of responsibilities, prior and current period performance, attainment of individual and overall Company performance objectives, and external market data. In addition, the Compensation Committee considered the results of the advisory vote by shareholders on the “say-on-pay” proposal presented to shareholders at Vericel’s 20202022 annual meeting.
Table of Contentsmeeting, which had an 86% support rate.
Executive Compensation
Base Salary
The Compensation Committee performsalso reviews the allocation of compensation components regularly to help ensure alignment with strategic and operating goals, competitive market practices and legislative changes. The Compensation Committee does not apply a reviewspecific formula to determine the allocation between cash and non-cash forms of base salaries for our executive officers annually. We may also change the base salary of an executive officer at other times due to market conditions or if a change in the scope of the officer’s responsibilities justifies such adjustment. compensation.
We believe that a competitive base salary is a necessary element of any compensation program that is designed to attract and retain talented and experienced executives. Base salaries are established, in part, based on the individual experience, skills and expected contributions of our executives and our executives’ performance during the prior year, with market data considered as context. The Compensation Committee reviews base salaries for our executive officers annually. We may also change the base salary of an executive officer at other times due to market conditions or if a change in the scope of the officer’s responsibilities justifies such adjustment.
In February 2021,2023, our Compensation Committee approved merit increases in base salary increases for each of our named executive officers serving at that time, based upon various factors, including a review of individual performance during 20202022 and a comparison of cash compensation versus peer group market data. Base salaries were below the peer group median for the CEO and every other executive officer before the adjustments in February 2021. Salary adjustments were basedfocused on the goal of providing cash compensation at or near the peer group median,in a competitive range relative to market benchmarks, also taking into account each executive’s tenure in the executive’s position and the executive’s performance during a strong 2020.performance. The table below sets forth the adjustments to base salary, in dollars and as a percentage,salaries for each of our named executive officers:
Base Salary Adjustments | ||||||
Name | 2020 Base Salary ($) | 2021 Base Salary ($) | Increase (%) | |||
Dominick C. Colangelo | 675,000 | 730,000 | 8.1% | |||
Joe Mara | — | 415,000 | — | |||
Michael Halpin | 395,000 | 440,000 | 11.4% | |||
Sean C. Flynn | 350,000 | 375,000 | 7.1% | |||
Jonathan Hopper | 365,000 | 390,000 | 6.8% | |||
Sandra Pennell(1) | 222,500 | 240,000 | 7.9% |
Base Salary Adjustments | ||||||
Name | 2022 Base Salary ($) | 2023 Base Salary ($) | Increase (%) | |||
Dominick Colangelo | 760,000 | 790,000 | 3.9% | |||
Joe Mara | 440,000 | 475,000 | 8.0% | |||
Michael Halpin | 470,000 | 505,000 | 7.4% | |||
Sean Flynn | 400,000 | 430,000 | 7.5% | |||
Jonathan Hopper | 415,000 | 440,000 | 6.0% |
The determinationWe maintain an annual incentive program (or “AIP”) that is designed to drive annual performance against important strategic, operational and financial aspects of annual incentives for our executives in 2021 was tied to achieving our financial targets,organization. We believe the AIP focuses management on advancing our commercialoverall corporate strategy and development stage products and accomplishing operational goals. In addition, for 2021 a portionfurthering both the short-and long-term growth of annual incentive compensation was tied to achieving ESG-related goals and an upside value goal.the Company. Each executive officer has a target cash incentive amount that is set as a percentage of base salary, based upon consideration of potential contribution, level and market data.
The amountdetermination of the cashannual incentives awarded by the Compensation Committeefor our executives in 2023 was tied to achieving our named executive officers each year is based on the achievementfinancial targets, advancing our commercial and development stage products and accomplishing operational goals. In addition, a portion of corporate performance goals setannual incentive compensation was tied to a stretch upside value goal. These metrics were established by the Compensation Committee and approved by the full Board in advance, which are designed to captureat the important operating and financial outcomes as well as ESG-related goals important to the Company. The 2021 corporate goals approved by our Compensation Committee were:beginning of 2023.
Weighting | Our Goals | Our Metrics | Achievement | |||||
Commercial and Financial Performance Goals | Total net revenue Budget expense | •Generate total net | ||||||
•Achieve | ||||||||
Commercial Product Goals Long-Term Brand Development Goals Product Development Goals | •Achieve budgeted MACI | |||||||
burn centers •Complete MACI, Epicel and NexoBrid long-term brand development initiatives • Complete MACI Arthro human factors study and submit label update to the FDA by December 1, 2023 | ||||||||
Goals | ||||||||
Manufacturing Capacity and Operational Improvement Initiatives | •Complete manufacturing facility and key manufacturing/IT efficiency improvement initiatives | |||||||
Upside Value Goals | ||||||||
Business Development | •Execute | |||||||
No more than 200% of target may be earned under the annual incentive program.AIP. The Compensation Committee reviewed the Company’s
Executive Compensation
performance in 20212023 against the corporate goals and made a determination of a 100%110% achievement of our corporate goals for 2021,2023, based on the following:
1. | |
Despite the widespread effects of the COVID-19 pandemic on the national healthcare infrastructure, to include periodic restrictions on the performance of elective surgical procedures throughout the country, including MACI procedures, the Committee made no adjustments to the manner in which the goals were scored to account for COVID-19 or other external events.
The table below shows the target award under the 2021 annual incentive program as a percent of each named executive officer’s annual base salary in 2021, the target cash award opportunity in dollars for 2021, and the actual cash bonus payments and percent of award opportunity paid to our named executive officers for 2021 performance.
2021 Annual Incentive Program | ||||||||
Name | 2021 Target Award (% of Base Salary) | 2021 Target Award Opportunity ($) | 2021 Actual Bonus Payment ($) | 2021 Actual Bonus Payment (% of Target Award Opportunity) | ||||
Dominick C. Colangelo | 85% | 620,500 | 620,500 | 100% | ||||
Joe Mara(1) | 50% | 193,300 | 193,300 | 100% | ||||
Michael Halpin | 50% | 220,000 | 220,000 | 100% | ||||
Sean C. Flynn | 45% | 168,750 | 168,800 | 100% | ||||
Jonathan Hopper | 45% | 175,500 | 175,500 | 100% | ||||
Sandra Pennell(2) | 30% | 72,000 | — | — |
* | For more information concerning Vericel’s presentation of non-GAAP measures, including a reconciliation of reported net (loss) income (GAAP) to adjusted EBITDA (non-GAAP), please refer to the Company’s discussion of “GAAP versus non-GAAP Measures”, on page |
2024 Proxy Statement | 49 |
2. | 56% out of a target 50% was awarded for Product Goals. The Compensation Committee awarded above the target percentage for these goals primarily as a result of the Company conducting and completing a human factors study of the arthroscopic method of delivery for MACI to the knee and submitting a prior approval supplement to the FDA seeking to add instructions for MACI Arthro to the product’s approved labeling ahead of schedule. We now expect a commercial launch of MACI Arthro during the third quarter of 2024, which would provide surgeons with a simpler and less invasive method for delivering MACI and, we expect, help drive continued product growth. In addition to continuing to advance the MACI Ankle program, the Company achieved certain of its commercial product metrics, including its MACI biopsy surgeon engagement goal and the number of burn centers taking Epicel biopsies. A goal related to the MACI biopsy conversion rate was slightly below target, while a goal related to the number of NexoBrid P&T committee approvals was below target as a result of the delay in the commercial launch of the product due to a now-corrected deviation in MediWound’s manufacturing process. Overall, when considering the Company’s significant achievements in advancing its pipeline, the Compensation Committee awarded above the target percentage. | |
3. | 11% out of a target 10% was awarded for the Operational Goals. The Compensation Committee awarded slightly above the target level for these goals as a result of the Company meeting or exceeding each of its budgeted goals relating to: material and vendor cost savings and material movement controls to improve financial management at the operational level; the advancement of plans to occupy the Company’s new manufacturing facility and corporate headquarters later in 2024; and various IT improvement initiatives. | |
4. | 0% out of a maximum 15% was awarded for the Upside Goal. During 2023, the Company chose not to execute any business development transactions. |
The Compensation Committee made no adjustments to the goals or the manner in which they were scored to account for external events.
The table below shows the target award under the 2023 AIP as a percentage of Contentseach named executive officer’s annual base salary in 2023, the target cash award opportunity in dollars for 2023, and the actual cash bonus payments and percent of award opportunity paid to our named executive officers for 2023 performance.
Executive Compensation
2023 Annual Incentive Program | ||||||||
Name | 2023 Target Award (% of Base Salary) | 2023 Target Award Opportunity ($) | 2023 Actual Bonus Payment ($) | 2023 Actual Bonus Payment (% of Target Award Opportunity) | ||||
Dominick C. Colangelo | 85% | 671,500 | 738,700 | 110% | ||||
Joe Mara | 50% | 237,500 | 261,300 | 110% | ||||
Michael Halpin | 50% | 252,500 | 277,800 | 110% | ||||
Sean C. Flynn | 45% | 193,500 | 212,900 | 110% | ||||
Jonathan Hopper | 45% | 198,000 | 217,800 | 110% |
Equity incentive compensation aligns executives with shareholders and allows them to share in any appreciation in the value of our common stock. In 2021,2023, the Compensation Committee awarded stock options and RSUs to our named executive officers to aid in their retention, to motivate them to achieve both near-term and long-term corporate objectives and increase share price. In determining the form and value of a grant, the Compensation Committee considers the contributions and responsibilities of each named executive officer, appropriate incentives for the achievement of our long-term growth, the size and value of grants made to other executives at peer companies holding comparable positions, individual achievement of designated performance goals, Vericel’s overall performance relative to corporate objectives, and our overall equity compensation burn rate.
Stock options and RSU awards vest over time, generally four years, subject to continued employment with Vericel over the vesting period, which promotes executive retention. All stock options have a ten-year term and an exercise price equal to the fair market value of our common stock on the date of grant, which is equal to our closing market price on such date.
Awards are made at levels calculated to be competitive within our peer group. In determining the amount of each grant, the Compensation Committee also reviews the number of shares held by the executive prior to the grant. In late 2020,2022, the Compensation Committee engaged FW Cook to independently review the equity incentive grant practices of Vericel as compared to our peer group, and this market data was used to support 2021 compensation decisions.decisions for 2023. The Compensation Committee considered our significant 78%20% three-year compound annual shareholder return over the preceding three-year period,through January 13, 2023, which was atin the 100th percentile when compared totop quartile of our peer group, and well above the peer group median of 7%-4% compound annual shareholder return.return over this period.
The executive equity award strategy for 2021 was consistent with the strategy used in 2020 and2023 focused on providing a competitive number of shares underlying stock options and RSUs with the vast majority of grant date value of equity awards provided in the form of stock options to ensure that our executives are aligned with shareholder value creation and to ensure the program pays for performance. The Compensation Committee reviewed the Company’s projected 20212023 equity compensation burn rate and determined that the number of shares granted to executives would maintain the burn rate nearbelow the median relative toof our peer group, which was verified at the end of the year (4.2%), even though 2021 included a sign-on grant to our new CFO and the hiring of 56 employees to support our growth during the year. The specific number of shares granted to individual executives varied somewhat compared to 2020 as a result of changes to the competitive market data reviewed at the end of 2020 and the Compensation Committee’s consideration of individual contributions towards our strong 2020 performance that included a 77% increase in our stock price and significant improvement in operating cash flow, from negative $7.2 million in 2019 to $17.6 million in 2020.group.
50 |
On February 19, 2021,17, 2023, the Board of Directors granted our CEO, and the Compensation Committee granted our other named executive officers, the following stock options and RSUs at a $51.40$29.82 price. The grant date fair value of these awards is also reported in the 20212023 Summary Compensation Table below.
Option and RSU Awards Granted February 19, 2021 | ||||||||
Name | Number of Shares Underlying Options (#) | Number of RSUs (#) | Stock Awards and Option Awards Fair Value($)(1) | Stock Awards and Option Awards Intrinsic Value($)(2) | ||||
Dominick C. Colangelo | 300,000 | 35,750 | 11,819,409 | 1,458,243 | ||||
Joe Mara(3) | — | — | — | — | ||||
Michael Halpin | 100,000 | 11,250 | 3,905,536 | 458,888 | ||||
Sean C. Flynn | 60,000 | 7,000 | 2,356,172 | 285,530 | ||||
Jonathan Hopper | 60,000 | 7,000 | 2,356,172 | 285,530 | ||||
Sandra Pennell(4) | 25,000 | 2,750 | 973,172 | — |
Option and RSU Awards Granted February 17, 2023 | ||||||||
Name | Number of Shares Underlying Options (#) | Number of RSUs (#) | Stock Awards and Option Awards Fair Value ($)(1) | Stock Awards and Option Awards Intrinsic Value ($)(2) | ||||
Dominick Colangelo | 182,500 | 73,000 | 5,513,083 | 11,548,600 | ||||
Joe Mara | 46,250 | 18,500 | 1,397,151 | 2,926,700 | ||||
Michael Halpin | 52,500 | 21,000 | 1,585,955 | 3,322,200 | ||||
Sean Flynn | 30,000 | 12,000 | 906,260 | 1,898,400 | ||||
Jonathan Hopper | 30,000 | 12,000 | 906,260 | 1,898,400 |
(1) | Amounts reflect the grant date fair value of the stock option awards and RSUs made to the named executive officers, calculated in accordance with FASB ASC Topic 718. For purposes of this calculation, we have disregarded forfeiture assumptions related to service-based vesting conditions. For a discussion of the assumptions used in calculating these values, see Note 7 to our consolidated financial statements in our annual report on Form 10-K for the fiscal year ended December 31, | |
(2) | Amounts reflect the intrinsic value which is calculated as the number of RSUs and stock options granted on February 17, 2023 multiplied by the proxy record date stock price of | |
Each of Contents
Executive Compensation
The resulting 2021our named executive equity grant values appear materially higher than in 2020 primarily because the $51.40 stock price on February 19, 2021, when awards were granted, was almost three-times the $18.00 stock price on February 11, 2020, when 2020 awards were granted. Similarly, our market capitalization was $2.34 billion at the time of 2021 awards, significantly higher than our market capitalization of $805 million at the time of 2020 awards. The majority of the 2021 award has no current value because the stock options, which were the largest component of 2021 executive equity incentive compensation, only deliver value if the stock price exceeds the $51.40 grant price, which was $40.79 on the proxy record date (March 3, 2022).
We continued to maintain a similar equity compensation strategy during 2022, and on February 18, 2022, the following awards were granted to our executive officers when our stock price was $34.90. We project that our equity compensation burn rate during 2022, including these awards, will continue to be in a median range compared to our peers. The grant date fair value of these awards (excluding the CFO’s January 2021 sign-on award), calculated in accordance with FASB ASC Topic 718,officer’s base salary is anticipated* to be approximately 30% to 40% lower on a per award basis than the grant date fair value of the February 19, 2021 awards disclosed in the summary compensation table, and approximately 5% fewer shares were granted to each executive.
On February 18, 2022, the Board of Directors granted our CEO, andreviewed annually by the Compensation Committee granted our otherCommittee. The named executive officers are also eligible to receive cash incentive compensation and equity awards from time to time at the following stock optionsdiscretion of the Compensation Committee. The current base salary as of March 4, 2024, and RSUs attarget annual incentive compensation (as a $34.90 price.percentage of the base salary) for each of our currently serving named executive officers is as follows:
Option and RSU Awards Granted February 18, 2022 | ||||
Name | Number of Shares Underlying Options (#) | Number of RSUs (#) | ||
Dominick C. Colangelo | 273,000 | 46,800 | ||
Joe Mara(1) | 64,269 | 11,018 | ||
Michael Halpin | 89,250 | 15,300 | ||
Sean C. Flynn | 54,250 | 9,300 | ||
Jonathan Hopper | 54,250 | 9,300 |
Name | Base Salary | Target Annual Incentive Compensation (%) | |
Dominick Colangelo | $830,000 | 85% | |
Joe Mara | $505,000 | 50% | |
Michael Halpin | $535,000 | 50% | |
Sean Flynn | $465,000 | 45% | |
Jonathan Hopper | $475,000 | 45% |
Generally, benefits available to executive officers are available to all employees on similar terms and include health and welfare benefits, paid time-off, life and disability insurance and a 401(k) plan.
We provide the benefits above to attract and retain our executive officers and other employees by offering compensation that is competitive with other companies that are similar in size and stage of development. These benefits represent a relatively small portion of the total compensation of our named executive officers.
Peer Group
As part of its engagement, FW Cook analyzed compensation data relating to our peer group companies as approved by the Compensation Committee with input and guidance from FW Cook. The peer group companies were selected in Fall 2020 and consisted of 17 publicly-traded biotechnology/pharmaceutical and health care equipment and supplies companies, which had a median market capitalization of $1.42 billion in 2019 (consistent with our $1.40 billion market capitalization on December 31, 2020), and the majority of which either have commercial operations or an FDA-approved product. All peers had a 2019 average market capitalization in a range of 0.3 to to 2.0 times our market capitalization on December 31, 2020. Our peer group selection process focused on peers’ market capitalization during 2019 to align their size with the timing of their compensation information disclosed in proxy statements filed in Spring 2020. The peer group companies that informed 2021 and 2022 executive officer compensation decisions were: Agenus, Inc., Agios Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Anika Therapeutics, Inc., Artivion, Inc., AtriCure, Inc., AxoGen, Inc., Cardiovascular Systems, Inc., Corcept Therapeutics, Inc., Cryoport, Inc., Flexion Therapeutics, Inc., Glaukos Corporation, Ironwood Pharmaceuticals, Inc., PTC Therapeutics, Inc., STAAR Surgical Company, Supernus Pharmaceuticals, Inc., and Vanda Pharmaceuticals, Inc.
Executive Compensation
We believe that risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect on the Company. In addition, the Compensation Committee believes that the mix and design of the elements of executive compensation do not encourage management to assume excessive risks.
The Compensation Committee, with the assistance of FW Cook, extensively reviewed the elements of executive compensation to determine whether any portion of executive compensation encouraged excessive risk-taking and concluded:
• | Inclusion of significant long-term incentive compensation discourages short-term risk | |
• | Compensation is in a market range and is not set as an | |
• | ||
The mix of | ||
• | Goals are appropriately set to avoid targets that, if not achieved, result in a large percentage loss of | |
• | The prohibition on hedging or pledging of our stock discourages short-term and excessive risk taking. Furthermore, as described in this CD&A section, compensation decisions include subjective considerations to moderate the effects that formulae or objective factors might have on excessive risk |
EffectiveIn April 28, 2021, the Board has adopted Stock Ownership Guidelines applicable to non-employee directors and to the Company’s named executive officers. Pursuant to these guidelines, non-employee directors are expected to meet share ownership targets that are determined based on their annual retainer, and named executive officers are expected to meet share ownership targets that are determined based on their annual salary, within five years of the adoption of the guidelines. In addition, non-employee directors and named executive officers who join the Board or the Company after the establishment of the guidelines have five years from such date to reach their target. The share ownership target for non-employee directors is three times (3X) their annual retainer. The share ownership target for the Company’s CEO is five times (5X)(5x) his or her base salary, while other named executive officers have a target of two times (2X)(2x) base salary. For purposes of determining stock ownership levels, the following forms of equity interests in the Company are included: (i) shares owned directly (shares obtained through open market purchases or acquired and held upon vesting of Company equity awards); (ii) shares owned indirectly (shares owned jointly or separately by the individual’s spouse and shares held in trust for the benefit of the named executive officer, the named executive officer’s spouse and/or children); (iii) shares or units represented by amounts invested in a Company sponsored employee stock purchase plan, 401(k) plan or deferred compensation plan; and (iv) unvested awards of time-based RSUs. Unexercised stock options are not included when determining compliance with the required stock ownership levels. As of December 31, 2023, all of our named executive officers were in compliance with their respective stock ownership targets.
Effective March 14, 2022, weWe maintain a robust compensation recoveryPolicy for Recoupment of Erroneously Awarded Incentive Compensation or “clawback” policy“Clawback” Policy covering each of our executive officers.officers (including our named executive officers). In June 2023, the SEC approved the Nasdaq’s proposed listing rules implementing the incentive-based compensation recovery provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act (“Dodd-Frank Act”) and Rule 10D-1 of the Exchange Act, which require listed companies to develop and implement a policy providing for the recovery of erroneously awarded incentive-based compensation received by current or former executive officers and to satisfy related disclosure obligations. Effective October 2, 2023, we amended and restated our previous clawback policy to reflect these new requirements. The policy provides thatClawback Policy requires the prompt recovery of certain excess incentive-based compensation received during an applicable three-year recovery period by current or former executive officers in the event an executive engages in certain acts of misconduct, as defined in the policy, which result in the Company beingwe are required to restate or republish previously disclosed financial statementsprepare an accounting restatement due to material non-compliancenoncompliance with any financial reporting requirementsrequirement under applicablethe securities laws,laws. Incentive-based compensation potentially subject to recovery under the Board may seek reimbursementClawback Policy is, in general, limited to any compensation granted, earned, or vested based wholly or in part on the attainment of one or more financial reporting measures (whether cash or equity-based).
For taxable years after 2017, Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), generally disallows the deduction to a public corporation of any cash or equity-based incentive compensation (including vested and unvested equity) paid or awarded to the executive officer, or effect the cancellation of previously-granted equity awards, to the extent the compensation was based on erroneous financial data and exceeded what would have been paid to a “covered employee” in excess of $1,000,000, unless paid pursuant to a grandfathered arrangement within the meaning of Section 162(m) of the Code. The Compensation Committee believes that shareholder interests are best served if the Compensation Committee retains maximum flexibility to design executive officercompensation programs that meet stated business objectives. For these reasons, the Compensation Committee, while considering tax deductibility as a factor in determining executive compensation, will not limit such compensation to those levels that will be deductible under Section 162(m) of the restatement.Code.
The Compensation Committee has reviewed and discussed the foregoing Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement. COMPENSATION COMMITTEE MEMBERS: This report shall not constitute “soliciting material,” shall not be deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any of our other filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate this report by reference therein. During the fiscal year ended December 31, The following table presents information on all grants of plan-based awards made in the fiscal year ended December 31, The table below reflects all outstanding equity awards held by each of the named executive officers as of December 31, The following table sets forth information with respect to the exercise of options by our named executive officers as well as the vesting of RSUs during the year ended December 31, On May 3, 2023, the Board approved and adopted the Vericel Corporation Deferred Compensation Plan (the “Deferred Compensation Plan”), which is a non-qualified deferred compensation plan that is intended to comply with Section 409A of the Code. Participation in the Plan is limited to non-employee directors and, as determined by the Compensation Committee in its sole discretion, a select group of management or highly compensated employees of the Company, including our executive officers. Pursuant to the Deferred Compensation Plan, a participant may elect to defer up to 100% of his or her annual base salary, annual bonus and/or cash director fees, as applicable. In addition, a participant may elect to defer up to 100% of each of his or her RSU grants under the Company’s 2022 Plan. The Company may also be required, in accordance with employment or other agreements, to contribute amounts to a participant’s Deferred Compensation Plan account. The Deferred Compensation Plan also permits, but does not require, the Company to make discretionary contributions to participants’ Deferred Compensation Plan accounts. Any RSUs deferred under the Deferred Compensation Plan are reflected on the books of the Company as an unfunded, unsecured promise to deliver to the participant a specific number of actual shares of common stock in the future at the time the RSU would otherwise vest and become transferable to the participant under the terms of the 2022 Plan. All other deferrals under the Deferred Compensation Plan are paid in cash to the participants. Participants’ deferrals of cash compensation are 100% vested at all times. All unvested contributions to a participant’s account from the Company, if any, become 100% vested in the event of a change of control (as defined in the Deferred Compensation Plan) or upon a participant’s death or disability. Each participant’s deferred compensation account is deemed invested in investments selected by the participant from a list of measurement funds selected by the Compensation Committee. Distributions are made in a lump sum or annual installment payments as elected by the participant in accordance with the Deferred Compensation Plan’s terms and conditions. Obligations of the Company under the Deferred Compensation Plan represent at all times an unfunded and unsecured promise to pay money in the future. Each participant in the Deferred Compensation Plan is an unsecured general creditor of the Company with respect to deferred compensation obligations. Any amounts set aside to defray the liabilities assumed by the Company will remain the general, unpledged unrestricted assets of the Company. The following table presents information regarding our Deferred Compensation Plan as of December 31, 2023. No withdrawals or distributions from the Deferred Compensation Plan were made in 2023. We do not offer any defined benefit pension plans or arrangements. We entered into employment agreements with our currently serving named executive officers on the following dates: January 25, 2021 for Mr. Mara, November 4, 2019 for Mr. Flynn, August 20, 2018 for Dr. Hopper, September 14, 2017 (as amended on June 3, 2019) for Mr. Halpin, and March 1, 2013 (as amended on September 14, 2017) for Mr. Colangelo (each, an “Employment Agreement” and together, the “Employment Agreements”). In the event of a termination of a named executive officer’s employment with Vericel without Cause or by the named executive officer for Good Reason (as such terms are defined in the Employment Agreements), Vericel shall pay the named executive officer an amount equal to twelve months of the named executive officer’s then-current base salary in equal installments over the 12-month period beginning within sixty days following the date of termination of the named executive officer’s employment. All of Mr. Colangelo’s time-based equity awards that would have vested during such 12-month period shall vest and become exercisable or nonforfeitable upon the date of termination. If the named executive officer was participating in Vericel’s group health plan immediately prior to the date of termination and elects COBRA coverage, Vericel shall pay the named executive officer a monthly cash payment equal to the monthly employer contribution that Vericel would have made to provide health insurance to the named executive officer had he remained employed by Vericel (or, in the case of Mr. Colangelo, equal to the full monthly COBRA premium), until the earlier of twelve months following the termination or the end of the named executive officer’s COBRA health continuation period. In the event that the named executive officer breaches the restrictive covenants set forth in his Employment Agreement during the severance period, Vericel may cease severance payments to the named executive officer. In lieu of the severance payments and benefits described above, in the event of a termination of a named executive officer’s employment by Vericel without Cause or by the named executive officer for Good Reason, in either case within eighteen months following a Change-in-Control (as defined in the Employment In addition, during employment and after termination of the named executive officer’s Employment Agreement, each named executive officer has agreed to keep Vericel’s confidential information in confidence and trust and has agreed not to use or disclose such confidential information without Vericel’s written consent except as necessary in the ordinary course of performing duties for Vericel. During the term of the named executive officer’s Employment Agreement and for a period of twelve months (or, in the case of Mr. Colangelo, eighteen months) thereafter, the named executive officer has also agreed not to compete with Vericel and not to solicit employees, customers or suppliers of Vericel. Generally, in the event of a Change-in-Control of Vericel (as defined in our 2022 Plan, 2019 Plan, The following table sets forth aggregate estimated payment obligations to each of the named executive officers assuming a termination occurred on December 31, Pursuant to the Dodd-Frank As illustrated in the table below, our We determined the median employee compensation using W-2 compensation, plus estimated bonus, the fair market value of equity grants, life and disability insurance, and the estimated value of 401(k) match (whether or not vested), for all individuals who were employed by us on December 31, For the fiscal year ended December 31, The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules, based on our internal records and the methodology described above. The SEC rules for identifying the median compensated employee allow companies to adopt a variety of methodologies, to apply certain exclusions and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Accordingly, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may use different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios. Pursuant to the Dodd-Frank Act and Item 402(v) of Regulation S-K, we are required to provide the following information regarding the relationship between executive compensation paid to our named executive officers and Vericel’s financial performance for each of the last four completed calendar years. In determining the Compensation Actually Paid (or “CAP”) to our Principal Executive Officer, who is our CEO, and our other named executive officers, we are required to make various adjustments to the amounts that have been previously reported in the Summary Compensation Table, as summarized below. The CAP amounts reflected in the table below do not reflect the actual amount of compensation earned by or paid to our named executive officers during the applicable year. For information regarding decisions made by our Compensation Committee with respect to executive compensation, refer to the “Compensation Discussion and Analysis” section of this Proxy Statement. Total Net Revenue The following measures in our assessment represent the most important financial performance measures that link compensation actually paid to our named executive officers, for 2023, to Vericel’s performance: The relationship between Compensation Actually Paid (CAP) and the financial performance elements reflected in the above Pay versus Performance table are described in the below charts: Compensation Actually Paid versus Net Income 2020-2023 Compensation Actually Paid versus Revenue 2020-2023 Overview The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) requires us to submit a non-binding, advisory resolution, commonly known as a “say-on-frequency” proposal, to shareholders at least once every six years to determine whether advisory votes on executive compensation, such as Proposal 2, should be held every one, two or three years. At the 2018 annual meeting of shareholders, the shareholders voted to hold a “say-on-pay” proposal every year. Following the vote at this Annual Meeting, the next say-on-frequency proposal will be voted upon at the 2030 annual meeting of shareholders. After careful consideration, our Board of Directors has determined that an annual advisory vote to approve the compensation of our named executive officers will allow our shareholders to provide timely and direct input on Vericel’s executive compensation philosophy, policies and practices as disclosed in the proxy statement each year. The Board of Directors believes that an annual vote is therefore consistent with Vericel’s efforts to engage in an ongoing dialogue with our shareholders on executive compensation and corporate governance matters. Accordingly, we are asking our shareholders to vote for every “1 YEAR” as the frequency for future non-binding, advisory votes on the compensation of our named executive officers. This vote is advisory, and therefore will not have any binding legal effect on Vericel, the Board of Directors or the Compensation Committee. However, the Board of Directors and the Compensation Committee value the opinions of our shareholders and intend to take into account the outcome of the vote when considering the frequency of holding future advisory votes to approve the compensation of our named executive officers. The frequency that receives the highest number of votes cast on the proposal shall be deemed the frequency recommended by shareholders. Abstentions and broker non-votes will have no effect on this Proposal 3. If you sign and submit your proxy card without marking your voting instructions, your shares will be voted for every 1 YEAR. The Audit Committee has selected PwC as Vericel’s independent registered public accounting firm to audit the consolidated financial statements of Vericel for the fiscal year ending December 31, Shareholder ratification of the selection of PwC as our independent registered public accounting firm is not required by our Bylaws or otherwise. However, the Board of Directors is submitting the selection of PwC to the shareholders for ratification as a matter of good corporate practice. If the shareholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain PwC. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent accountant at any time during the year if it determines that such a change would be in the best interests of Vericel and its shareholders. Representatives of PwC attended all The affirmative vote of a majority of the votes cast on the proposal on the ratification of this appointment, at the Annual Meeting at which a quorum representing a majority of all outstanding shares of common stock of Vericel is present, either in person or by proxy, is required for ratification of this proposal. If you abstain from voting on this proposal, it has no effect on the voting of the proposal. If you submit your proxy without indicating your voting instructions, your shares will be voted “FOR” this proposal. Brokers, bankers and other nominees have discretionary voting power on this routine matter and, accordingly, “broker non-votes” will have no effect on the ratification. As part of its duties, the Audit Committee considered the provision of services, other than audit services, during the fiscal year ended December 31, The Audit Committee approves in advance the engagement and fees of the independent registered public accounting firm for all audit services and non-audit services, based upon independence, qualifications and, if applicable, performance. The Audit Committee may form and delegate to subcommittees of one or more members of the Audit Committee the authority to grant pre-approvals for audit and permitted non-audit services, up to specific amounts. All audit services provided by PwC for the fiscal years ended December 31, The Audit Committee oversees Vericel’s financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process, including internal control over financial reporting. PwC is responsible for expressing an opinion as to the conformity of our consolidated audited financial statements with generally accepted accounting principles. The Audit Committee acts pursuant to a written charter that has been adopted by the Board of Directors. The Audit Committee consists of three directors, each of whom, in the judgment of the Board of Directors, is an “independent director” as defined in Rule 5605(a)(2) of the Nasdaq listing standards. Robert The Committee has discussed and reviewed with the independent registered public accountants all matters required to be discussed by the Public Company Accounting Oversight Board (the “PCAOB”) in Auditing Standards No. 16 (Communication with Audit Committees). The Committee has received written disclosures and a letter from PwC confirming their independence, as required by applicable requirements of the PCAOB regarding the independent accountant’s communications with the Committee concerning independence, and has discussed with PwC the firm’s independence. The Committee has met with PwC, with and without management present, to discuss the overall scope of the PwC audit, the results of its audit, its evaluations of Vericel’s internal controls and the overall quality of its financial reporting. The Committee reviewed the performance and fees of PwC prior to recommending their appointment. The Committee reviewed our financial statements and discussed them with management and with PwC. Based on the review and discussions referred to above, the Committee recommended to the Board of Directors that Vericel’s consolidated audited financial statements be included in Vericel’s Form 10-K for the fiscal year ended December 31, AUDIT COMMITTEE Stock Ownership of Certain Beneficial Owners and Management The following table sets forth certain information, as of March General Information about the Meeting, Solicitation and Voting There are four proposals scheduled to be voted on at the Annual Meeting: Shareholders as of the close of business on March A majority in interest of all stock issued, outstanding and entitled to vote at a meeting must be present or represented by proxy to constitute a quorum at the Annual Meeting. Abstentions and shares represented by “broker non-votes,” as described below, are counted as present and entitled to vote for purposes of determining a quorum. As of the Record Date, The following explains how many votes are required to approve each proposal, provided that a majority of our shares is present at the Annual Meeting (present in person or represented by proxy) You may either vote “FOR” or “WITHHOLD” authority to vote for each nominee for the Board of Directors. Shares present or represented and not so marked as to withhold authority to vote for a particular nominee will be voted in favor of a particular nominee and will be counted toward such nominee’s achievement of a plurality. Shares present at the meeting or represented by proxy where the shareholder properly withholds authority to vote for such nominee in accordance with the proxy instructions and “broker non-votes” will not be counted toward such nominee’s achievement of a plurality. You may vote “FOR,” “AGAINST” or “ABSTAIN” on the non-binding, advisory resolution approving the compensation of our named executive officers. If you abstain from voting on the non-binding, advisory resolution approving the compensation of our named executive officers, it will have no effect on the voting of the proposal. “Broker non-votes” do not have discretionary voting power on this matter and, accordingly, “broker non-votes” will have no effect on the ratification. If you just sign and submit your proxy card without marking your voting instructions, your shares will be voted “FOR” the resolution approving the compensation of our named executive officers. You may vote “1 YEAR,” “2 YEARS,” “3 YEARS” or “ABSTAIN” on the non-binding, advisory vote on the frequency of You may vote “FOR,” “AGAINST” or “ABSTAIN” on the ratification of PricewaterhouseCoopers LLP. If you abstain from voting on the proposal to ratify PwC, it will have no effect on the voting of the proposal. Brokers, bankers and other nominees have discretionary voting power on this routine matter and, accordingly, “broker non-votes” will have no effect on the ratification. If you just sign and submit your proxy card without marking your voting instructions, your shares will be voted “FOR” the resolution ratifying PwC. The persons named as attorneys-in-fact in the proxies, Dominick If you hold your shares in street name and do not provide voting instructions to your broker, your shares will not be voted on any proposal on which your broker does not have discretionary authority to vote (a “broker non-vote”). Shares held by brokers who do not have discretionary authority to vote on a particular matter and who have not received voting instructions from their customers are counted as present for the purpose of determining whether there is a quorum at the Annual Meeting, but are not counted or deemed to be present or represented for the purpose of determining whether shareholders have approved that matter. Pursuant to applicable rules, brokers will have discretionary authority to vote on the proposal to ratify the appointment of PwC. Our Board of Directors recommends that you vote your shares: If you are a shareholder of record, you may vote by granting a proxy. For shares held in street name, you may vote by submitting voting instructions to your broker or nominee. In any circumstance, you may vote: Internet and telephone voting facilities will close at 11:59 p.m., Eastern Time, on April We will be hosting the Annual Meeting live via the internet. You will not be able to attend the Annual Meeting in person. Any shareholder can listen to and participate in the Annual Meeting live via the internet at www.virtualshareholdermeeting.com/ The Annual Meeting webcast will begin promptly at 9:00 a.m., Eastern Time, on You will need the 16-digit control number included on your Notice of Internet Availability or your proxy card or voting instruction form (if you received a printed copy of the proxy materials) or included in the email to you if you received the proxy materials by email in order to be able to vote your shares or submit questions during the Annual Meeting. Instructions on how to connect to the Annual Meeting and participate via the Internet, including how to demonstrate proof of stock ownership, will be posted at www.virtualshareholdermeeting.com/ We have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting or submitting questions. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual meeting web portal. It generally means that you hold shares registered in more than one account. To ensure that all of your shares are voted, vote according to the instructions for each proxy card you receive. Yes. Whether you have voted by Internet, telephone or mail, if you are a shareholder of record, you may revoke your proxy or change your vote before the proposal is voted on at the Annual Meeting by: The cost of soliciting proxies will be borne by us. Voting results will be tabulated and certified by Broadridge Financial Solutions. Vericel may solicit shareholders by mail through its regular employees, and will request banks and brokers, and other custodians, nominees and fiduciaries, to solicit their customers who have our stock registered in the names of such persons and will reimburse them for their reasonable, out-of-pocket costs. Vericel may use the services of its officers, directors, and others to solicit proxies, personally or by telephone, without additional compensation. Under Vericel’s Bylaws, in order for business and director nominations to be properly brought before a meeting by a shareholder, such shareholder must have given timely notice thereof in writing to the Senior Vice President, General Counsel and Secretary of Vericel. To be timely, such notice must be received at Vericel’s principal executive offices not less than 120 calendar days in advance of the one year anniversary of the date Vericel’s proxy statement was released to shareholders in connection with the previous year’s annual meeting, except that (i) if no annual meeting was held in the previous year, (ii) if the date of the Annual Meeting has been changed by more than thirty calendar days from the date contemplated at the time of the previous year’s proxy statement, or (iii) in the event of a special meeting, then notice must be received not later than the close of business on the tenth day following the day on which notice of the date of the meeting was mailed or public disclosure of the meeting date was made. If none of the events described in (i) through (iii) above occur, then the deadline for submitting shareholder proposals In order to be brought before the next annual meeting, any such proposal or nomination must include the relevant information as required under our Bylaws and must otherwise meet applicable requirements of the SEC’s proxy rules, The Board of Directors has adopted a Shareholder Communications with Directors Policy, which is available on the Investor Relations page of our website, www.vcel.com. The Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, The SEC allows us to “incorporate by reference” information into this Definitive Proxy Statement, which means that we can disclose important information to you by referring you to other documents that we filed separately with the SEC. You should consider the incorporated information as if we reproduced it in this Definitive Proxy Statement, except for any information directly superseded by information contained in this Definitive Proxy Statement. We incorporate by reference into this Definitive Proxy Statement the following financial statements and other information, which contain important information about us and our business and financial results: We may file additional documents with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this Definitive Proxy Statement and before the Annual Meeting. The SEC allows us to incorporate by reference into the Proxy Statement such documents. You should consider any statement contained in this Definitive Proxy Statement (or in a document incorporated into this Proxy Statement) to be modified or superseded to the extent that a statement in a subsequently filed document modifies or supersedes such statement. Shareholders may obtain a copy of the Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, Our most recent ESG Report, committee charters, compliance documents and policies, including our Code of Business Conduct and Ethics can be found on the Investor Relations page of our website, www.vcel.com. The reports and information contained in, or that can be accessed from, our website, are not incorporated by reference and are not part of this Proxy Statement. The SEC permits a single Proxy Statement to be sent to any household at which two or more shareholders reside if they appear to be members of the same family. Each shareholder continues to receive a separate proxy card. This procedure, referred to as householding, reduces the volume of duplicate information shareholders receive and reduces mailing and printing expenses. A number of brokerage firms have instituted householding. As a result, if you hold your shares through a broker and you reside at an address at which two or more shareholders reside, you will likely be receiving only one Proxy Statement unless any shareholder at that address has given the broker contrary instructions. However, if any such beneficial shareholder residing at such an address wishes to receive a separate Proxy Statement in the future, or if any such beneficial shareholder that elected to continue to receive a separate Proxy Statement wishes to receive a single Proxy Statement in the future, that shareholder should contact their broker or send a request to us care of the SVP, General Counsel and Secretary at Vericel Corporation, 64 Sidney St., Cambridge, Massachusetts 02139. Telephone requests may be directed to (617) 588-5555. We will deliver promptly upon written or oral request a separate copy of this Proxy Statement to a beneficial shareholder at a shared address to which a single copy of the documents was delivered. As of the date of this Proxy Statement, the only business which the Board of Directors intends to present or knows that others will present at the meeting is as set forth above. If any other matter or matters are properly brought before the meeting, or any adjournment thereof, it is the intention of the persons named in the accompanying form of proxy to vote the proxy on such matters in accordance with their best judgment. Vericel’s reported earnings, net revenue and other indicators of financial performance, as presented in this Proxy Statement, are generally prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the SEC. In this Proxy Statement, Vericel has provided certain financial information that has not been prepared in accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted EBITDA and adjusted EDITDA margin described in this Proxy Statement, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Vericel’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Vericel’s industry. However, the non-GAAP financial measures that Vericel uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP. RECONCILIATION OF REPORTED ANNUAL NET LOSS (GAAP) This Proxy Statement and other materials we are sending you or that are available on our website in connection with the Annual Meeting (the Other Materials) contain “forward-looking statements” as defined under federal securities laws. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions. These forward-looking statements are based on our current expectations and assumptions, and are subject to risk and uncertainties that could cause our actual results or experience and the timing of events to differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in Vericel’s Annual Report on Form 10-K for the year-ended December 31, These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law. The contents of this Proxy Statement and the sending thereof to shareholders have been authorized by the Board. By Order of the Board of Directors: Sean Senior Vice President, General Counsel and Secretary VERICEL CORPORATION SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of VOTE DURING VIRTUAL MEETING Go to www.virtualshareholdermeeting.com/ You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. The meeting will begin promptly at 9:00 a.m. Eastern Time on VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on April VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: VERICEL CORPORATION The undersigned hereby appoints Dominick C. Colangelo and Joseph Mara, and hereby authorizes each of them, with full power of substitution to represent the undersigned and to vote all of the shares of stock of Vericel Corporation (the “Company”), which undersigned is entitled to vote at the Annual Meeting of Shareholders of the Company to be held via live audio webcast at www.virtualshareholdermeeting.com/VCEL2024, on Wednesday, May 1, 2024 at 9:00 a.m. Eastern Time, and at any adjournment thereof (i) as hereinafter specified upon the proposals listed on the reverse side and as more particularly described in the Company’s Proxy Statement, receipt of which is hereby acknowledged, and (ii) in their discretion upon such other matters as may properly come before the meeting. The shares represented hereby shall be voted as specified. If no specification is made, such shares shall be voted “FOR” proposals 1, 2 and 4, and “1 YEAR” for proposal 3. If you abstain from voting on proposals 1, 2, 3 and 4 it will have no effect on the voting of the proposals. Continued and to be signed on reverse sideTable ofBack to Contents Executive CompensationCompensation Committee Report
Alan L. Rubino, Chairman
Heidi Hagen
Steven C. Gilman, Ph.D.Compensation Committee Interlocks and Insider Participation
2021,2023, Mr. Rubino, Ms. Hagen and Dr. Gilman served as the members of our Compensation Committee. None of the members of our Compensation Committee is, or has been, an officer or employee of ours or any of our subsidiaries. During the last year, none of our executive officers served as: (1) a member of the compensation committee (or other committee of the board of directors performing equivalent functions or, in the absence of any such committee, the entire board of directors) of another entity, one of whose executive officers served on the compensation committee; (2) a director of another entity, one of whose executive officers served on the compensation committee; or (3) a member of the compensation committee (or other committee of the board of directors performing equivalent functions or, in the absence of any such committee, the entire board of directors) of another entity, one of whose executive officers served as a director on our Board of Directors.502024 Proxy Statement 53(1) Amounts reflect the grant date fair value of awards of time-based RSUs made to the named executive officer in the year indicated, computed in accordance with FASB ASC Topic 718. For purposes of this calculation, we have disregarded forfeiture assumptions related to service-based vesting conditions. For a discussion of the assumptions used in calculating these values, see Note 7 to our consolidated financial statements in our annual report on Form 10-K for the fiscal year ended December 31, 2021,2023, filed with the SEC on February 24, 2022.29, 2024.(2) Amounts reflect the grant date fair value of the stock option awards made to the named executive officers in the year indicated, calculated in accordance with FASB ASC Topic 718. For purposes of this calculation, we have disregarded forfeiture assumptions related to service-based vesting conditions. For a discussion of the assumptions used in calculating these values, see Note 7 to our consolidated financial statements in our annual report on Form 10-K for the fiscal year ended December 31, 2021,2023, filed with the SEC on February 24, 2022.29, 2024.(3) Amounts reported in this column represent annual cash incentive bonuses, which were awarded based on achievement of corporate performance goals for the year indicated. The 20212023 cash incentive bonus determinations are described in more detail above under the heading “Annual Non-Equity Incentive Compensation.”(4) Amounts reported in the “All Other Compensation” column include Vericel’s contributions to its 401(k) Plan and life insurance premiums, as detailed in footnotes 5, 6, 7, 8, 9 and 10.9. None of the named executive officers received perquisites having an aggregate value of $10,000 or more in the fiscal years ended December 31, 2021, 20202023, 2022, or 2019, respectively.2021.(5) This amount includes Vericel’s contributions of $10,150$11,550 made to Mr. Colangelo’s 401(k) Plan and payments of $3,236$3,089 for life insurance premiums.(6) This amount includes Vericel’s contributions of $7,197$11,550 made to Mr. Mara’s 401(k) Plan and payments of $2,668$2,764 for life insurance premiums.(7) This amount includes Vericel’s contributions of $10,150$11,550 made to Mr. Halpin’s 401(k) Plan and payments of $2,710$2,563 for life insurance premiums.(8) This amount includes Vericel’s contributions of $10,150$11,550 made to Mr. Flynn’s 401(k) Plan and payments of $2,710$2,563 for life insurance premiums.(9) This amount includes Vericel’s contributions of $10,150$11,550 made to Dr. Hopper’s 401(k) Plan and payments of $2,710$2,815 for life insurance premiums.(10) This amount includes Vericel’s contributions of $4,244 made to Ms. Pennell’s 401(k) Plan and payments of $1,242 for life insurance premiums.(11)Mr. Mara was appointed Vericel’s Chief Financial Officer, effective January 25, 2021. The amount reported in the salary column reflects base salary earned during the year. The amount reported in the Non-Equity Incentive Plan column reflects Mr. Mara’s 2021 annual cash incentive bonus, which was prorated pursuant to Vericel’s standard procedures to reflect the period of time that he was employed by the Company during 2021.(12)Amount reflects the amount of a sign-on bonus paid to Mr. Mara pursuant to the terms of his offer of employment with Vericel.(13)(11)Ms. Pennell resigned as Vericel’s Vice President and Controller and her employment with Vericel terminated on July 2, 2021. The amount reported inDr. Hopper deferred $25,385 of his salary pursuant to the Salary column reflects her base salary paid through her date of termination. All of the RSUs (reported in the Stock Awards column), and 93.8% of the value of the stock option (reported in the Option Awards column) granted to Ms. Pennell in 2021 were forfeited prior to vesting, upon her departure.Company’s Deferred Compensation Plan.54 2022 Proxy StatementBack to Contents51Executive Compensation TablesGrants of Plan-Based Awards
20212023 to our named executive officers: Estimated Future
Payouts Under
Non-Equity
Incentive Plan
Awards(1) All Other
Stock Awards:
Number of
Shares of
Stock or
Units All Other
Option
Awards:
Number of
Securities
Underlying
Options (#) Exercise or
Base Price
of Option
Awards
($/Sh) Grant Date
Fair Value
of Stock
and Option
Awards(2) Name Grant Date Target
($) Maximum
($) Dominick C. Colangelo — 620,500 1,241,000 — — — — 2/19/2021 — — 35,750 — — 1,837,550 2/19/2021 — — — 300,000 51.40 9,981,859 Joe Mara(3) — 193,300 386,600 — — — — 1/25/2021 — — 16,000 — — 698,080 1/25/2021 — — — 160,000 43.63 4,438,361 Michael Halpin — 220,000 440,000 — — — — 2/19/2021 — — 11,250 — — 578,250 2/19/2021 — — — 100,000 51.40 3,327,286 Sean C. Flynn — 168,750 337,500 — — — — 2/19/2021 — — 7,000 — — 359,800 2/19/2021 — — — 60,000 51.40 1,996,372 Jonathan Hopper — 175,500 351,000 — — — — 2/19/2021 — — 7,000 — — 359,800 2/19/2021 — — — 60,000 51.40 1,996,372 Sandra Pennell(4) — 72,000 144,000 — — — — 2/19/2021 — — 2,750 — — 141,350 2/19/2021 — — — 25,000 51.40 831,822 Estimated Future
Payouts Under
Non-Equity
Incentive Plan
Awards(1) All Other
Stock Awards:
Number of
Shares of
Stock or
Units (#) All Other
Option
Awards:
Number of
Securities
Underlying
Options (#) Exercise or
Base Price
of Option
Awards
($/Sh) Grant Date
Fair Value
of Stock
and Option
Awards(2) Name Grant Date Target
($) Maximum
($) Dominick Colangelo — 738,700 1,477,400 — — — — 2/17/2023 — — 73,000 — — 2,176,860 2/17/2023 — — — 182,500 29.82 3,336,223 Joe Mara — 261,300 522,600 — — — — 2/17/2023 — — 18,500 — — 551,670 2/17/2023 — — — 46,250 29.82 845,481 Michael Halpin — 277,800 555,600 — — — — 2/17/2023 — — 21,000 — — 626,220 2/17/2023 — — — 52,500 29.82 959,735 Sean Flynn — 212,900 425,800 — — — — 2/17/2023 — — 12,000 — — 357,840 2/17/2023 — — — 30,000 29.82 548,420 Jonathan Hopper — 217,800 435,600 — — — — 2/17/2023 — — 12,000 — — 357,840 2/17/2023 — — — 30,000 29.82 548,420 (1) Non-equity incentive plan awards consist of performance-based cash bonuses earned based on achievement of pre-determined performance criteria during fiscal year 2021.2023. There is no threshold payout amount under the non-equity incentive plan. The 20212023 cash incentive bonus determinations are described in more detail above under the heading “Annual Non-Equity Incentive Compensation.”(2) This reflects the grant date fair value of option and RSU awards granted to our named executive officers during the year ended December 31, 2021,2023, calculated in accordance with FASB ASC Topic 718. For purposes of this calculation, we have disregarded forfeiture assumptions related to service-based vesting conditions. For a discussion of the assumptions used in calculating these values, see Note 7 to our consolidated financial statements in our annual report on Form 10-K for the fiscal year ended December 31, 2021,2023, filed with the SEC on February 24, 2022.(3)Mr. Mara was appointed Vericel’s Chief Financial Officer, effective January 25, 2021. Mr. Mara’s 2021 target bonus was prorated pursuant to Vericel’s standard procedures to reflect the period of time that he was employed by the Company during 2021. Mr. Mara’s initial grant of 16,000 RSUs vested in equal quarterly installments on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021, respectively.(4)Ms. Pennell resigned as Vericel’s Vice President and Controller and her employment with Vericel terminated on July 2, 2021. Because Ms. Pennell was not employed on the date that 2021 annual incentive bonuses were paid, she was not eligible to, and did not, receive an annual incentive bonus for 2021. In addition, all of the RSUs and 93.8% of the value of the stock option granted to Ms. Pennell in 2021 were forfeited prior to vesting, upon her departure.29, 2024.2024 Proxy Statement 55 52Back to ContentsExecutive Compensation TablesOutstanding Equity Awards at Fiscal Year End
2021.2023. We currently grant stock-based awards pursuant to our 20192022 Plan and have outstanding awards under our Amended and Restated 2019 Omnibus Incentive Plan (the “2019 Plan”), 2017 Omnibus Incentive Plan (the “2017 Plan”) and our Second Amended and Restated 2009 Omnibus Incentive Plan (the “2009 Plan”). Option Awards Stock Awards Name Grant Date Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable(1) Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1) Option
Exercise
Price
($) Option
Expiration
Date Number
Shares or
Units of
Stock That
Have Not
Vested
(#)(2) Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(3) Dominick C. Colangelo 3/6/2013 (4) 39,938 — 25.80 3/6/2023 — — 1/3/2014 48,397 — 3.57 1/3/2024 — — 1/5/2015 383,452 — 3.02 1/5/2025 — — 2/9/2016 53,183 — 1.95 2/9/2026 — — 2/8/2017 49,700 — 2.75 2/8/2027 — — 5/22/2017 (5) 28,125 — 2.65 5/22/2027 — — 2/7/2018 274,445 18,750 7.20 2/7/2028 — — 2/6/2019 213,125 96,875 16.66 2/6/2029 13,875 545,288 2/11/2020 98,437 126,563 18.00 2/11/2030 22,500 884,250 2/19/2021 56,250 243,750 51.40 2/19/2031 35,750 1,404,975 Joe Mara 1/25/2021 (4) — 160,000 43.63 1/25/2031 — — Michel Halpin 4/10/2017 (4) 2,063 — 2.65 4/10/2027 — — 2/7/2018 18,058 2,521 7.20 2/7/2028 — — 2/6/2019 52,421 23,829 16.66 2/6/2029 3,750 147,375 2/11/2020 45,937 59,063 18.00 2/11/2030 10,500 412,650 2/19/2021 18,750 81,250 51.40 2/19/2031 11,250 442,125 Sean C. Flynn 11/4/2019 (4) 55,000 75,000 16.25 11/4/2029 — — 2/19/2021 11,250 48,750 51.40 2/19/2031 7,000 275,100 Jonathan Hopper 8/20/2018 (4) 22,291 25,313 10.95 8/20/2028 — — 2/6/2019 7,875 8,125 16.66 2/6/2029 1,300 51,090 2/11/2020 21,328 27,422 18.00 2/11/2030 4,875 191,588 2/19/2021 11,250 48,750 51.40 2/19/2031 7,000 275,100 Sandra Pennell(6) — — — — — — — Option Awards Stock Awards Name Grant Date Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable(1) Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1) Option
Exercise
Price
($) Option
Expiration
Date Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)(2) Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(3) Dominick Colangelo 1/5/2015 383,452 — 3.02 1/5/2025 — — 2/9/2016 53,183 — 1.95 2/9/2026 — — 2/8/2017 49,700 — 2.75 2/8/2027 — — 5/22/2017 (5) 28,125 — 2.65 5/22/2027 — — 2/7/2018 293,195 — 7.20 2/7/2028 — — 2/6/2019 310,000 — 16.66 2/6/2029 — — 2/11/2020 210,937 14,063 18.00 2/11/2030 7,500 267,075 2/19/2021 206,250 93,750 51.40 2/19/2031 17,875 636,529 2/18/2022 119,437 153,563 34.90 2/18/2032 35,100 1,249,911 2/17/2023 34,218 148,282 29.82 2/17/2033 73,000 2,599,530 Joe Mara 1/25/2021 (4) 110,000 50,000 43.63 1/25/2031 — — 2/18/2022 28,117 36,152 34.90 2/18/2032 8,264 294,281 2/17/2023 8,671 37,579 29.82 2/17/2033 18,500 658,785 Michael Halpin 4/10/2017 (4) 2,063 — 2.65 4/10/2027 — — 2/7/2018 3,132 — 7.20 2/7/2028 — — 2/6/2019 76,250 — 16.66 2/6/2029 — — 2/11/2020 98,437 6,563 18.00 2/11/2030 3,500 124,635 2/19/2021 68,750 31,250 51.40 2/19/2031 5,625 200,306 2/18/2022 39,046 50,204 34.90 2/18/2032 11,475 408,625 2/17/2023 9,843 42,657 29.82 2/17/2033 21,000 747,810 Sean Flynn 11/4/2019 (4) 130,000 — 16.25 11/4/2029 — — 2/19/2021 41,250 18,750 51.40 2/19/2031 3,500 124,635 2/18/2022 23,734 30,516 34.90 2/18/2032 6,975 248,380 2/17/2023 5,625 24,375 29.82 2/17/2033 12,000 427,320 Jonathan Hopper 8/20/2018 (4) 32,604 — 10.95 8/20/2028 — — 2/6/2019 16,000 — 16.66 2/6/2029 — — 2/11/2020 35,703 3,047 18.00 2/11/2030 1,625 57,866 2/19/2021 41,250 18,750 51.40 2/19/2031 3,500 124,635 2/18/2022 23,734 30,516 34.90 2/18/2032 6,975 248,380 2/17/2023 5,625 24,375 29.82 2/17/2033 12,000 427,320 (1). Unless otherwise noted, options vest over a period of four years, with 6.25% vesting each quarter following the grant date. (2). RSUs vest over four years with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal annual installments thereafter. (3). Based on a price of $39.30$35.61 per share, which was the closing price per share of our common stock as reported by the Nasdaq CapitalGlobal Market on December 31, 2021.29, 2023.(4). This option vests over a period of four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter. (5). This option vests over a period of four years, with 6.25% vesting each quarter following February 8, 2017. (6)56Ms. Pennell resigned as Vericel’s Vice President and Controller and her employment with Vericel terminated on July 2, 2021. She held no outstanding stock options or unvested stock awards as of December 31, 2021. 2022 Proxy StatementBack to Contents53Executive Compensation TablesOption Exercises and Stock Vested
2021.2023. None of our named executive officers held equity awards other than stock options and RSUs that were exercised or vested during the year ended December 31, 2021.2023. Option Awards Stock Awards Name Number of Shares
Acquired on Exercise
(#) Value Realized
on Exercise
($)(1) Number of Shares
Acquired on Vesting
(#)(2) Value Realized
on Vesting
($)(3) Dominick C. Colangelo 43,418 1,678,564 14,438 696,560 Joe Mara(4) — — 16,000 784,600 Michael Halpin 45,000 2,197,750 5,375 260,768 Sean C. Flynn 20,000 749,184 — — Jonathan Hopper 54,132 1,953,996 2,275 110,666 Sandra Pennell 71,899 3,466,475 1,000 56,275 Option Awards Stock Awards Name Number of Shares
Acquired on Exercise
(#) Value Realized
on Exercise
($)(1) Number of Shares
Acquired on Vesting
(#)(2) Value Realized
on Vesting
($)(3)Dominick Colangelo 88,335 1,513,939 35,076 1,044,178 Joe Mara — — 2,754 82,124 Michael Halpin 17,447 492,260 12,013 356,330 Sean Flynn — — 4,075 121,517 Jonathan Hopper 5,000 127,250 6,350 188,304 (1) Value realized on exercise of stock option awards does not represent proceeds from any sale of any common stock acquired upon exercise but is determined by multiplying the number of shares acquired upon exercise by the difference between the per share exercise price of the option and the closing price of a share of our common stock on the Nasdaq CapitalGlobal Market on the date of exercise.(2) This represents total RSUs that vested for the named executive officer. A portion of these shares were withheld to cover the tax liability of the vesting and the amounts reported do not represent the total shares received by the employee. (3) Value realized on vesting of RSUs is determined by multiplying the number of shares vested by the closing price of a share of our common stock on the Nasdaq CapitalGlobal Market on the date of vesting.Nonqualified Deferred Compensation
Nonqualified Deferred Compensation Table
Name DCP
Contributions in
Last Fiscal Year
($) Vericel
Contributions in
Last Fiscal Year
($) Aggregate
Earnings at fiscal
Year-end
($)(1) Aggregate
Withdrawals/
Distributions
($) Aggregate
Balance at
Fiscal Year-End
($)(1)Jonathan Hopper 23,385 (1) — 2,383 — 27,768 (4)(1)$25,385 of this contribution relates to Mr. MaraHopper’s deferred base salary that was appointed Vericel’s Chief Financial Officer, effective January 25, 2021. Upon his appointment, Mr. Mara was awarded an initial grant of an optioncontributed to purchase 160,000 shares and 16,000 RSUs.the Deferred Compensation Plan. The option vests over a period of four years, with 25% vesting onamount is reflected in the first anniversary“salary” column of the grant date and the remainder vesting in equal monthly installments thereafter. Consequently, Mr. Mara was unable to exercise option awards during 2021.2023 Summary Compensation Table.2024 Proxy Statement 57 Pension Benefits
Nonqualified Deferred CompensationThere were no nonqualified deferred compensation plans or arrangements offered to any of our executive officers during 2021.Employment Contracts, including Termination of Employment and Change-in-Control Arrangements
We were not party to an employment agreement with Ms. Pennell. Each Employment Agreement provides for specified payments and benefits in connection with a termination of employment by us without Cause or a resignation by the named executive officer for Good Reason (as such terms are defined in the Employment Agreements). Our goal in providing severance and change-in-control benefits is to offer sufficient cash continuity protection such that our executives will focus their full time and attention on the requirements of the business rather than the potential implications for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the named executive officers, rather than negotiating severance at the time that a named executive officer’s employment terminates. We have also determined that accelerated vesting provisions with respect to equity awards in connection with a qualifying termination are appropriate because they encourage our named executive officers to stay focused on the business in those circumstances, rather than focusing on the potential implications for them personally.54Executive Compensation TablesAgreement)Agreements), (i) Vericel shall pay the named executive officer a lump sum amount equal to (A) the sum of the named executive officer’s then-effective base salary and target bonus for the year in which termination occurs (or, in the case of Mr. Colangelo, 1.5 times the sum of his base salary and target bonus) plus (B) a pro-rated portion of the named executive officer’s target bonus for the year of termination, (ii) if the named executive officer was participating in Vericel’s group health plan immediately prior to the date of termination and elects COBRA coverage, Vericel shall pay the named executive officer a monthly cash payment equal to the monthly employer contribution that Vericel would have made to provide health insurance to the named executive officer had he remained employed by Vericel (or, in the case of Mr. Colangelo, the full monthly COBRA premium) until the earlier of twelve months (or, in the case of Mr. Colangelo, eighteen months) following termination or the end of the named executive officer’s COBRA health continuation period, and (iii) all time-based equity awards held by the named executive officer shall immediately vest and become fully exercisable or nonforfeitable as of the date of termination. The named executive officer’s right to receive any severance payments and benefits under the applicable Employment Agreement is conditioned upon and subject to the named executive officer’sofficer signing and not revoking a general release of claims.Each of our named executive officer’s base salary is reviewed annually by the Compensation Committee. The named executive officers are also eligible to receive cash incentive compensation and equity awards from time to time at the discretion of the Compensation Committee. The current base salary as of March 7, 2022, and target annual incentive compensation (as a percentage of the base salary) for each of our currently serving named executive officers is as follows:Name Base Salary Target Annual Incentive
Compensation (%) Dominick C. Colangelo $ 760,000 85% Joe Mara $ 440,000 50% Michael Halpin $ 470,000 50% Sean C. Flynn $ 400,000 45% Jonathan Hopper $ 415,000 45% 58 Acceleration of Vesting Under Stock Option Plans
the 2017 Plan or the 2009 Plan, as applicable), if awards under the 2019 Plan, the 2017 Plan or the 2009 Plan, as applicable plan are not assumed, continued or substituted, awards shall vest immediately prior to the Change-in-Control and terminate on the day of the Change-in-Control. If assumed, continued or substituted and the participant’s services to Vericel are terminated by Vericel or its successor without cause within twelve months following the Change-in-Control, the awards shall become fully vested and exercisable and may be exercised at any time prior to the earlier of the expiration date of the award or three months following the date of termination.2022 Proxy Statement55Table Additionally, upon termination of Contentsemployment as a result of the participant’s death or disability (as such term is defined in Treas. Reg. Section 1.409A-3(i)(4)), awards issued to the participant under the applicable plan shall become fully vested and exercisable by a person or persons legally entitled to do so at any time prior to the expiration of the award or within one (1) year, whichever, in the case of option awards, is the shorter period.Executive Compensation TablesPotential Payments Upon a Termination or Change-in-Control
2021,2023, and using the salary in effect on such date. Sandra Pennell resigned as Vericel’s Vice President and Controller and her employment with Vericel terminated on July 2, 2021. She received no severance payments or benefits in connection with her termination and has therefore been omitted from this table.Name Benefit Termination w/o Cause
or for Good Reason other
than in connection with
a Change-in-Control
($) Termination w/o Cause
or for Good Reason
in connection with a
Change-in-Control
($) Dominick C. Colangelo Severance Pay 730,000 2,646,250 Health Care Benefits 23,882 35,824 Equity Award Acceleration 4,473,198 (1) 8,325,429 (2) Total 5,227,080 11,007,503 Joe Mara Severance Pay 415,000 830,000 Health Care Benefits 19,252 19,252 Equity Award Acceleration — — Total 434,252 849,252 Michael Halpin Severance Pay 440,000 880,000 Health Care Benefits 19,267 19,267 Equity Award Acceleration — 2,880,605 (2) Total 459,267 3,779,872 Sean C. Flynn Severance Pay 375,000 712,600 Health Care Benefits 19,267 19,267 Equity Award Acceleration — 2,003,850 (2) Total 394,267 2,735,717 Jonathan Hopper Severance Pay 390,000 741,000 Health Care Benefits 19,267 19,267 Equity Award Acceleration — 2,003,440 Total 409,267 2,763,707 Name Benefit Termination w/o Cause
or for Good Reason other
than in connection with
a Change-in-Control
($) Termination w/o Cause
or for Good Reason
in connection with a
Change-in-Control
($) Termination as a Result
of Death or Disability Nick Colangelo Severance Pay 790,000 3,031,750 — Health Care Benefits 26,727 40,091 — Equity Award Acceleration 2,212,117 (1) 5,968,277 (2) 5,968,277 (3) Total 3,028,844 9,040,118 5,968,277 Joseph Mara Severance Pay 475,000 997,600 — Health Care Benefits 26,727 26,727 — Equity Award Acceleration — 1,196,316 (2) 1,196,316 (3) Total 501,727 2,220,643 1,196,316 Michael Halpin Severance Pay 505,000 1,060,600 — Health Care Benefits 26,727 26,727 — Equity Award Acceleration — 1,879,579 (2) 1,879,579 (3) Total 531,727 2,966,906 1,879,579 Jonathan Hopper Severance Pay 440,000 875,600 — Health Care Benefits 26,727 26,727 — Equity Award Acceleration — 1,074,656 (2) 1,074,656 (3) Total 466,727 1,976,983 1,074,656 Sean Flynn Severance Pay 430,000 855,800 — Health Care Benefits 22,175 22,175 — Equity Award Acceleration — 963,132 (2) 963,132 (3) Total 452,175 1,841,107 963,132 (1) This represents the cumulative value of the equity awards that would accelerate upon a termination of employment not in connection with a Change-in-Control. The amount represents the difference between the closing price of our common stock on December 31, 2021,29, 2023, of $39.30$35.61 and the exercise price (if any) multiplied by the number of shares subject to any in-the-money options and RSUs that would accelerate.(2) This represents the cumulative value of the equity awards that would accelerate upon a qualifying termination of employment within 18 months following a Change-in-Control (or upon a Change-in-Control if equity awards are not assumed in such Change-in-Control). The amount represents the difference between the closing price of our common stock on December 31, 2021,29, 2023, of $39.30$35.61 and the exercise price (if any) multiplied by the number of shares subject to any in-the-money options and RSUs that would accelerate.(3) This represents the cumulative value of the equity awards that would accelerate upon the named executive officer’s death or disability. The amount represents the difference between the closing price of our common stock on December 29, 2023, of $35.61 and the exercise price (if any) multiplied by the number of shares subject to any in-the-money options and RSUs that would accelerate. 562024 Proxy Statement59Table ofBack to Contents Executive Compensation TablesCEO Pay Ratio
Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are required to disclose the median of the annual total compensation of our employees, the annual total compensation of our Principal Executive Officer (“PEO”), Mr. Colangelo, and the ratio of these two amounts. We believe that our compensation philosophy must be consistent and internally equitable to motivate our employees to create shareholder value. The purpose of the required disclosure is to provide a measure of pay equity within the organization. We are committed to internal pay equity, and our Compensation Committee monitors the relationship between the pay our PEO receives and the pay our non-executive employees receive.20212023 PEO to median employee pay ratio was approximately 82:38:1.Dominick C. Colangelo (PEO) 2021 Compensation $13,183,295Median Employee 2021 Compensation $160,777Ratio of PEO to Median Employee Compensation82:1Dominick Colangelo (PEO) 2023 Compensation $ 7,056,422 Median Employee 2023 Compensation $ 184,128 Ratio of PEO to Median Employee Compensation 38:1 20212023 (whether employed on a full-time, part-time or seasonal basis). Employees on leave of absence were included in the list and reportable wages were annualized for those employees who were not employed for the full calendar year.2021,2023, we calculated that median employee’s total compensation using the same methodology that we used to calculate the total compensation for our CEO. The 20212023 annual total compensation of the median employee and our CEO, respectively, were $160,777$7,056,422 and $13,183,295.$184,128. The ratio of the 20212023 annual total compensation for our CEO to that of our median employee was 8238 to 1.Pay versus Performance
Value of Initial $100
Investment Based On: Year Summary
Compensation
Table Total
for CEO Compensation
Actually
Paid to CEO(1) Average
Summary
Compensation
Table Total for
Other NEOs(2) Average
Compensation
Actually Paid
to Other
NEOs(1)(2) Vericel
TSR(3) NASDAQ
Biotechnology
Index TSR(3) Net
Income
($M)(4) Total Net
Revenue
($M)(5) 2023 $ 7,056,422 $ 11,004,671 $ 1,918,083 $ 2,851,774 $ 205 $ 115 $ -3 $ 198 2022 $ 8,708,367 $ 905,166 $ 2,398,900 $ 467,192 $ 151 $ 111 $ -17 $ 164 2021 $ 13,183,295 $ 15,233,917 $ 3,459,670 $ 3,204,518 $ 226 $ 125 $ -7 $ 156 2020 $ 4,412,718 $ 10,300,425 $ 1,158,216 $ 1,740,344 $ 177 $ 126 $ 3 $ 124 2022 Proxy Statement(1)57To calculate CAP, the following amounts were deducted from and added to the applicable Summary Compensation Table total compensation:(2) The other NEOs in each covered year were as follows: 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell. (3) TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index. (4) Reflects net Income as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2023, 2022, 2021 and 2020. (5) Reflects total net revenue, the “company-selected measure” as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2023, 2022, 2021 and 2020. (1) To calculate CAP, the following amounts were deducted from and added to the applicable Summary Compensation Table total compensation: 60 CEO 2020 2021 2022 2023 Summary Compensation Table Total $ 4,412,718 $ 13,183,295 $ 8,708,367 $ 7,056,422 Less: Grant Date Fair Value of Stock and Option Awards in the Covered Year -$ 3,218,783 -$ 11,819,409 -$ 7,288,603 -$ 5,513,083 Plus: Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year* +$ 5,022,331 +$ 6,387,501 +$ 4,402,751 +$ 5,834,763 Plus: Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year* +$ 522,347 +$ 1,618,248 +$ 724,137 +$ 711,181 Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years* +$ 3,550,577 +$ 1,965,721 -$ 3,564,080 +$ 1,963,617 Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year* +$ 11,235 +$ 3,898,560 -$ 2,077,406 +$ 951,771 = Compensation Actually Paid $ 10,300,425 $ 15,233,917 $ 905,166 $ 11,004,671 Average of Other NEOs 2020 2021 2022 2023 Summary Compensation Table Total $ 1,158,216 $ 3,459,670 $ 2,398,900 $ 1,918,083 Less: Grant Date Fair Value of Stock and Option Awards in the Covered Year -$ 714,993 -$ 2,945,499 -$ 1,748,862 -$ 1,198,907 Plus: Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year* +$ 756,348 +$ 1,626,544 +$ 1,056,425 +$ 1,275,999 Plus: Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year* +$ 83,133 +$ 271,626 +$ 173,955 +$ 147,705 Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years* +$ 636,734 +$ 299,760 -$ 902,246 +$ 445,775 Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year* +$ 5,675 +$ 594,099 -$ 510,980 +$ 263,119 Less: Fair Value of Stock and Option Awards Forfeited During the Covered Year* -$ 184,769 -$ 101,683 +$ 0 +$ 0 = Compensation Actually Paid $ 1,740,344 $ 3,204,518 $ 467,192 $ 2,851,774 * All stock option valuations included in “Compensation Actually Paid” values were performed using the Black-Scholes option pricing model in a manner generally consistent with the process used to determine stock option grant date fair values under FASB ASC Topic 718 (refer to our Annual Report on Form 10-K for the year ending December 31, 2023 for additional detail). (2) The other NEOs in each covered year were as follows: 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell. (3) TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index. (4) Reflects net Income as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2023, 2022, 2021 and 2020. (5) Reflects total net revenue, the “company-selected measure” as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2023, 2022, 2021 and 2020. Audit MattersTabular List of Financial Performance Measures• Total Net Revenue • Stock Price • Budget expense (excluding depreciation, amortization and stock-based compensation, and unusual one-time expenses or changes in accounting methodology) 2024 Proxy Statement 61 Compensation Actually Paid Comparisons
62 PROPOSAL 3: Advisory Vote on the Frequency of Future Advisory Votes to Approve the Compensation of our Named Executive Officers
The Board of Directors unanimously recommends that you vote, on an advisory basis, that future advisory votes on the compensation of our named executive officers be held every 1 YEAR. Vote Required
2024 Proxy Statement 63 Audit
MattersOverview
2022.2024. PwC has acted in such capacity since its appointment in fiscal year 1996.except oneof the meetings of the Audit Committee to which they were invited during the fiscal year ended December 31, 2022, and all of the meetings of the Audit Committee during the fiscal year ended December 31, 2020, and all except two of the meetings of the Audit Committee during the fiscal year ended December 31, 2021.2023. We expect that a representative of PwC will attend the Annual Meeting, and the representative will have an opportunity to make a statement if he or she so desires. The representative will also be available to respond to appropriate questions from shareholders.Vote Required
5864 Table ofBack to Contents Audit MattersFees of Independent Registered Public Accounting Firm
2021,2023, by PwC, our independent registered public accounting firm for that period, to ensure the firm maintains its independence. The following table sets forth the aggregate fees accrued by Vericel for the fiscal years ended December 31, 2020,2022, and 2021,2023, respectively, for PwC: Fiscal Year
Ended
December 31,
2020
($) Fiscal Year
Ended
December 31,
2021
($)Audit Fees 991,000 (1) 1,215,608 (1) Audit Related Fees — — Tax Fees 20,893 (2) — (2) All Other Fees 2,000 (3) 2,700 (3) Total 1,013,893 1,218,308 Fiscal Year Ended
December 31, 2022 ($) Fiscal Year Ended
December 31, 2023 ($) Audit Fees 1,261,700 (1) 1,329,500 (1) Audit Related Fees — — Tax Fees — — All Other Fees 2,993 (2) 3,074 (2) Total 1,264,693 1,332,574 (1) The Audit Fees for the years ended December 31, 20202022 and 20212023 were for professional services rendered for the audits and reviews of the consolidated financial statements of Vericel, professional services rendered for issuance of consents, comfort letters, assistance with review of documents filed with the SEC and out-of-pocket expenses incurred.(2) The Tax Fees were for professional tax consulting services rendered.(3)All other Fees represent an annual license fee for technical accounting research software and the use of accounting disclosure checklists. Pre-Approval Policy
20202022 and 20212023 were pre-approved by the Audit Committee.Report of the Audit Committee of the Board of Directors
L. Zerbe, M.D., Alan L. Rubino and Kevin F. McLaughlin were members of the Audit Committee during the fiscal year ended December 31, 2021.2023.2022 Proxy Statement59Audit Matters2021.2023.
Kevin F. McLaughlin, Chairman
Alan L. Rubino
Robert L. Zerbe, M.D.60Omnibus Incentive Plan ProposalProposal 4: To Approve our 2022 Omnibus Incentive PlanThe Board of Directors unanimously recommends a vote FOR the approval of Vericel’s 2022 Omnibus Incentive Plan.OverviewAt the Annual Meeting, shareholders will be asked to approve Vericel’s 2022 Omnibus Incentive Plan (the “2022 Plan”). The 2022 Plan was approved by the Board of Directors on February 16, 2022, subject to shareholder approval of this proposal at the Annual Meeting. The 2022 Plan is intended to provide flexibility to Vericel in its ability to motivate, attract, and retain the services of directors, officers, and employees upon whose judgment, interest, and special effort the successful conduct of Vericel’s business is largely dependent.As of December 31, 2021, there were stock options to acquire 5,669,690 shares of common stock outstanding under our equity compensation plans, with a weighted average exercise price of $22.49 and a weighted average remaining term of 7.2 years. In addition, as of December 31, 2021, there were 398,748 unvested RSU awards with time-based vesting outstanding under our equity compensation plans. Other than the foregoing, no awards under our equity compensation plans were outstanding as of December 31, 2021.As of December 31, 2021, there were 2,822,710 shares of common stock available for awards under our equity compensation plans.Summary of Material FeaturesThe material features of the 2022 Plan are:●The maximum number of shares of common stock available for awards under the 2022 Plan is 5,572,710 shares, less one share of common stock for every share subject to an option or stock appreciation right granted after December 31, 2021 and prior to the effective date of the 2022 Plan under our 2019 Plan and 1.5 shares for each share of common stock subject to an award other than an option or stock appreciation right granted after December 31, 2021 and prior to the effective date of the 2022 Plan under the 2019 Plan (the 5,572,710 shares reflect the 2,822,710 shares that were available under the 2019 Plan as of December 31, 2021, plus an incremental 2,750,000 shares);●After the effective date of the 2022 Plan, no awards may be granted under the Prior Plans (as defined below);●The award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, RSUs, performance awards and dividend equivalents is permitted under the 2022 Plan;●Grants of “full-value” awards are deemed for purposes of determining the number of shares available for future grants under the 2022 Plan as an award for 1.5 shares for each share of common stock subject to the award. Grants of stock options or stock appreciation rights are deemed to be an award of one share for each share of common stock subject to the award;●Shares tendered or withheld for taxes with respect to options or stock appreciation rights will not be added back to the reserved pool under the 2022 Plan. Upon the exercise of a stock appreciation right that is settled in shares of common stock, the full number of shares underlying the award will be charged to the reserved pool. Additionally, shares tendered by a participant or withheld by Vericel in payment of the purchase price of an option and shares we reacquire on the open market or otherwise using cash proceeds from the exercise of options will not be added to the reserved pool;●Stock options and stock appreciation rights may not be repriced in any manner without shareholder approval (except as permitted in the event of certain equitable adjustments or a change-in-control of Vericel);●The aggregate value of all equity and cash awards payable to any non-employee director in any calendar year for service as a non-employee director may not exceed $800,000; provided, however, that with respect to the Chairman of the Board of Directors, the lead independent director, or any newly-elected non-employee director in his or her first calendar year of service, such amount shall not exceed $1,000,000;●The 2022 Plan does not provide for automatic acceleration of vesting upon a change-in-control;●Dividends and dividend equivalents are subject to restrictions and risk of forfeiture to the same extent as the underlying award and will not be paid unless and until the underlying award vests; 20222024 Proxy Statement6165Omnibus Incentive Plan Proposal●Any material amendment to the 2022 Plan is subject to approval by our shareholders; and●The term of the 2022 Plan will expire on April 27, 2032.Based solely on the closing price of our common stock as reported by the Nasdaq Capital Market on March 3, 2022 ($40.79) and the maximum number of shares that would have been available for awards as of such date under the 2022 Plan had it existed at that time, the maximum aggregate market value of the common stock that could potentially be issued under the 2022 Plan is $227,310,841. The shares we issue under the 2022 Plan will be authorized but unissued shares, treasury shares or shares of common stock purchased in the open market or otherwise. The shares of common stock underlying any awards that are forfeited, expired or settled in cash (in whole or in part), under the 2022 Plan, the 2019 Plan, the 2017 Plan, and the 2009 Plan (the 2009 Plan, the 2017 Plan and the 2019 Plan, the “Prior Plans”) after December 31, 2021 will be added back to the shares of common stock available for issuance under the 2022 Plan. In the event that withholding tax liabilities arising from an award other than an option or stock appreciation right under the 2022 Plan, or, after December 31, 2021, an award other than an option or stock appreciation right under any Prior Plan, are satisfied by the tendering of shares or by the withholding of shares by Vericel, the shares so tendered or withheld will be added to the shares available for awards under the 2022 Plan. Any shares that again become available for grant under the 2022 Plan will be added back as (i) one share for each share subject to a stock option or stock appreciation right, and (ii) 1.5 shares for each share subject to an award other than a stock option or stock appreciation right. Shares tendered or withheld for taxes with respect to options or stock appreciation rights will not be added back to the reserved pool under the 2022 Plan. Upon the exercise of a stock appreciation right that is settled in shares of common stock, the full number of shares underlying the award will be charged to the reserved pool. Additionally, shares tendered by a participant or withheld by Vericel in payment of the purchase price of an option and shares we reacquire on the open market or otherwise using cash proceeds from the exercise of options will not be added to the reserved pool.Rationale for Adoption of the 2022 PlanThe 2022 Plan is critical to our ongoing effort to build stockholder value. Equity incentive awards are an important component of our executive and non-executive employees’ compensation. Our Compensation Committee and the Board of Directors believe that we must continue to offer a competitive equity compensation program in order to attract, retain and motivate the talented and qualified employees necessary for our continued growth and success. By ensuring that our employees and directors hold equity awards, we link the interests of those employees and directors with those of our shareholders and motivate our employees and directors to act as owners of the business. Equity-based compensation is a critical component of our overall competitive pay mix, which is designed to achieve the appropriate balance between short- and long-term incentives through annual cash bonuses and equity awards, respectively.We manage our long-term stockholder dilution by limiting the number of equity incentive awards granted annually. The Compensation Committee carefully monitors our annual net burn rate, total dilution and equity expense in order to maximize stockholder value by granting only the number of equity incentive awards that it believes are necessary and appropriate to attract, reward and retain our employees and non-employee directors. Our compensation philosophy reflects broad-based eligibility for equity incentive awards for high-performing employees.Burn RateThe following table sets forth information regarding historical awards granted for the 2019 through 2021 period, and the corresponding burn rate, which is defined as the number of shares subject to equity-based awards granted in a year divided by the weighted-average number of shares of common stock outstanding for that year:Share Element 2021 2020 2019 Stock Options Granted 1,683,568 1,356,540 2,033,760 Full-Value Awards Granted 266,759 196,836 186,922 Total Awards Granted 1,950,327 1,553,376 2,220,682 Weighted-average common shares outstanding during the fiscal year 46,472,000 45,221,000 44,180,000 Annual Burn Rate 4.2% 3.4% 5.0% Three-Year Average Burn Rate 4.2% Information About
Stock OwnershipOmnibus Incentive Plan ProposalOur Compensation Committee determined the size of the reserved pool under the 2022 Plan based on projected equity awards to anticipated new hires, projected annual equity awards to existing employees and directors and an assessment of the magnitude of increase that our institutional investors and the firms that advise them would likely find acceptable. We anticipate that the share reserve will last for approximately two to three years. As of December 31, 2021, the sum of outstanding equity awards and total shares available for future grant if the 2022 Plan is approved would be 19.9% of fully-diluted shares outstanding, which we define as the sum of outstanding equity awards, total shares available for future grant including new shares, and common shares outstanding on December 31, 2021.Summary of the 2022 PlanThe following description of certain features of the 2022 Plan is intended to be a summary only. The summary is qualified in its entirety by the full text of the 2022 Plan, which is attached hereto as Appendix I.Share ReserveThe maximum number of shares of common stock available for awards under the 2022 Plan is 5,572,710 shares, less one share of common stock for every share subject to an option or stock appreciation right granted after December 31, 2021 and prior to the effective date of the 2022 Plan under the 2019 Plan and 1.5 shares for each share of common stock subject to an award other than an option or stock appreciation right granted after December 31, 2021 and prior to the effective date of the 2022 Plan under the 2019 Plan. The shares of common stock underlying any awards that are forfeited, expire or are settled in cash (in whole or in part) under the 2022 Plan and the Prior Plans after December 31, 2021, will be added back to the shares of common stock available for issuance under the 2022 Plan. In the event that withholding tax liabilities arising from an award other than an option or stock appreciation right under the 2022 Plan or, after December 31, 2021, an award other than an option or stock appreciation right under any Prior Plan, are satisfied by the tendering of shares or by the withholding of shares by Vericel, the shares so tendered or withheld will be added to the shares available for awards under the 2022 Plan. Any shares that again become available for grant under the 2022 Plan will be added back as (i) one share for each share subject to a stock option or stock appreciation right, and (ii) 1.5 shares for each share subject to an award other than a stock option or stock appreciation right. Shares tendered or withheld for taxes with respect to options or stock appreciation rights will not be added back to the reserved pool under the 2022 Plan. Upon the exercise of a stock appreciation right that is settled in shares of common stock, the full number of shares underlying the award will be charged to the reserved pool. Additionally, shares tendered by a participant or withheld by Vericel in payment of the purchase price of an option and shares we reacquire on the open market or otherwise using cash proceeds from the exercise of options will not be added to the reserved pool.Plan AdministrationThe 2022 Plan will be administered by the Compensation Committee. The Compensation Committee will have the full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2022 Plan. The Compensation Committee may delegate to one or more executive officers or a committee of executive officers the right to grant awards to employees under the 2022 Plan who are not directors or executive officers of Vericel and the authority to take action on behalf of the Compensation Committee pursuant to the 2022 Plan to cancel or suspend awards to employees who are not directors or executive officers of Vericel.EligibilityPersons eligible to participate in the 2022 Plan will be those employees, non-employee directors and consultants of Vericel and its affiliates as selected from time to time by the Compensation Committee in its discretion. Approximately 285 individuals are currently eligible to participate in the 2019 Plan (and would be eligible to participate in the 2022 Plan were it currently in effect), which includes five (5) executive officers, 272 employees who are not executive officers, seven (7) non-employee directors and zero (0) consultants.Cap on Annual Director CompensationThe aggregate value of all awards granted to any non-employee director during any single calendar year plus the aggregate amount of all cash earned and paid or payable to such non-employee director for services rendered as a non-employee director for the same year shall not exceed $800,000; provided, however, that with respect to the Chairman of the Board of Directors, the lead independent director, or any newly-elected non-employee director in his or her first calendar year of service, such amount shall not exceed $1,000,000.2022 Proxy Statement63Omnibus Incentive Plan ProposalPlan LimitsSubject to adjustments for mergers, reorganizations, recapitalizations, stock splits and similar events, no more than 5,572,710 shares of common stock may be issued in the form of incentive stock options. After the effective date of the 2022 Plan, no awards may be granted under the Prior Plans.Effect of AwardsFor purposes of determining the number of shares of common stock available for issuance under the 2022 Plan, the grant of any “full value” award, such as a restricted stock award, RSU or share-based performance award will be counted as 1.5 shares for each share of common stock actually subject to the award. The grant of any stock option or stock appreciation right will be counted for this purpose as one share for each share of common stock actually subject to the award.Stock OptionsThe 2022 Plan permits the granting of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code and (2) options that do not so qualify. Options granted under the 2022 Plan will be non-qualified options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options. Incentive stock options may only be granted to employees of Vericel and its subsidiaries. Non-qualified options may be granted to any persons eligible to receive incentive options and to non-employee directors and consultants. The option exercise price of each option will be determined by the Compensation Committee but may not be less than 100% of the fair market value of the common stock on the date of grant. Fair market value for this purpose will be the closing price of the shares of common stock on the Nasdaq Capital Market on the grant date. Other than to appropriately reflect changes in our capital structure, the Compensation Committee may not without the approval of our shareholders (a) lower the exercise price of an option after it is granted, (b) cancel an option when the exercise price per share exceeds the fair market value of one share in exchange for cash or another award (other than in connection with a change-in-control or with respect to a substitute award), or (c) take any other action with respect to an option that would be treated as a repricing under the rules and regulations of the Nasdaq Stock Market.The term of each option will be fixed by the Compensation Committee and may not exceed ten years from the date of grant. The Compensation Committee will determine at what time or times each option may be exercised.Unless otherwise provided in the applicable award agreement, upon exercise of options, the exercise price must be paid in full by one of the following methods: (i) in cash or cash equivalents (including certified check or bank check or wire transfer of immediately available funds), (ii) by tendering previously acquired shares (either actually or by attestation), valued at their then fair market value, (iii) with the consent of the Compensation Committee, by delivery of other consideration having a fair market value on the exercise date equal to the total purchase price, (iv) with respect to options that are not incentive stock options, by a “net exercise” arrangement pursuant to which we will reduce the number of shares issuable upon exercise by the largest whole number of shares with a fair market value that does not exceed the aggregate exercise price, (v) through any other method specified in an award agreement (including same-day sales through a broker), or (vi) any combination of any of the foregoing.To qualify as incentive options, options must meet additional federal tax requirements, including a $100,000 limit on the value of shares subject to incentive options that first become exercisable by a participant in any one calendar year.Stock Appreciation RightsThe Compensation Committee may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to cash or shares of common stock equal to the value of the appreciation in the stock price over the exercise price. The grant price of a stock appreciation right may not be less than the fair market value of the common stock on the date of grant. The maximum term of a stock appreciation right is ten years.64Omnibus Incentive Plan ProposalRestricted Stock and Restricted Stock UnitsThe Compensation Committee may award shares of common stock and RSUs to participants subject to such conditions and restrictions as the Compensation Committee may determine. These conditions and restrictions may include the achievement of certain performance goals (as summarized above) and/or continued employment with us through a specified restricted period. RSUs are ultimately payable in the form of cash, shares of common stock or other property, in the discretion of the Compensation Committee. During the vesting period, restricted stock awards and RSUs may be credited with dividend equivalents (but dividend equivalents shall at all times be subject to restrictions and risk of forfeiture to the same extent as the underlying award and shall not be paid unless and until the underlying award vests). In no event shall the holder of RSUs have voting rights until the RSUs vest and are settled in shares of common stock.Performance AwardsThe Compensation Committee may grant performance awards to any participant that entitle the recipient to receive cash, shares of common stock or other property upon the achievement of performance goals and such other conditions as the Compensation Committee shall determine.Dividend EquivalentsThe Compensation Committee may grant dividend equivalents as a component of any award other than a stock option or stock appreciation right. Dividend equivalents shall at all times be subject to restrictions and risk of forfeiture to the same extent as the underlying award and shall not be paid unless and until the underlying award vests.Change of Control ProvisionsThe 2022 Plan provides that, in the event of a “change-in-control,” as defined in the 2022 Plan, the Compensation Committee may determine that (i) stock options and stock appreciation rights outstanding as of the date of the change-in-control shall be cancelled and terminated without payment therefor if the fair market value of one share of common stock as of the date of the change-in-control is less than the per share exercise price of a stock option or the per share grant price of a stock appreciation right and (ii) all performance awards shall be considered to be earned and payable as provided in the applicable award agreement, and any limitations or other restrictions shall lapse and such performance awards shall be immediately settled or distributed. Unless otherwise provided in an award agreement, in the event of a change-in-control, to the extent that the successor company does not assume, continue or substitute an award, then immediately prior to the change-in-control: (i) stock options and stock appreciation rights outstanding as of the date of the change-incontrol shall immediately vest and become fully exercisable and (ii) the restrictions, limitations and conditions on restricted stock awards and RSU awards shall lapse and such awards shall become fully vested and transferable. In the event of a change-in-control in which awards are assumed, substituted or continued, such awards shall be subject to double-trigger acceleration to the extent set forth in the applicable award agreement. The Compensation Committee may determine that, upon the occurrence of a change-in-control, each outstanding stock option and stock appreciation right shall terminate within a specified number of days after notice to the participant, and/ or that each participant shall receive, with respect to each share subject to such stock option or stock appreciation right, an amount equal to the excess (if any) of the fair market value of such share immediately prior to the occurrence of the change-in-control over the exercise price per share of such stock option or stock appreciation right. The Compensation Committee shall also have the option to make or provide for a payment to the grantees holding other awards in an amount equal to the fair market value of one share immediately prior to the occurrence of such change-in-control multiplied by the number of vested shares under such awards.Adjustments for Stock Dividends, Stock Splits, Etc.In the event of a merger, reorganization, consolidation, recapitalization, dividend or distribution (whether in cash, shares or other property, other than a regular cash dividend), stock split, reverse stock split, spin-off or similar transaction or other change in corporate structure affecting the common stock or the value thereof, such adjustments and other substitutions shall be made to the 2022 Plan and to awards thereunder as the Compensation Committee deems equitable or appropriate taking into consideration the accounting and tax consequences.Tax WithholdingParticipants in the 2022 Plan are responsible for the payment of any federal, state or local taxes that we are required by law to withhold upon the exercise of options or stock appreciation rights or vesting or settlement of other awards. The Compensation Committee may permit the tax withholding obligations to be satisfied by allowing a participant to authorize us to withhold from shares of common stock to be issued pursuant to any award a number of shares with an aggregate fair market value (as of the date the withholding is effected)2022 Proxy Statement65Omnibus Incentive Plan Proposalthat would satisfy the withholding amount due. The Compensation Committee may also require that (i) awards be subject to mandatory share withholding up to the required withholding amount, or (ii) Vericel’s tax withholding obligation be satisfied, in whole or in part, by an arrangement whereby a certain number of shares issued pursuant to the award are immediately sold and the proceeds from such sale are remitted to Vericel in an amount that would satisfy the withholding amount due.Clawback PolicyAll awards made under the 2022 Plan will be subject to the terms and provisions of any clawback policy of Vericel in effect from time to time.Amendments and TerminationThe Board of Directors may, at any time, amend or discontinue the 2022 Plan and the Compensation Committee may, at any time, amend or cancel any outstanding award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding award without the holder’s consent. To the extent required under Nasdaq rules, any amendments that materially change the terms of the 2022 Plan will be subject to approval by our shareholders. Amendments shall also be subject to approval by our shareholders if and to the extent determined to be required by the Code to preserve the qualified status of incentive options.Effective Date of the 2022 PlanThe Board of Directors adopted the 2022 Plan on February 16, 2022. The 2022 Plan will become effective on the date it is approved by shareholders. Awards of incentive options may be granted under the 2022 Plan until February 16, 2032. No other awards may be granted under the 2022 Plan after the date that is ten years from the date of shareholder approval.Plan BenefitsNo awards have been granted under the 2022 Plan. Any future awards under the 2022 Plan will be granted at the discretion of the Compensation Committee, and, accordingly, are not yet determinable. In addition, benefits under the 2022 Plan, will depend on a number of factors, including the fair market value of our common stock on future dates. Consequently, it is not possible to determine the benefits that might be received by participants under the 2022 Plan.Tax Aspects of the CodeThe following is a summary of the principal U.S. federal income tax consequences of certain transactions under the 2022 Plan. It does not describe all federal tax consequences under the 2022 Plan, nor does it describe foreign, state or local tax consequences.Incentive OptionsNo taxable income is generally realized by the optionee upon the grant or exercise of an incentive option. If shares of common stock issued to an optionee pursuant to the exercise of an incentive option are sold or transferred after two years from the date of grant and after one year from the date of exercise, then, (i) upon the sale of such shares, any amount realized in excess of the option price (the amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital loss, and (ii) we will not be entitled to any deduction for federal income tax purposes. The exercise of an incentive option will give rise to an item of tax preference that may result in alternative minimum tax liability for the optionee.If shares of common stock acquired upon the exercise of an incentive option are disposed of prior to the expiration of the two-year and one-year holding periods described above, which is referred to as a “disqualifying disposition,” generally (i) the optionee will realize ordinary income in the year of disposition in an amount equal to the excess (if any) of the fair market value of the shares of common stock at exercise (or, if less, the amount realized on a sale of such shares of common stock) over the exercise price thereof, and (ii) we will be entitled to deduct such amount. Special rules will apply where all or a portion of the exercise price of the incentive option is paid by tendering shares of common stock.66Omnibus Incentive Plan ProposalIf an incentive option is exercised at a time when it no longer qualifies for the tax treatment described above, the option is treated as a non-qualified option. Generally, an incentive option will not be eligible for the tax treatment described above if it is exercised more than three months following termination of employment (or one year in the case of termination of employment by reason of disability). In the case of termination of employment by reason of death, the three-month rule does not apply.Non-Qualified OptionsNo income is realized by the optionee at the time the option is granted. Generally (i) at exercise, ordinary income is realized by the optionee in an amount equal to the difference between the exercise price and the fair market value of the shares of common stock on the date of exercise, and we receive a tax deduction for the same amount, and (ii) at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain or loss depending on how long the shares of common stock have been held. Special rules will apply where all or a portion of the exercise price of the non-qualified option is paid by tendering shares of common stock. Upon exercise, the optionee will also be subject to Social Security taxes on the excess of the fair market value over the exercise price of the option.Other AwardsWe will generally be entitled to a tax deduction in connection with an award under the 2022 Plan in an amount equal to the ordinary income realized by the participant at the time the participant recognizes such income. Participants typically are subject to income tax and recognize that tax at the time that an award is exercised, vests or becomes non-forfeitable, unless the award provides for a further deferral.Parachute PaymentsThe vesting of any portion of an option or other award that is accelerated due to the occurrence of a change-in-control may cause a portion of the payments with respect to such accelerated awards to be treated as “parachute payments” as defined in the Code. Any such parachute payments may be non-deductible by us, in whole or in part, and may subject the recipient to a non-deductible 20% federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable).Limitation on DeductionsUnder Section 162(m) of the Code, our deduction for certain awards under the 2022 Plan may be limited to the extent that the Chief Executive Officer, Chief Financial Officer or other covered employee receives compensation in excess of $1 million a year.Equity Compensation Plan InformationThe following table provides information as of December 31, 2021, regarding shares of common stock that may be issued under our equity compensation plans, consisting of the 2019 Plan, the 2017 Plan, the 2009 Plan, and the 2015 Employee Stock Purchase Plan (the “ESPP”).Plan category1 Number of securities
to be issued
upon exercise of
outstanding options,
warrants and rights
(a) Weighted-average
exercise price of
outstanding options,
warrants and rights
($)(b) Number of securities
remaining available for
future issuance under
equity compensation
plan (excluding securities
referenced in column
(a))(c)Equity compensation plans approved by security holders: 6,814,093(1) 23.76(2) 3,077,055(3) Equity compensation plans not approved by security holders: — — — Total 6,814,093 23.76 3,077,055 (1)Includes 5,669,690 shares of common stock issuable upon the exercise of outstanding options, 398,748 shares of common stock issuable upon the vesting of RSUs and 745,655 shares of common stock issuable from the exercise of the ESPP offering period ended on December 31, 2021.(2)Since RSUs do not have any exercise price, such units are not included in the weighted average exercise price calculation.(3)As of December 31, 2021, there were zero shares available for grants under our 2009 Plan, zero shares available for grants under our 2017 Plan, 2,822,710 shares available for grants under our 2019 Plan and 254,345 shares available for grants under our ESPP.2022 Proxy Statement67Omnibus Incentive Plan ProposalVote Required and the Board of Directors’ RecommendationThe affirmative vote of a majority of the votes cast is required for approval of the 2022 Omnibus Incentive Plan. If you abstain from voting on this Proposal, it will have no effect on the voting of the proposal. If you submit your proxy without indicating your voting instructions, your shares will be voted “FOR” this proposal. Brokers, bankers and other nominees do not have discretionary voting power on this matter and, accordingly, “broker non-votes” will have no effect on the voting for this proposal.The Board of Directors unanimously recommends a vote FOR the approval of the 2022 Omnibus Incentive Plan.68Information about Stock Ownership3, 2022,8, 2024, or as otherwise set forth below, with respect to the beneficial ownership of Vericel’s common stock by (i) all persons known by Vericel to be the beneficial owners of more than 5% of the outstanding common stock of Vericel, (ii) each director and director nominee of Vericel, (iii) each executive officer of Vericel, and (iv) all executive officers and directors of Vericel as a group. Shares Owned(1) Name and Address of Beneficial Owner Shares
Subject to
Options
Exercisable
within the
60-Day Period
following
March 3, 2022 Shares
Individuals
Have Rights to
Acquire upon
the Vesting of
RSUs within the
60-Day Period
following
March 3, 2022 Number of
Shares Percentage of
Class(2)5% Shareholders: BlackRock, Inc.(3) 7,073,199 15.0% Brown Capital Management, LLC(4) 5,789,989 12.3% RTW Investments, LP(5) 4,517,570 9.6% Alger Associates, Inc.(6) 3,203,362 6.8% The Vanguard Group(7) 3,049,063 6.5% State Street Corporation(8) 2,809,660 6.0% Directors and Named Executive Officers: Robert L. Zerbe 63,250 2,600 97,645 * Alan L. Rubino 110,750 2,600 122,744 * Heidi Hagen 101,750 2,600 114,600 * Steven C. Gilman 55,250 2,600 61,350 * Kevin F. McLaughlin 102,750 2,600 108,850 * Paul K. Wotton 6,500 2,600 35,702 * Lisa Wright 6,870 2,351 9,221 Dominick C. Colangelo 1,315,990 1,472,650 3.1% Joe Mara 50,000 61,670 Michael Halpin 157,329 167,667 * Sean C. Flynn 79,375 83,027 * Jonathan Hopper 69,604 118,915 * All officers and directors as a group (12 persons)(9) 2,119,418 17,951 2,454,041 5.2% Shares Owned(1) Name and Address of Beneficial Owner Shares Subject to
Options Exercisable
within the 60-Day
Period following
March 8, 2024 Shares Individuals Have
Rights to Acquire upon
the Vesting of RSUs
within the 60-Day Period
following March 8, 2024 Number of
Shares Percentage of
Class(2) 5% Shareholders: BlackRock, Inc.(3) 7,937,063 16.4 % Brown Capital Management, LLC(4) 6,818,933 14.1 % The Vanguard Group(5) 3,374,093 7.0 % RTW Investments, LP(6) 3,212,794 6.6 % State Street Corporation(7) 2,664,883 5.5 % Conestoga Capital Advisors, LLC(8) 2,495,619 5.2 % Directors and Named Executive Officers: Robert Zerbe 68,028 3,200 94,623 * Alan Rubino 119,250 3,200 140,044 * Heidi Hagen 116,250 3,200 134,900 * Steven Gilman 69,750 3,200 80,750 * Kevin McLaughlin 117,250 3,200 129,150 * Paul Wotton 21,000 3,200 51,002 * Lisa Wright 23,536 3,200 32,553 * Dominick Colangelo 1,681,328 1,876,620 3.9 % Joe Mara 173,696 193,068 * Michael Halpin 319,195 328,153 * Sean Flynn 209,625 210,098 * Jonathan Hopper 166,979 225,089 * All officers and directors as a group (12 persons)(9) 3,085,887 22,400 3,496,049 7.2 % * Represents less than 1% of the outstanding shares of Vericel’s common stock equivalents. (1) Beneficial ownership is determined in accordance with the rules of the SEC and includes voting and investment power with respect to shares. Except as indicated in the footnotes to this table, to the knowledge of Vericel, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws, where applicable. The number of shares owned and percentage ownership amounts include certain options under our 2022 Plan, 2019 Plan, 2017 Plan, and 2009 Plan, and our ESPP shares and RSUs under our 2022 Plan, 2019 Plan and 2017 Plan. Pursuant to the rules of the SEC, the number of shares of Vericel’s common stock deemed outstanding includes shares issuable pursuant to options held by the respective person or group that are currently exercisable or may be exercised within 60 days of March 3, 2022,8, 2024, and shares of our common stock that may be acquired upon the vesting of RSUs within 60 days of March 3, 2022.8, 2024.(2) Calculated on the basis of 47,035,47748,380,458 shares of common stock outstanding as of March 3, 2022.8, 2024.(3) As reported in a Schedule 13G/A filed with the SEC on January 27, 2022,22, 2024, BlackRock, Inc. has sole voting power with respect to 7,017,8707,846,544 shares and shared voting power with respect to 0 shares. BlackRock, Inc. has sole dispositive power with respect to all 7,073,1997,937,063 shares and shared dispositive power with respect to 0 shares. The address for BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055.66 (4) As reported in a Schedule 13G/A filed with the SEC on February 14, 2022,2024, Brown Capital Management, LLC beneficially owns 5,789,9896,818,933 shares of which 3,137,5532022 Proxy Statement69Information about Stock Ownership3,869,381 shares are beneficially owned by The Brown Capital Management Small Company Fund, a registered investment company, which is managed by Brown Capital Management, LLC. Brown Capital Management, LLC has sole voting power with respect to 3,690,3694,639,814 shares and sole dispositive power with respect to all 5,789,9896,818,933 shares. The address for Brown Capital Management, LLC is 1201 N. Calvert Street, Baltimore, MD 21202.(5) As reported in a Schedule 13G/A filed with the SEC on February 12, 2021, RTW Investments, LP has shared voting and dispositive power with respect to all 4,517,570 shares, which voting and dispositive power is shared with Roderick Wong, the managing partner of RTW Investments LP. RTW Master Fund, Ltd. has shared voting and dispositive power with respect to 3,172,630 shares, which voting and dispositive power is shared with RTW Investments LP and Roderick Wong. The address for RTW Investments LP is 40 10th Avenue Floor 7, New York, NY 10014.(6)As reported in a Schedule 13G filed with the SEC on February 14, 2022, Alger Associates, Inc. beneficially owns 3,203,362 shares, which are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (“FAM”), a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC (“AGH”), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company. Alger Associates, Inc. has sole voting power with respect to all 3,203,362 shares and sole dispositive power with respect to all 3,203,362 shares. The address for Alger Associates, Inc. is 100 Pearl Street, 27th Floor, New York, NY 10004.(7)As reported in a Schedule 13G/A filed with the SEC on February 10, 2022,13, 2024, The Vanguard Group has sole voting power with respect to 0 shares and shared voting power with respect to 486,68686,366 shares. The Vanguard Group has sole dispositive power with respect to 2,928,8193,246,251 shares and shared dispositive power with respect to 120,244127,842 shares. The address for theThe Vanguard Group is 100 Vanguard Boulevard, Malvern, PA 19355.(8)(6)As reported in a Schedule 13G/A filed with the SEC on February 14, 2024, RTW Investments, LP has shared voting and dispositive power with respect to all 3,212,794 shares, which voting and dispositive power is shared with Roderick Wong, the managing partner of RTW Investments LP. The address for RTW Investments LP is 40 10th Avenue Floor 7, New York, NY 10014. (7) As reported in a Schedule 13G filed with the SEC on February 11, 2022,January 25, 2024, State Street Corporation has sole voting power with respect to 0 shares and shared voting power with respect to 2,712,7622,539,423 shares. State Street Corporation has sole dispositvedispositive power with respect to 0 shares and shared dispostiviedispositive power with respect to all 2,809,6602,664,883 shares. The address for State Street Corporation is 1 Lincoln Street, Boston, MA 02111.(8) As reported in a Schedule 13G filed with the SEC on January 5, 2024, Conestoga Capital Advisors LLC has sole voting power with respect to 2,339,960 shares and sole dispositive power with respect to 2,495,619 shares. The address for Conestoga Capital Advisors LLC is 550 E. Swedesford Rd. Ste. 120, Wayne, PA 19087. (9) The address for the twelve beneficial owners that are persons is c/o Vericel Corporation, 64 Sidney St., Cambridge, Massachusetts 02139. 702024 Proxy Statement67Additional
InformationWhat am I voting on?
1. To elect eight (8) directors, each to each serve a term of one year expiring at the 20232025 annual meeting of shareholders;2. To approve, on an advisory basis, the compensation of our named executive officers; 3. To cast an advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers; and 4. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; and4.To approve the adoption of our 2022 Omnibus Incentive Plan.2024.Who is entitled to vote?
3, 20228, 2024 (the “Record Date”) may vote at the Annual Meeting. You have one vote for each share of common stock you held on the Record Date, including shares:• Held directly in your name as “shareholder of record” (also referred to as “registered shareholder”); and • Held for you in an account with a broker, bank or other nominee (also referred to as shares held in “street name”). Street name holders generally cannot vote their shares directly and must instead instruct the brokerage firm, bank or nominee how to vote their shares. What constitutes a quorum?
47,035,47748,380,458 shares of Vericel’s common stock were outstanding and entitled to vote.How many votes are required to approve each proposal?
.:• The election of each of our eight (8) director candidates requires the affirmative vote of a plurality of the total shares of common stock entitled to vote and represented in person or by proxyproxy;• Approval of the non-binding, advisory resolution to approve the compensation of our named executive officers requires the affirmative vote of a majority of the votes cast on the proposalproposal;• With respect to the advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers, the frequency (every one, two or three years) that receives the highest number of votes cast on the proposal shall be deemed the frequency recommended by shareholders; and • Ratifying PricewaterhouseCoopers LLP as Vericel’s independent registered public accounting firm for the fiscal year ending December 31, 20222024 requires the affirmative vote of a majority of the votes cast on the proposal, and•Approval of the 2022 Omnibus Incentive Plan requires the affirmative vote of a majority of the votes cast on the proposalproposal.How are votes counted and who are the proxies?
68 2022 Proxy Statement71Contentsfuture non-binding, advisory resolutions to approve the compensation of our named executive officers. If you abstain from voting on the frequency of future non-binding, advisory resolutions to approve the compensation of the Company’s named executive officers, it will have no effect on the voting of the proposal. If you just sign and submit your proxy card without marking your voting instructions, your shares will be voted for holding non-binding, advisory votes to approve the compensation of the Company’s named executive officers every “1 YEAR”.Additional InformationYou may vote “FOR,” “AGAINST,” or “ABSTAIN” on the approval of our 2022 Omnibus Incentive Plan. If you abstain from voting on the approval of our 2022 Omnibus Incentive Plan, it will have no effect on the voting of the proposal. If you just sign and submit your proxy card without marking your voting instructions, your shares will be voted “FOR” the resolution approving our 2022 Omnibus Incentive Plan. C. Colangelo and Joseph Mara, were selected by the Board of Directors and are officers of Vericel. All properly executed proxies submitted in time to be counted at the Annual Meeting will be voted by such persons at the Annual Meeting. Where a choice has been specified on the proxy with respect to the foregoing matters, the shares represented by the proxy will be voted in accordance with the specifications.What is a broker non-vote?
How does the Board of Directors recommend that I vote?
• “FOR” the election of each of the nominees to the Board of DirectorsDirectors;• “FOR” the advisory resolution to approve the compensation of our named executive officersofficers;• Every “1 YEAR” on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers; and • “FOR” the ratification of the appointment of PricewaterhouseCoopers LLP as Vericel’s independent registered public accounting firm for the fiscal year ending December 31, 2022•“FOR” the approval of the 2022 Omnibus Incentive Plan2024.How do I vote my shares without attending the meeting?
• •By Internet or Telephone—YouTelephone-You may vote by Internet or telephone by following the voting instructions on the proxy card and on www. proxyvote.comwww.proxyvote.com or as directed by your broker or other nominee. In order to vote via the Internet or by telephone, you must have the shareholder identification number which is provided in your Notice.• •By Mail—IfMail-If you requested a proxy card by mail, you may vote by signing, voting and returning your proxy card in the envelope provided. You should sign your name exactly as it appears on the proxy card. If you are signing in a representative capacity (for example, as guardian, executor, trustee, custodian, attorney or officer of a corporation), you should indicate your name and title or capacity. If you vote by Internet or telephone, please do not mail the proxy card. Your proxy card must be received prior to the Annual Meeting.26, 2022.30, 2024.2024 Proxy Statement 69 How do I attend the Annual Meeting?
VCEL2022.VCEL2024. Our Board annually considers the appropriate format of our annual meeting and this year has decided to again hold a virtual annual meeting due to the ongoing COVID-19 global pandemic. In addition, wemeeting. We intend the virtual meeting format to provide shareholders with a similar level of transparency to the traditionalan in-person meeting format and we will take steps to ensure such an experience. Our shareholders will be afforded the same opportunities to participate at the Annual Meeting as they would at an in-person annual meeting of shareholders. Our Annual Meeting will allow shareholders to submit questions and comments during the meeting. After the meeting, we will spend 15 minutes answering shareholder questions that comply with the meeting rules of conduct, which will be posted on the virtual meeting web portal. If we receive substantially similar questions, we will group such questions together and provide a single response to avoid repetition.72Additional InformationApril 27, 2022.May 1, 2024. We encourage you to access the Annual Meeting webcast prior to the start time. Online check-in will begin, and shareholders may begin submitting written questions, at 8:45 a.m., Eastern Time, and you should allow ample time for check-in procedures.VCEL2022VCEL2024 two weeks prior to the date of the Annual Meeting. If you do not have your 16-digit control number, you will be able to access and listen to the Annual Meeting as a guest, but you will not be able to vote your shares or submit questions during the Annual Meeting.What does it mean if I receive more than one proxy card?
May I change my vote?
• Sending a written statement to that effect to the attention of the Senior Vice President, General Counsel and Secretary of Vericel at 64 Sidney Street, Cambridge, Massachusetts 02139, provided such statement is received no later than April 26, 2022;30, 2024;• Voting again by Internet or telephone at a later time before the closing of those voting facilities at 11:59 p.m., Eastern Time, on April 26, 2022;30, 2024;• Submitting a properly signed proxy card with a later date that is received no later than April 26, 2022;30, 2024; or• Attending the Annual Meeting and revoking your proxy and voting during the Annual Meeting. What are the costs associated with the solicitation of proxies?
Shareholder Proposals
To Beto be Presented at Next Annual Meeting70 or nominations for directors for inclusion in our proxy statement and form of proxy pursuant to Rule 14a-8 of the SEC’s proxy rules or other business or director nominations for the next annual meeting of shareholders will be November 18, 2022 and shareholder proposals submitted outside the processes of Rule 14a-8 received after November 18, 2022 will be considered untimely under Vericel’s Bylaws. 21, 2024. if such proposal or nomination isincluding Rule 14a-19(b) to be included in our proxy statement for the next annual meeting.extent applicable.Shareholder proposals and director nominations should be delivered to: Vericel Corporation, 64 Sidney St., Cambridge, Massachusetts2022 Proxy Statement73Additional Information02139, Attention: General Counsel and Secretary. Vericel recommends that such proposals be sent by certified mail, return receipt requested.Shareholder Communications with Directors
Where You Can Find More Information
20212023 is available at www.proxyvote.com.the financial statements, quarterly data, management’s discussion and analysis of financial condition and results of operations, changes in and disagreements with accountants on accounting and financial disclosure and market risk disclosures contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.• The financial statements, quarterly data, management’s discussion and analysis of financial condition and results of operations, changes in and disagreements with accountants on accounting and financial disclosure and market risk disclosures contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. 20212023 by writing to Vericel at the following address: Vericel Corporation, 64 Sidney St., Cambridge, Massachusetts 02139, Attention: General Counsel and Secretary. Copies of our SEC filings are also available to the public on the SEC’s web site at www.sec.gov.Householding
2024 Proxy Statement 71 74Additional InformationTransaction of Other Business
GAAP versus Non-GAAP Measures
Reconciliation of Reported Annual Net (Loss) Incometo AdjustedTO ADJUSTED EBITDA (non-GAAP Measure)(NON-GAAP MEASURE) – UnauditedUNAUDITEDAnnual Adjusted EBITDA (In Thousands) 2019
($) 2020
($) 2021
($) Net (Loss) Income (GAAP) (9,665 ) 2,864 (7,471 ) NexoBrid upfront license agreement payment 17,500 — — Stock-based compensation expense 13,179 13,843 34,322 Depreciation and amortization 1,744 2,383 2,965 Loss on extinguishment of debt — — — Net interest income (1,606 ) (685 ) (220 ) Income tax expense (benefit) — 180 (111 ) Adjusted EBITDA (Non-GAAP) 21,152 18,585 29,485 Adjusted EBITDA margin 18% 15% 19% Annual Adjusted EBITDA (In Thousands) 2021
($) 2022
($) 2023
($) Net Loss (GAAP) (7,471 ) (16,709 ) (3,182 ) Stock-based compensation expense 34,322 37,183 32,325 Depreciation and amortization 2,965 3,981 4,632 Net interest income (220 ) (975 ) (4,032 ) Income tax (benefit) expense (111 ) 721 814 Pre-occupancy lease expense — — 3,323 Adjusted EBITDA (Non-GAAP) 29,485 24,201 33,880 Adjusted EBITDA margin 19% 15% 17% Special Note Regarding Forward-Looking Statements
2021,2023, as filed with the SEC on February 24, 202229, 2024 under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition” and “Results of Operations” and elsewhere in the Annual Report. You should carefully consider that information before voting.72 2022 Proxy StatementBack to Contents75Approval
Additional InformationAPPROVAL C. Flynn
March 17, 202221, 20242024 Proxy Statement 73
ATTN: SEAN C. FLYNN
64 SIDNEY STREET
CAMBRIDGE, MA 02139Appendix I2022 Omnibus Incentive Plan2022 Proxy StatementI-1Appendix IVericel Corporation 2022 Omnibus Incentive Plan(Effective as of April 27, 2022)Vericel Corporation (the “Company”), a Michigan corporation, hereby establishes and adopts the following 2022 Omnibus Incentive Plan (the “Plan”).1.PURPOSE OF THE PLANThe purpose of the Plan is to assist the Company and its Affiliates in attracting and retaining certain individuals to serve as directors, employees, consultants and/or advisors of the Company and its Affiliates who are expected to contribute to the Company’s success and achieve long-term objectives that will inure to the benefit of all shareholders of the Company through the additional incentives inherent in the Awards hereunder.2.DEFINITIONS2.1.“2019 Plan” shall have the meaning set forth in Section 3.1(a).2.2.“Affiliate” shall mean, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board or the Committee shall have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.2.3.“Award” shall mean any Option, Stock Appreciation Right, Restricted Stock Award, Restricted Stock Unit Award, Performance Award or any other right, interest or option relating to Shares or other property (including cash) granted pursuant to the provisions of the Plan.2.4.“Award Agreement” shall mean any agreement, contract or other instrument or document evidencing any Award granted hereunder, whether in writing or through an electronic medium.2.5.“Board” shall mean the board of directors of the Company.2.6.“Change in Control” shall have the meaning set forth in Section 10.3.2.7.“Code” shall mean the Internal Revenue Code of 1986, as amended from time to time.2.8.“Committee” shall mean the Compensation Committee of the Board or a subcommittee thereof formed by the Compensation Committee to act as the Committee hereunder. The Committee shall consist of no fewer than two Directors, each of whom is (i) a “Non-Employee Director” within the meaning of Rule 16b-3 of the Exchange Act, and (ii) an “independent director” for purpose of the rules of the NASDAQ Stock Market (or such other principal U.S. national securities exchange on which the Shares are traded) to the extent required by such rules.2.9.“Consultant” shall mean any consultant or advisor who provides bona fide services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under the Securities Act.2.10.“Director” shall mean a non-employee member of the Board.2.11.“Dividend Equivalents” shall have the meaning set forth in Section 11.5.2.12.“Effective Date” shall have the meaning set forth in Section 12.13.2.13.“Employee” shall mean any employee of the Company or any Affiliate and any prospective employee conditioned upon, and effective not earlier than, such person becoming an employee of the Company or any Affiliate.2.14.“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.2.15.“Fair Market Value” shall mean, with respect to Shares as of any date, (i) the per Share closing price of the Shares as reported on the NASDAQ Stock Market on that date (or if there was no reported closing price on such date, on the last preceding date on which the closing price was reported), (ii) if the Shares are not then listed on the NASDAQ Stock Market, the closing price on the principal U.S. national securities exchange on which the Shares are listed (or if there was no reported closing price on such date, on the last preceding date on which the closing price was reported), or (iii) if the Shares are not listed on a U.S. national securities exchange, the Fair Market Value of Shares shall be determined by the Committee in its sole discretionI-2 Appendix Iusing appropriate criteria, a reasonable application of a reasonable method in accordance with the regulations under Section 409A of the Code and, with respect to Incentive Stock Options, in accordance with the requirements of Section 422 of the Code. The Fair Market Value of any property other than Shares shall mean the market value of such property determined by such methods or procedures as shall be established from time to time by the Committee.2.16.“Incentive Stock Option” shall mean an Option which when granted is intended to qualify as an incentive stock option for purposes of Section 422 of the Code.2.17.“Option” shall mean any right granted to a Participant under the Plan allowing such Participant to purchase Shares at such price or prices and during such period or periods as the Committee shall determine.2.18.“Participant” shall mean an Employee, Director or Consultant who the Committee determines to receive an Award under the Plan.2.19.“Payee” shall have the meaning set forth in Section 12.1.2.20.“Performance Award” shall mean any Award of Performance Cash, Performance Shares or Performance Units granted pursuant to Section 9.2.21.“Performance Cash” shall mean any cash incentives granted pursuant to Section 9 payable to the Participant upon the achievement of such performance goals as the Committee shall establish.2.22.“Performance Period” shall mean the period established by the Committee during which any performance goals specified by the Committee with respect to an Award are to be measured.2.23.“Performance Share” shall mean any grant pursuant to Section 9 of a unit valued by reference to a designated number of Shares, which value may be paid to the Participant upon achievement of such performance goals during the Performance Period as the Committee shall establish.2.24.“Performance Unit” shall mean any grant pursuant to Section 9 of a unit valued by reference to a designated amount of cash or property other than Shares, which value may be paid to the Participant upon achievement of such performance goals during the Performance Period as the Committee shall establish.2.25.“Permitted Assignee” shall have the meaning set forth in Section 11.3.2.26.“Prior Plans” shall mean, collectively, the 2019 Plan, the Vericel Corporation 2017 Omnibus Incentive Plan and the following Aastrom Biosciences, Inc. plan: Amended and Restated 2009 Omnibus Incentive Plan.2.27.“Restricted Stock” shall mean any Share issued with the restriction that the holder may not sell, transfer, pledge or assign such Share and with such other restrictions as the Committee, in its sole discretion, may impose (including any restriction on the right to vote such Share and the right to receive any dividends), which restrictions may lapse separately or in combination at such time or times, in installments or otherwise, as the Committee may deem appropriate.2.28.“Restricted Stock Award” shall have the meaning set forth in Section 7.1.2.29.“Restricted Stock Unit Award” shall have the meaning set forth in Section 8.1.2.30.“Restricted Stock Unit” shall mean an Award that is valued by reference to a Share, which value may be paid to the Participant upon satisfaction of such vesting restrictions as the Committee in its sole discretion shall impose, which restrictions may lapse separately or in combination at such time or times, in installments or otherwise, as the Committee may deem appropriate.2.31.“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.2.32.“Separation from Service” shall have the meaning set forth in Section 12.15.2.33.“Shares” shall mean the shares of common stock, no par value, of the Company.2.34.“Stock Appreciation Right” shall mean the right granted to a Participant pursuant to Section 6.2.35.“Substitute Awards” shall mean Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Affiliate or with which the Company or any Affiliate combines.2022 Proxy StatementI-3Appendix I3.SHARES SUBJECT TO THE PLAN3.1.Number of Shares.(a)Subject to adjustment as provided in Sections 3.1(b) and 11.2 and as of the Effective Date, the number of Shares that shall be authorized for grant under the Plan shall equal a total of (i) 5,572,710 Shares1, as increased pursuant to paragraph (b) of this Section, less (ii) one (1) Share for every one (1) Share that was subject to an option or stock appreciation right granted after December 31, 2021 and prior to the Effective Date under the Vericel Corporation Amended and Restated 2019 Omnibus Incentive Plan (the “2019 Plan”) and 1.5 Shares for every one (1) Share that was subject to an award other than an option or stock appreciation right granted after December 31, 2021 and prior to the Effective Date under the 2019 Plan. Any Shares that are subject to Options or Stock Appreciation Rights shall be counted against this limit as one (1) Share for every one (1) Share granted, and any Shares that are subject to Awards other than Options or Stock Appreciation Rights shall be counted against this limit as 1.5 Shares for every one (1) Share granted. After the Effective Date, no awards may be granted under any Prior Plan.(b)If (i) any Shares subject to an Award are forfeited, an Award expires or an Award is settled for cash (in whole or in part), or (ii) after December 31, 2021, any Shares subject to an award under the Prior Plans are forfeited, or an award under the Prior Plans expires or is settled for cash (in whole or in part), the Shares subject to such Award or award under the Prior Plans shall, to the extent of such forfeiture, expiration or cash settlement, be available for Awards under the Plan, in accordance with Section 3.1(d) below. In the event that withholding tax liabilities arising from an Award other than an Option or Stock Appreciation Right or, after December 31, 2021, an award other than an option or stock appreciation right under any Prior Plan are satisfied by the tendering of Shares (either actually or by attestation) or by the withholding of Shares by the Company, the Shares so tendered or withheld shall be added to the Shares available for Awards under the Plan in accordance with Section 3.1(d) below. Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the Shares authorized for grant under paragraph (a) of this Section: (i) Shares tendered by the Participant or withheld by the Company in payment of the purchase price of an Option or, after December 31, 2021, an option granted under the Prior Plans, or to satisfy any tax withholding obligation with respect to an Option or Stock Appreciation Right or, after December 31, 2021, an option or stock appreciation right granted under the Prior Plans, and (ii) Shares subject to a Stock Appreciation Right or, after December 31, 2021, a stock appreciation right granted under the Prior Plans that are not issued in connection with the stock settlement of the Stock Appreciation Right on exercise thereof and (iii) Shares reacquired by the Company on the open market or otherwise using cash proceeds from the exercise of Options or, after December 31, 2021, options granted under the Prior Plans.(c)Shares issued under Substitute Awards shall not reduce the Shares authorized for grant under the Plan nor shall Shares subject to a Substitute Award again be available for Awards under the Plan to the extent of any forfeiture, expiration or cash settlement as provided in paragraph (b) above.(d)Any Shares that again become available for grant pursuant to paragraph (b) of this Section shall be added back as (i) one (1) Share if such Shares were subject to Options or Stock Appreciation Rights granted under the Plan or options or stock appreciation rights granted under the Prior Plans, and (ii) as 1.5 Shares if such Shares were subject to Awards other than Options or Stock Appreciation Rights granted under the Plan or awards other than options or stock appreciation rights granted under the Prior Plans.3.2.Character of Shares. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares purchased in the open market or otherwise.3.3.Limit on Awards to Directors. Notwithstanding any other provision of the Plan to the contrary, the aggregate grant date fair value (computed as of the date of grant in accordance with applicable financial accounting rules) of all Awards granted to any Director during any single calendar year plus the aggregate amount of all cash earned and paid or payable to such Director for services rendered as a Director for the same year shall not exceed $800,000; provided, however, that with respect to the Chairman of the Board, the lead independent Director, or any newly-elected Director in his or her first calendar year of service, such amount shall not exceed $1,000,000.1 Comprised2,822,710 shares that were available under the 2019 Plan as of December 31, 2021, plus an incremental 2,750,000 shares.I-4 Appendix I4.ELIGIBILITY AND ADMINISTRATION4.1.Eligibility. Any Employee, Director or Consultant shall be eligible to participate, in accordance with the terms of the Plan.4.2.Administration.(a)The Plan shall be administered by the Committee. The Committee shall have full power and authority, subject to the provisions of the Plan and subject to such orders or resolutions not inconsistent with the provisions of the Plan as may from time to time be adopted by the Board, to:(i)select the Employees, Directors and Consultants to whom Awards may from time to time be granted hereunder;(ii)determine the type or types of Awards, not inconsistent with the provisions of the Plan, to be granted to each Participant hereunder;(iii)determine the number of Shares (or dollar value) to be covered by each Award granted hereunder;(iv)determine the terms and conditions, not inconsistent with the provisions of the Plan, of any Award granted hereunder (including the power to amend outstanding Awards);(v)accelerate at any time the exercisability or vesting of all or any portion of any Award;(vi)determine whether, to what extent and under what circumstances Awards may be settled in cash, Shares or other property;(vii)determine whether, to what extent, and under what circumstances cash, Shares, other property and other amounts payable with respect to an Award made under the Plan shall be deferred either automatically or at the election of the Participant;(viii)determine whether, to what extent and under what circumstances any Award shall be canceled or suspended;(ix)interpret and administer the Plan and any instrument or agreement entered into under or in connection with the Plan, including any Award Agreement;(x)correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent that the Committee shall deem desirable to carry it into effect;(xi)establish such rules and regulations and appoint such agents as it shall deem appropriate for the proper administration of the Plan;(xii)determine whether any Award, other than an Option or Stock Appreciation Right, will have Dividend Equivalents; and(xiii)make any other determination and take any other action that the Committee deems necessary or desirable for administration of the Plan.Subject to Section 4.2(b) below, in determining whether to make an Award, to whom to make an Award, the type of Award or the size of the Award, the Committee may consult with management of the Company.(b)Decisions of the Committee shall be final, conclusive and binding on all persons or entities, including the Company, any Participant, and any Affiliate. Subject to applicable law, majority of the members of the Committee may determine its actions, including fixing the time and place of its meetings.(c)To the extent not inconsistent with applicable law or the rules and regulations of the NASDAQ Stock Market (or such other principal U.S. national securities exchange on which the Shares are traded), the Committee may delegate to: (i) a committee of one or more members of the Board the authority to take action on behalf of the Committee under the Plan including the right to grant, cancel, suspend or amend Awards and (ii) one or more “executive officers” within the meaning of Rule 16a-1(f) of the Exchange Act or a committee of executive officers the right to grant Awards to Employees who are not directors or executive officers of the Company and the authority to take action on behalf of the Committee pursuant to the Plan to cancel or suspend Awards to Employees who are not directors or executive officers of the Company.(d)The Board in its discretion may ratify and approve actions taken by the Committee. In addition, to the extent not inconsistent with applicable law or the rules and regulations of the NASDAQ Stock Market or such other principal U.S. national securities exchange on which the Shares are traded, the Board may take any action under the Plan that the Committee is authorized to take. In the event the Board takes such action, references to the Committee hereunder shall be understood to refer to the Board.2022 Proxy StatementI-5Appendix I5.OPTIONS5.1.Grant of Options. Options may be granted hereunder to Participants either alone or in addition to other Awards granted under the Plan. Any Option shall be subject to the terms and conditions of this Section 5 and to such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall deem desirable.5.2.Award Agreements. All Options granted pursuant to this Section 5 shall be evidenced by a written Award Agreement in such form and containing such terms and conditions as the Committee shall determine which are not inconsistent with the provisions of the Plan. The terms of Options need not be the same with respect to each Participant. Granting an Option pursuant to the Plan shall impose no obligation on the recipient to exercise such Option. Any individual who is granted an Option pursuant to this Section may hold more than one Option granted pursuant to the Plan at the same time.5.3.Option Price. Other than in connection with Substitute Awards, the option price per each Share purchasable under any Option granted pursuant to this Section 5 shall not be less than 100% of the Fair Market Value of one Share on the date of grant of such Option; provided, however, that in the case of an Incentive Stock Option granted to a Participant who, at the time of the grant, owns stock representing more than 10% of the voting power of all classes of stock of the Company or any Affiliate, the option price per share shall be no less than 110% of the Fair Market Value of one Share on the date of grant. Other than pursuant to Section 11.2, the Committee shall not without the approval of the Company’s shareholders (a) lower the option price per Share of an Option after it is granted, (b) cancel an Option when the option price per Share exceeds the Fair Market Value of one Share in exchange for cash or another Award (other than in connection with a Change in Control or Substitute Awards), and (c) take any other action with respect to an Option that would be treated as a repricing under the rules and regulations of the NASDAQ Stock Market (or such other principal U.S. national securities exchange on which the Shares are traded).5.4.Option Term. The term of each Option shall be fixed by the Committee in its sole discretion; provided, that no Option shall be exercisable after the expiration of ten (10) years from the date the Option is granted; provided, however, that the term of the Option shall not exceed five (5) years from the date the Option is granted in the case of an Incentive Stock Option granted to a Participant who, at the time of the grant, owns stock representing more than 10% of the voting power of all classes of stock of the Company or any Affiliate.5.5.Exercise of Options.(a)Vested Options granted under the Plan may be exercised by the Participant or by a Permitted Assignee thereof (or by the Participant’s executors, administrators, guardian or legal representative, as may be provided in an Award Agreement) as to all or part of the Shares covered thereby, by the giving of notice of exercise to the Company or its designated agent, specifying the number of Shares to be purchased. The notice of exercise shall be in such form, made in such manner, and shall comply with such other requirements consistent with the provisions of the Plan as the Committee may from time to time prescribe.(b)Unless otherwise provided in an Award Agreement, full payment of such purchase price shall be made at the time of exercise and shall be made (i) in cash or cash equivalents (including certified check or bank check or wire transfer of immediately available funds), (ii) by tendering previously acquired Shares (either actually or by attestation), valued at their then Fair Market Value, (iii) with the consent of the Committee, by delivery of other consideration having a Fair Market Value on the exercise date equal to the total purchase price, (iv) with respect to Options that are not Incentive Stock Options, by a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price, (v) through any other method specified in an Award Agreement (including same-day sales through a broker), or (vi) any combination of any of the foregoing. In no event may any Option granted hereunder be exercised for a fraction of a Share. No adjustment shall be made for cash dividends or other rights for which the record date is prior to the date of such issuance.(c)Notwithstanding the foregoing, an Award Agreement may provide that if on the last day of the term of an Option the Fair Market Value of one Share exceeds the option price per Share, the Participant has not exercised the Option (or, if applicable, a tandem Stock Appreciation Right) and the Option has not expired, the Option shall be deemed to have been exercised by the Participant on such day with payment made by withholding Shares otherwise issuable in connection with the exercise of the Option. In such event, the Company shall deliver to the Participant the number of Shares for which the Option was deemed exercised, less the number of Shares required to be withheld for the payment of the total purchase price and required withholding taxes (subject to Section 12.1); provided, however, any fractional Share shall be settled in cash.I-6 Appendix I5.6.Form of Settlement. In its sole discretion, the Committee may provide that the Shares to be issued upon an Option’s exercise shall be in the form of Restricted Stock or other similar securities.5.7.Incentive Stock Options. The Committee may grant Incentive Stock Options to any employee of the Company or any Affiliate, subject to the requirements of Section 422 of the Code; provided, however, that for purposes of this Section “Affiliate shall mean, at the time of determination, any “parent” or “subsidiary of the Company as such terms are defined in Section 424 of the Code and the regulations thereunder. Notwithstanding anything in Section 3.1 to the contrary and solely for the purposes of determining whether Shares are available for the grant of Incentive Stock Options under the Plan, the maximum aggregate number of Shares that may be issued pursuant to Incentive Stock Options granted under the Plan shall be 5,572,710 Shares, subject to adjustment as provided in Section 11.2.6.STOCK APPRECIATION RIGHTS6.1.Grant and Exercise. The Committee may provide Stock Appreciation Rights (a) in tandem with all or part of any Option granted under the Plan or at any subsequent time during the term of such Option, (b) in tandem with all or part of any Award (other than an Option) granted under the Plan or at any subsequent time during the term of such Award, or (c) without regard to any Option or other Award, in each case upon such terms and conditions as the Committee may establish in its sole discretion.6.2.Terms and Conditions. Stock Appreciation Rights shall be subject to such terms and conditions, not inconsistent with the provisions of the Plan, as shall be determined from time to time by the Committee, including the following:(a)Upon the exercise of a Stock Appreciation Right, the holder shall have the right to receive the excess of (i) the Fair Market Value of one Share on the date of exercise (or such amount less than such Fair Market Value as the Committee shall so determine at any time during a specified period before the date of exercise) over (ii) the grant price of the Stock Appreciation Right.(b)The Committee shall determine in its sole discretion whether payment upon the exercise of a Stock Appreciation Right shall be made in cash, in whole Shares or other property, or any combination thereof.(c)The terms and conditions of Stock Appreciation Rights need not be the same with respect to each recipient.(d)The Committee may impose such other conditions on the exercise of any Stock Appreciation Right, as it shall deem appropriate. A Stock Appreciation Right shall have (i) a grant price per Share of not less than the Fair Market Value of one Share on the date of grant or, if applicable, on the date of grant of an Option with respect to a Stock Appreciation Right granted in exchange for or in tandem with, but subsequent to, the Option (subject to the requirements of Section 409A of the Code), except in the case of Substitute Awards or in connection with an adjustment provided in Section 11.2 and (ii) a term not greater than ten (10) years. In addition to the foregoing, but subject to Section 11.2, the Committee shall not without the approval of the Company’s shareholders (x) lower the grant price per Share of any Stock Appreciation Right after it is granted, (y) cancel any Stock Appreciation Right when the grant price per Share exceeds the Fair Market Value of the underlying Shares in exchange for cash or another Award (other than in connection with a Change in Control as defined in Section 10.3 or Substitute Awards), and (z) take any other action with respect to any Stock Appreciation Right that would be treated as a repricing under the rules and regulations of the NASDAQ Stock Market (or such other principal U.S. national securities exchange on which the Shares are traded).(e)In no event may any Stock Appreciation Right granted hereunder be exercised for a fraction of a Share. No adjustment shall be made for cash dividends or other rights for which the record date is prior to the date of such issuance.(f)An Award Agreement may provide that if on the last day of the term of a Stock Appreciation Right the Fair Market Value of one Share exceeds the grant price per Share of the Stock Appreciation Right, the Participant has not exercised the Stock Appreciation Right or the tandem Option (if applicable), and the Stock Appreciation Right has not expired, the Stock Appreciation Right shall be deemed to have been exercised by the Participant on such day. In such event, the Company shall make payment to the Participant in accordance with this Section, reduced by the number of Shares (or cash) required for withholding taxes (subject to Section 12.1); any fractional Share shall be settled in cash.7.RESTRICTED STOCK AWARDS7.1.Grants. Awards of Restricted Stock may be issued hereunder to Participants either alone or in addition to other Awards granted under the Plan (a “Restricted Stock Award”), and such Restricted Stock Awards may also be available as a form of payment of Performance Awards and other earned cash-based incentive compensation. A Restricted Stock Award shall be subject to vesting restrictions imposed by the Committee covering a period of time specified by the Committee. The Committee has absolute discretion to determine whether any consideration (other than services) is to be received by the Company or any Affiliate as a condition precedent to the issuance of Restricted Stock.7.2.Award Agreements. The terms of any Restricted Stock Award granted under the Plan shall be set forth in an Award Agreement, which shall contain provisions determined by the Committee and not inconsistent with the Plan. The terms of Restricted Stock Awards need not be the same with respect to each Participant.2022 Proxy StatementI-7Appendix I7.3.Rights of Holders of Restricted Stock. Unless otherwise provided in the Award Agreement, beginning on the date of grant of the Restricted Stock Award, the Participant shall become a shareholder of the Company with respect to all Shares subject to the Award Agreement and shall have all of the rights of a shareholder, including the right to vote such Shares and the right to receive distributions made with respect to such Shares; provided, however, that any Shares, cash or any other property distributed as a dividend or otherwise with respect to any Restricted Stock as to which the restrictions have not yet lapsed shall be accumulated or credited, and shall be subject to the same restrictions and risk of forfeiture as such Restricted Stock and shall not be paid until and unless the underlying Award vests.8.RESTRICTED STOCK UNIT AWARDS8.1.Grants. Other Awards of units having a value equal to an identical number of Shares (“Restricted Stock Unit Awards”) may be granted hereunder to Participants either alone or in addition to other Awards granted under the Plan. Restricted Stock Unit Awards shall also be available as a form of payment of other Awards granted under the Plan and other earned cash-based incentive compensation.8.2.Award Agreements. The terms of Restricted Stock Unit Award granted under the Plan shall be set forth in an Award Agreement, which shall contain provisions determined by the Committee and not inconsistent with the Plan. Restricted Stock Unit Awards shall be subject to vesting restrictions imposed by the Committee covering a period of time specified by the Committee. The terms of such Awards need not be the same with respect to each Participant.8.3.Payment. Except as provided in Section 10 or as may be provided in an Award Agreement, Restricted Stock Unit Awards may be paid in cash, Shares, other property, or any combination thereof, in the sole discretion of the Committee. Restricted Stock Unit Awards may be paid in a lump sum or in installments or, in accordance with procedures established by the Committee, on a deferred basis subject to the requirements of Section 409A of the Code.8.4.Rights of Holders of Restricted Stock Units. A Participant who holds a Restricted Stock Unit Award shall only have those rights specifically provided for in the Award Agreement and subject to the terms of the Plan, including Section 11.5; provided, however, in no event shall the Participant have voting rights with respect to such Award.9.PERFORMANCE AWARDS9.1.Grants. Performance Awards in the form of Performance Cash, Performance Shares or Performance Units, as determined by the Committee in its sole discretion, may be granted hereunder to Participants, for no consideration or for such minimum consideration as may be required by applicable law, either alone or in addition to other Awards granted under the Plan. The performance goals to be achieved for each Performance Period shall be conclusively determined by the Committee.9.2.Award Agreements. The terms of any Performance Award granted under the Plan shall be set forth in an Award Agreement, which shall contain provisions determined by the Committee and not inconsistent with the Plan, including Section 11.5. The terms of Performance Awards need not be the same with respect to each Participant.9.3.Terms and Conditions. The performance criteria to be achieved during any Performance Period and the length of the Performance Period shall be determined by the Committee upon the grant of each Performance Award. The amount of the Award to be distributed shall be conclusively determined by the Committee.9.4.Payment. Except as provided in Section 10 or as may be provided in an Award Agreement, Performance Awards will be distributed only after the end of the relevant Performance Period. Performance Awards may be paid in cash, Shares, other property, or any combination thereof, in the sole discretion of the Committee. Performance Awards may be paid in a lump sum or in installments following the close of the Performance Period or, in accordance with procedures established by the Committee, on a deferred basis subject to the requirements of Section 409A of the Code.10.CHANGE IN CONTROL PROVISIONS10.1.Impact on Certain Awards. The Committee, in its discretion, may determine that in the event of a Change in Control of the Company (i) Options and Stock Appreciation Rights outstanding as of the date of the Change in Control shall be cancelled and terminated without payment therefor if the Fair Market Value of one Share as of the date of the Change in Control is less than the Option per Share option price or Stock Appreciation Right per Share grant price and (ii) all Performance Awards shall be considered to be earned and payable (either in full or pro rata based on the portion of Performance Period completed as of the date of the Change in Control, or otherwise) as provided in the Award Agreement, and any limitations or other restrictions shall lapse and such Performance Awards shall be immediately settled or distributed.10.2.Assumption or Substitution of Certain Awards.(a)Unless otherwise provided in an Award Agreement, in the event of a Change in Control of the Company in which the successor company assumes or substitutes for an Option, Stock Appreciation Right, Restricted Stock Award orI-8 Appendix IRestricted Stock Unit Award (or in which the Company is the ultimate parent corporation and continues the Award), if a Participant’s employment with such successor company (or the Company) or a subsidiary thereof terminates within the time period following such Change in Control set forth in the Award Agreement (or prior thereto if applicable) and under the circumstances specified in the Award Agreement: (i) Options and Stock Appreciation Rights outstanding as of the date of such termination of employment will immediately vest, become fully exercisable, and may thereafter be exercised for the period of time set forth in the Award Agreement, (ii) the restrictions, limitations and other conditions applicable to Restricted Stock shall lapse and the Restricted Stock shall become free of all restrictions, limitations and conditions and become fully vested, and (iii) the restrictions, limitations and other conditions applicable to any Restricted Stock Unit Awards or any other Awards shall lapse, and such Restricted Stock Unit Awards or such other Awards shall become free of all restrictions, limitations and conditions and become fully vested and transferable to the full extent of the original grant. For the purposes of this Section, an Option, Stock Appreciation Right, Restricted Stock Award or Restricted Stock Unit Award shall be considered assumed or substituted for if following the Change in Control the Award confers the right to purchase or receive, for each Share subject to the Option, Stock Appreciation Right, Restricted Stock Award or Restricted Stock Unit Award immediately prior to the Change in Control, the consideration (whether stock, cash or other securities or property) received in the transaction constituting a Change in Control by holders of Shares for each Share held on the effective date of such transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares); provided, however, that if such consideration received in the transaction constituting a Change in Control is not solely common stock of the successor company, the Committee may, with the consent of the successor company, provide that the consideration to be received upon the exercise or vesting of an Option, Stock Appreciation Right, Restricted Stock Award or Restricted Stock Unit Award, for each Share subject thereto, will be solely common stock of the successor company substantially equal in fair market value to the per Share consideration received by holders of Shares in the transaction constituting a Change in Control. The determination of such substantial equality of value of consideration shall be made by the Committee in its sole discretion and its determination shall be conclusive and binding.(b)Unless otherwise provided in an Award Agreement, in the event of a Change in Control of the Company, to the extent that the successor company does not assume or substitute for an Option, Stock Appreciation Right, Restricted Stock Award or Restricted Stock Unit Award (or in which the Company is the ultimate parent corporation and does not continue the Award), then immediately prior to the Change in Control: (i) those Options and Stock Appreciation Rights outstanding as of the date of the Change in Control that are not assumed or substituted for (or continued) shall immediately vest and become fully exercisable, (ii) restrictions, limitations and conditions on Restricted Stock not assumed or substituted for (or continued) shall lapse and the Restricted Stock shall become free of all restrictions, limitations and conditions and become fully vested, and (iii) the restrictions limitations and conditions applicable to any Restricted Stock Unit Awards or any other Awards not assumed or substituted for (or continued) shall lapse, and such Restricted Stock Unit Awards or such other Awards shall become free of all restrictions, limitations and conditions and become fully vested and transferable to the full extent of the original grant.(c)The Committee, in its discretion, may determine that, upon the occurrence of a Change in Control of the Company, each Option and Stock Appreciation Right outstanding shall terminate within a specified number of days after notice to the Participant, and/or that each Participant shall receive, with respect to each Share subject to such Option or Stock Appreciation Right, an amount equal to the excess (if any) of the Fair Market Value of such Share immediately prior to the occurrence of such Change in Control over the exercise price per Share of such Option and/or Stock Appreciation Right; such amount to be payable in cash, in one or more kinds of stock or property (including the stock or property, if any, payable in the transaction) or in a combination thereof, as the Committee, in its discretion, shall determine. The Committee shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Fair Market Value of one Share immediately prior to the occurrence of such Change in Control multiplied by the number of vested Shares under such Awards.10.3.Change in Control. For purposes of the Plan, unless otherwise provided in an Award Agreement, Change in Control means the occurrence of any one of the following events:(a)During any twenty-four (24) month period, individuals who, as of the beginning of such period, constitute the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the beginning of such period whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be deemed to be an Incumbent Director;2022 Proxy StatementI-9Appendix I(b)Any “person” (as such term is defined in the Exchange Act and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided, however, that the event described in this paragraph (b) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions: (A) by the Company or any Affiliate, (B) by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, (D) pursuant to a Non-Qualifying Transaction, as defined in paragraph (c), or (E) by any person of Company Voting Securities from the Company, if a majority of the Incumbent Board approves in advance the acquisition of beneficial ownership of 50% or more of Company Voting Securities by such person;(c)The consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company or any of its Affiliates that requires the approval of the Company’s shareholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination: (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”), or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee benefit plan (or related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or becomes the beneficial owner, directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) following the consummation of the Business Combination were Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”);(d)The shareholders of the Company approve a plan of complete liquidation or dissolution of the Company; or(e)The consummation of a sale of all or substantially all of the Company’s assets.Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because any person acquires beneficial ownership of more than 50% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Company which reduces the number of Company Voting Securities outstanding; provided, that if after such acquisition by the Company such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person, a Change in Control of the Company shall then occur.11.GENERALLY APPLICABLE PROVISIONS11.1.Amendment and Termination of the Plan. The Board may, at any time, amend or discontinue the Plan and the Committee may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the holder’s consent. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, to the extent determined by the Committee to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Subject to Section 11.2, the Board may not without the approval of the Company’s shareholders take any action with respect to an Option or Stock Appreciation Right that may be treated as a repricing under the rules and regulations of the NASDAQ Stock Market (or such other principal U.S. national securities exchange on which the Shares are traded), including a reduction of the exercise price of an Option or the grant price of a Stock Appreciation Right or the cancellation of an Option or Stock Appreciation Right when the exercise price or grant price per Share exceeds the Fair Market Value of the underlying Shares in exchange for cash or another Award (other than in connection with a Change in Control or Substitute Awards). In addition, no amendments to, or termination of, the Plan shall in any way impair the rights of a Participant under any Award previously granted without such Participant’s consent.11.2.Adjustments. In the event of any merger, reorganization, consolidation, recapitalization, dividend or distribution (whether in cash, shares or other property, other than a regular cash dividend), stock split, reverse stock split, spin-off or similar transaction or other change in corporate structure affecting the Shares or the value thereof, such adjustments and otherI-10 Appendix Isubstitutions shall be made to the Plan and to Awards as the Committee deems equitable or appropriate taking into consideration the accounting and tax consequences, including such adjustments in the aggregate number, class and kind of securities that may be delivered under the Plan, the limits in Section 3.1, the maximum number of Shares that may be issued pursuant to Incentive Stock Options and the number, class, kind and option or exercise price of securities subject to outstanding Awards granted under the Plan (including, if the Committee deems appropriate, the substitution of similar options to purchase the shares of, or other awards denominated in the shares of, another company) as the Committee may determine to be appropriate in its sole discretion; provided, however, that the number of Shares subject to any Award shall always be a whole number.11.3.Transferability of Awards. Except as provided below, no Award and no Shares subject to Awards that have not been issued or as to which any applicable restriction, performance or deferral period has not lapsed, may be sold, assigned, transferred, pledged or otherwise encumbered, other than by will or the laws of descent and distribution or pursuant to a qualified domestic relations order, and such Award may be exercised during the life of the Participant only by the Participant or the Participant’s guardian or legal representative. To the extent and under such terms and conditions as determined by the Committee, a Participant may assign or transfer an Award (each transferee thereof, a “Permitted Assignee”) to a “family member” as such term is defined in the General Instructions to Form S-8 (whether by gift or a domestic relations order); provided that such Permitted Assignee shall be bound by and subject to all of the terms and conditions of the Plan and the Award Agreement relating to the transferred Award and shall execute an agreement satisfactory to the Company evidencing such obligations; and provided further that such Participant shall remain bound by the terms and conditions of the Plan. The Company shall cooperate with any Permitted Assignee and the Company’s transfer agent in effectuating any transfer permitted under this Section 11.3. In no event may any Award be transferred for consideration to a third-party financial institution.11.4.Termination of Employment or Service. The Committee shall determine and set forth in each Award Agreement whether any Awards granted in such Award Agreement will continue to be exercisable, continue to vest or be earned and the terms of such exercise, vesting or earning, on and after the date that a Participant ceases to be employed by or to provide services to the Company or any Affiliate (including as a Director or a Consultant), whether by reason of death, disability, voluntary or involuntary termination of employment or services, or otherwise. The date of termination of a Participant’s employment or services will be determined by the Committee, which determination will be final. A Participant’s employment or services will not be deemed terminated merely because of a change in the capacity in which the Participant provides services for the Company or an Affiliate as a Consultant, Director or Employee, or because of a change from providing services to the Company to an Affiliate or vice versa or from one Affiliate to another, provided that there is no interruption or termination of the Participant’s service between such changes.11.5.Deferral; Dividend Equivalents. The Committee shall be authorized to establish procedures pursuant to which the payment of any Award may be deferred in accordance with the requirements of Section 409A of the Code. Subject to the provisions of the Plan and any Award Agreement, the recipient of an Award (including any deferred Award) other than an Option or Stock Appreciation Right may, if so determined by the Committee, be entitled to receive cash, stock or other property dividends, or cash payments in amounts equivalent to cash, stock or other property dividends on Shares (“Dividend Equivalents”) with respect to the number of Shares covered by the Award, as determined by the Committee, in its sole discretion. The Committee may provide that such amounts and Dividend Equivalents (if any) shall be deemed to have been credited or accumulated and reinvested in additional Shares or otherwise reinvested. Notwithstanding the foregoing, Dividend Equivalents shall at all times be subject to restrictions and risk of forfeiture to the same extent as the underlying Award and shall not be paid unless and until the underlying Award vests.12.MISCELLANEOUS12.1.Tax Withholding. The Company shall have the right to make all payments or distributions pursuant to the Plan to a Participant (or a Permitted Assignee thereof) (any such person, a “Payee”) net of any applicable federal, state and local taxes required to be paid or withheld as a result of (a) the grant of any Award, (b) the exercise of an Option or Stock Appreciation Right, (c) the delivery of Shares or cash, (d) the lapse of any restrictions in connection with any Award or (e) any other event occurring pursuant to the Plan. The Company or any Affiliate shall have the right to withhold from wages or other amounts otherwise payable to such Payee such withholding taxes as may be required by law, or to otherwise require the Payee to pay such withholding taxes. If the Payee shall fail to make such tax payments as are required, the Company or its Affiliates shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to such Payee or to take such other action as may be necessary to satisfy such withholding obligations. The Committee shall be authorized to establish procedures for election by Participants to satisfy such obligation for the payment of such taxes by tendering previously acquired Shares (either actually or by attestation, valued at their then Fair Market Value), or by directing the Company to retain Shares (up to the Participant’s maximum required tax withholding rate or such other lesser rate that will not cause an adverse accounting consequence or cost) otherwise deliverable in connection with the Award, subject to2022 Proxy StatementI-11Appendix Ithe discretion of the Committee. The Committee may also require (i) Awards to be subject to mandatory share withholding up to the required withholding amount or (ii) the Company’s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a certain number of Shares issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of shares includible in income of the grantees.12.2.Right of Discharge Reserved; Claims to Awards. Nothing in the Plan nor the grant of an Award hereunder shall confer upon any Employee, Director or Consultant the right to continue in the employment or service of the Company or any Affiliate or affect any right that the Company or any Affiliate may have to terminate the employment or service of (or to demote or to exclude from future Awards under the Plan) any such Employee, Director or Consultant at any time for any reason. Except as specifically provided by the Committee, the Company shall not be liable for the loss of existing or potential profit from an Award granted in the event of termination of an employment or other relationship. No Employee, Director or Consultant shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment of Employees, Directors or Consultants under the Plan.12.3.Prospective Recipient. The prospective recipient of any Award under the Plan shall not, with respect to such Award, be deemed to have become a Participant, or to have any rights with respect to such Award, until and unless such recipient shall have executed an agreement or other instrument evidencing the Award and delivered a copy thereof to the Company, and otherwise complied with the then applicable terms and conditions.12.4.Substitute Awards. Notwithstanding any other provision of the Plan, the terms of Substitute Awards may vary from the terms set forth in the Plan to the extent the Committee deems appropriate to conform, in whole or in part, to the provisions of the awards in substitution for which they are granted.12.5.Cancellation of Award; Forfeiture of Gain.(a)Notwithstanding anything to the contrary contained herein, an Award Agreement may provide that the Award shall be canceled if the Participant, without the consent of the Company, while employed by, or providing services to, the Company or any Affiliate or after termination of such employment or services, establishes a relationship with a competitor of the Company or any Affiliate or engages in activity that is in conflict with or adverse to the interest of the Company or any Affiliate (including conduct contributing to any financial restatements or financial irregularities), as determined by the Committee in its sole discretion. The Committee may provide in an Award Agreement that, if within the time period specified in the Award Agreement, the Participant establishes a relationship with a competitor or engages in an activity referred to in the preceding sentence, the Participant will forfeit any gain realized on the vesting or exercise of the Award and must repay such gain to the Company. For purposes of this section, the term “competitor” shall mean any business of the same nature as, or in competition with, the business in which the Company or an Affiliate is now engaged, or in which Company or Affiliate becomes engaged during the term of a Participant’s employment, consultancy or service on the Board, or which is involved in science or technology, which is similar to the Company’s or an Affiliate’s science or technology; provided, however, that a Participant shall not be deemed to have established a relationship or engaged in a competitive activity due to the ownership of 2% or less of the shares of a public company that would otherwise be a competitor so long as the Participant does not actively participate in the management of such company.(b)In the event the Participant ceases to be employed by, or provide services to, the Company or an Affiliate on account of a termination for Cause (as defined below), any Award held by the Participant shall terminate as of the date the Participant ceases to be employed by, or provide services to, the Company or the Affiliate unless the Committee notifies the Participant that his or her Award(s) will not terminate. In addition, notwithstanding any other provisions of this Section 12.5, if, after an Award is made, or an Option or a Stock Appreciation Right is exercised, after the act or omission of the Participant that defines the termination as a termination for Cause, but before the Company determines that termination is for Cause, such Award, or exercise, as the case may be, will be void ab initio and reversed by the parties. In the event a Participant’s employment or services is terminated for Cause, in addition to the immediate termination of all Awards, the Participant shall automatically forfeit all Shares underlying any exercised portion of an Option for which the Company has not yet delivered the share certificates, upon refund by the Company of the option price paid by the Participant for such Shares. Notwithstanding the foregoing, this provision is not intended to, and shall be interpreted in a manner that does not, limit or restrict the Participant from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Exchange Act).(c)For purposes of this Section 12.5, “Cause” shall mean, unless otherwise provided in an Award Agreement or another agreement between the Participant and the Company or an Affiliate or a plan maintained by the Company or an Affiliate in which the Participant participates, a determination by the Committee that the Participant has (i) materiallyI-12 Appendix Ibreached his or her employment or service contract with the Company, (ii) been engaged in disloyalty to the Company or an Affiliate, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty in the course of his or her employment or service, which will materially harm the interests of the Company or the Affiliate (iii) disclosed trade secrets or confidential information of the Company to persons not entitled to receive such information, (iv) breached any written noncompetition or nonsolicitation agreement between the Participant and the Company or an Affiliate in a manner which the Committee determines will cause material harm to the interests of the Company or an Affiliate, or (v) engaged in such other behavior materially detrimental to the interests of the Company, in each case as the Committee determines.(d)Further, this provision also applies to any policy adopted by any exchange on which the securities of the Company are listed pursuant to Section 10D of the Exchange Act. To the extent any such policy requires the repayment of incentive-based compensation received by a Participant, whether paid pursuant to an Award granted under this Plan or any other plan of incentive-based compensation maintained in the past or adopted in the future by the Company, by accepting an Award under this Plan, the Participant agrees to the repayment of such amounts to the extent required by such policy and applicable law.12.6.Stop Transfer Orders. All certificates for Shares delivered under the Plan pursuant to any Award shall be subject to such stop-transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Shares are then listed, and any applicable federal or state securities law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.12.7.Nature of Payments. All Awards made pursuant to the Plan are in consideration of services performed or to be performed for the Company or any Affiliate, division or business unit of the Company. Any income or gain realized pursuant to Awards under the Plan constitutes a special incentive payment to the Participant and shall not be taken into account, to the extent permissible under applicable law, as compensation for purposes of any of the employee benefit plans of the Company or any Affiliate except as may be determined by the Committee or by the Board or board of directors of the applicable Affiliate.12.8.Other Plans. Nothing contained in the Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.12.9.Severability. The provisions of the Plan shall be deemed severable. If any provision of the Plan shall be held unlawful or otherwise invalid or unenforceable in whole or in part by a court of competent jurisdiction or by reason of a change in a law or regulation, such provision shall (a) be deemed limited to the extent that such court of competent jurisdiction deems it lawful, valid and/or enforceable and as so limited shall remain in full force and effect, and (b) not affect any other provision of the Plan or part thereof, each of which shall remain in full force and effect. If the making of any payment or the provision of any other benefit required under the Plan shall be held unlawful or otherwise invalid or unenforceable by a court of competent jurisdiction, such unlawfulness, invalidity or unenforceability shall not prevent any other payment or benefit from being made or provided under the Plan, and if the making of any payment in full or the provision of any other benefit required under the Plan in full would be unlawful or otherwise invalid or unenforceable, then such unlawfulness, invalidity or unenforceability shall not prevent such payment or benefit from being made or provided in part, to the extent that it would not be unlawful, invalid or unenforceable, and the maximum payment or benefit that would not be unlawful, invalid or unenforceable shall be made or provided under the Plan.12.10.Construction. As used in the Plan, the words “include” and “including” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”12.11.Unfunded Status of the Plan. The Plan is intended to constitute an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant by the Company, nothing contained herein shall give any such Participant any rights that are greater than those of a general creditor of the Company. In its sole discretion, the Committee may authorize the creation of trusts or other arrangements to meet the obligations created under the Plan to deliver the Shares or payments in lieu of or with respect to Awards hereunder; provided, however, that the existence of such trusts or other arrangements is consistent with the unfunded status of the Plan.12.12.Governing Law. The Plan and all determinations made and actions taken thereunder, to the extent not otherwise governed by the Code or the laws of the United States, shall be governed by the laws of the State of Michigan, without reference to principles of conflict of laws, and construed accordingly.2022 Proxy StatementI-13Appendix I12.13.Effective Date of Plan; Termination of Plan. The Plan shall be effective on the date of the approval of the Plan by the holders of the shares entitled to vote at a duly constituted meeting of the shareholders of the Company (the “Effective Date”). Awards may be granted under the Plan at any time and from time to time on or prior to the tenth anniversary of the Effective Date, on which date the Plan will expire except as to Awards then outstanding under the Plan, and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is most recently approved by the Board. Such outstanding Awards shall remain in effect until they have been exercised or terminated, or have expired.12.14.Foreign Employees and Consultants. Awards may be granted to Participants who are foreign nationals or employed or providing services outside the United States, or both, on such terms and conditions different from those applicable to Awards to Employees, Directors or Consultants employed or providing services in the United States as may, in the judgment of the Committee, be necessary or desirable in order to recognize differences in local law or tax policy. The Committee also may impose conditions on the exercise or vesting of Awards in order to minimize the Company’s obligation with respect to tax equalization for Employees, Directors or Consultants on assignments outside their home country.12.15.Compliance with Section 409A of the Code. This Plan is intended to comply and shall be administered in a manner that is intended to be exempt from or comply with Section 409A of the Code and shall be construed and interpreted in accordance with such intent. To the extent that an Award or the payment, settlement or deferral thereof is subject to Section 409A of the Code, the Award shall be granted, paid, settled or deferred in a manner that will comply with Section 409A of the Code, including regulations or other guidance issued with respect thereto, except as otherwise determined by the Committee. Any provision of this Plan that would cause the grant of an Award or the payment, settlement or deferral thereof to fail to satisfy Section 409A of the Code shall be amended to comply with Section 409A of the Code on a timely basis, which may be made on a retroactive basis, in accordance with regulations and other guidance issued under Section 409A of the Code.Should any payments made in accordance with the Plan to a specified employee, as defined by Section 409A of the Code, be determined to be payments from a nonqualified deferred compensation plan, as defined by Section 409A of the Code, and are payable in connection with a Participant’s Separation from Service (as defined below), that are not exempt from Section 409A of the Code as a short-term deferral or otherwise, these payments, to the extent otherwise payable within six (6) months after the Participant’s date of Separation from Service, will be paid in a lump sum on the earlier of the date that is six (6) months after the Participant’s date of Separation from Service or the date of the Participant’s death, to the extent necessary in order to avoid the imposition of taxes under Section 409A of the Code. For purposes of the Plan, a “Separation from Service” means an anticipated permanent reduction in a Participant’s level of bona fide services to twenty percent (20%) or less of the average level of bona fide services performed by a Participant over the immediately preceding thirty-six (36) month period. For purposes of Section 409A of the Code, the payments to be made to a Participant in accordance with this Plan shall be treated as a right to a series of separate payments.12.16.Captions. The captions in the Plan are for convenience of reference only, and are not intended to narrow, limit or affect the substance or interpretation of the provisions contained herein.12.17.Clawback Policy. Awards under the Plan shall be subject to the Company’s clawback policy, as in effect from time to time.I-14 64 Sidney StreetCambridge, MA 02139www.vcel.comVERICEL CORPORATIONATTN: SEAN C. FLYNN64 SIDNEY STREETCAMBRIDGE, MA 02139VOTE BY INTERNETBefore The Meeting - Go to www.proxyvote.com or scan the QR Barcode aboveUse the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on April 26, 2022.information. Vote by 11:59 P.M. ET on April 30, 2024. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.VCEL2022VCEL2024April 27, 2022.May 1, 2024.26, 2022.30, 2024. Have your proxy card in hand when you call and then follow the instructions.TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: V30339-P05731 KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:D71791-P69571KEEP THIS PORTION FOR YOUR RECORDSTHIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLYVERICEL CORPORATIONForAllWithholdAllFor AllExcept The Board of Directors recommends you vote FOR the following:ooo VERICEL CORPORATION For
AllWithhold
AllFor All
ExceptTo withhold authority to vote for any individual nominee(s), mark “For All Except” and write the number(s) of the nominee(s) on the line below. 1.ElectionThe Board of Directors recommends you vote FOR All of the following: Nominees: 01) Robert L. Zerbe 05) Kevin F. McLaughlin 02) Alan L. Rubino 06) Paul K. Wotton 03) Heidi Hagen 07) Dominick C. Colangelo 04) Steven C. Gilman 08) Lisa Wright 1. Election of Directors o o o Nominees: 01) Robert L. Zerbe 05) Kevin F. McLaughlin 02) Alan L. Rubino 06) Paul K. Wotton 03) Heidi Hagen 07) Dominick C. Colangelo 04) Steven C. Gilman 08) Lisa Wright The Board of Directors recommends you vote FOR proposal 2. For Against Abstain 2. To approve, on an advisory basis, the compensation of Vericel Corporation’s named executive officers. o o o The Board of Directors recommends you vote 1 YEAR on proposal 3. 1 Year 2 Years 3 Years Abstain 3. To approve, on an advisory basis, the frequency of future named executive officer compensation advisory votes. o o o o The Board of Directors recommends you vote FOR proposal 4. For Against Abstain 4. To ratify the appointment of PricewaterhouseCoopers LLP as Vericel Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2024. o o o NOTE: In their discretion, the proxies are authorized to vote upon any other matters that are properly brought by or at the direction of the Board of Directors before the Annual Meeting and at any adjournments or postponements thereof. Even if you are planning to attend the meeting virtually, you are urged to sign and mail this Proxy in the return envelope so that the stock may be represented at the meeting. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. The Board of Directors recommends you vote FOR proposals 2, 3 and 4. ForAgainstAbstain 2.To approve, on an advisory basis, the compensation of Vericel Corporation’s named executive officers. ooo 3.To ratify the appointment of PricewaterhouseCoopers LLP as Vericel Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2022.ooo4.To approve the adoption of Vericel Corporation’s 2022 Omnibus Incentive Plan.oooNOTE: In their discretion, the proxies are authorized to vote upon any other matters that are properly brought by or at the direction of the Board of Directors before the Annual Meeting and at any adjournments or postponements thereof. Even if you are planning to attend the meeting virtually, you are urged to sign and mail this Proxy in the return envelope so that the stock may be represented at the meeting.Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.Signature [PLEASE SIGN WITHIN BOX]DateSignature (Joint Owners)Date Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:The 2022 Notice of Virtual Annual Meeting of Shareholders and Proxy Statement and Form 10-K are available
The 2024 Notice of Virtual Annual Meeting of Shareholders and Proxy Statement and Form 10-K are available
at www.proxyvote.comD71792-P69571V30340-P05731
Annual Meeting of Shareholders
May 1, 2024 9:00 a.m. ET
This proxy is solicited by the Board of DirectorsVERICEL CORPORATIONAnnual Meeting of ShareholdersApril 27, 2022 9:00 a.m. ETThis proxy is solicited by the Board of DirectorsThe undersigned hereby appoints Dominick C. Colangelo and Joseph Mara, and hereby authorizes each of them, with full power of substitution to represent the undersigned and to vote all of the shares of stock of Vericel Corporation (the “Company”), which undersigned is entitled to vote at the Annual Meeting of Shareholders of the Company to be held via live audio webcast at www.virtualshareholdermeeting.com/VCEL2022, on Wednesday, April 27, 2022 at 9:00 a.m. Eastern Time, and at any adjournment thereof (i) as hereinafter specified upon the proposals listed on the reverse side and as more particularly described in the Company’s Proxy Statement, receipt of which is hereby acknowledged, and (ii) in their discretion upon such other matters as may properly come before the meeting.The shares represented hereby shall be voted as specified. If no specification is made, such shares shall be voted “FOR” proposals 1, 2, 3 and 4. If you abstain from voting on proposals 1, 2, 3 and 4 it will have no effect on the voting of the proposals.Continued and to be signed on reverse side